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This thesis focuses on impulsive compulsive behaviours (ICBs) in Parkinson’s 
disease (PD), behavioural complications that can arise in association with 
dopaminergic treatment. 
 
Initially, the long-term outcome of ICBs was assessed, revealing that 58% of the 
patients remained symptomatic after 8 years of follow up. Reduction of 
dopaminergic treatment was effective in decreasing symptoms but did not 
guarantee long-term remission. The presence of ICBs was associated with 
depression and worse quality of life but it did not increase the risk of cognitive 
impairment. 
 
Compulsive sexual behaviour in PD was found to be more frequent in males 
and associated with multiple ICBs and higher doses of levodopa when 
compared to other ICBs. The outcome of patients with dopamine dysregulation 
syndrome (DDS) until death was investigated in a brain bank cohort showing 
that half of the patients remained symptomatic and that remission was 
associated with lower levodopa dose at death. Punding in PD was associated 
with higher impulsivity and worse frontal function compared to other ICBs. 
Apomorphine infusion was found to be less likely to trigger or worsen ICBs in 
PD patients than other dopamine agonists in a retrospective analysis. 
 
Automatic and voluntary saccadic eye movements of PD patients with ICBs 
(PD+ICB) were compared to PD patients without ICBs and healthy controls. 
PD+ICB had hypometric voluntary saccades and made a significantly higher 
number of direction errors in the anti-saccades task. Considering that ICBs are 
under-reported, this finding, if confirmed, could lead to the development of a 
novel way of identifying these abnormal behaviours. 
 
Lastly, brain tissue from 24 PD patients with DDS were assessed for alpha-
synuclein, tyrosine hydroxylase, and dopamine D2 and D3 receptors protein 
levels. Lower levels of alpha-synuclein were found in the nucleus accumbens of 
patients with ICBs suggesting a central role for this structure in the 
pathophysiology of ICBs.  
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Impact statement  
 
Although nearly two decades have passed since the initial description of 
impulsive compulsive behaviours (ICBs) in Parkinson’s disease (PD), little is 
known about the long-term prognosis and the pathophysiology of these 
disabling behavioural abnormalities. 
 
The characteristic lack of insight that accompanies ICBs means that diagnosis 
often comes too late, when patients have incurred significant debt and personal 
relationships have been irreversibly affected. Benefits for clinical practice are 
likely to derive from the findings reported in this thesis. By showing that more 
than half of the patients remain symptomatic in the long-term, the need for close 
clinical vigilance is reinforced, even after patients have experienced remission 
of ICBs and, particularly, after increases in medication required for disease 
progression. Furthermore, the data shows that, despite the low remission rate, 
reduction of dopaminergic treatment is indeed an effective way to decrease the 
severity of ICBs, confirming this strategy as the gold standard treatment of 
these troubling behaviours. 
 
The main points for the management of compulsive sexual behaviour (CSB) in 
PD are: dopamine agonists (DA) should be discontinued if possible; and 
patients using higher doses of levodopa should be carefully screened for CSB, 
considering its reported association with higher doses of levodopa. Data on the 
safety of apomorphine continuous infusion in patients with ICBs was provided, 
suggesting that this medication could be safely prescribed to patients with a 
previous history of ICBs, to patients who become handicapped after cessation 
of DA and to patients with active ICBs in an attempt to reduce other 
dopaminergic medications.  
 
An insight into the mechanisms behind punding was provided. The finding that 
punding is associated with frontal dysfunction and higher impulsivity levels 
could aid future studies to unravel the cause of punding and perhaps contribute 
to the development of novel treatments. 
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A much-needed development in the field of ICBs in PD is the correct 
identification of patients who are at risk or who have already developed ICBs 
and lack insight. In this thesis, a novel way of identifying these behavioural 
abnormalities using anti-saccadic direction error was presented. The potential 
for anti-saccadic error rate to be a clinical marker for ICBs should be assessed 
in future studies. If confirmed, this finding has the potential to become an 
important compass to guide treatment choices in patients at risk of developing 
ICBs. 
 
The post mortem study is one important step towards unravelling the 
pathophysiology of ICBs. Reduced alpha-synuclein load was found in the 
nucleus accumbens (NAc) of PD patients with ICBs. Dopamine overdose of the 
ventral striatum with a relatively preserved NAc could be an important 
mechanism behind ICBs. Benefits for both the field of ICBs in PD and drug 
addiction are likely to ensue considering the shared pathophysiological 
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Chapter 1: Impulsive compulsive behaviours in 
Parkinson’s disease 
 
1.1 Parkinson’s disease 
 
Parkinson’s disease (PD) is the second most common neurodegenerative 
condition affecting approximately 1 to 2 individuals per 1000 population (Tysnes 
and Storstein, 2017). There is a significant age-related increase in the risk of 
developing PD. The prevalence of 0.3% in the general population increases 
from 1% of individuals with 60 years of age to approximately 3% of individuals 
with 80 years or older (Fahn et al., 2011a). Gender also appears to influence 
the risk as it has been shown that PD affects more men than women (Cantuti-
Castelvetri et al., 2007). 
 
The disease is characterized by loss of dopaminergic neurons in the substantia 
nigra and degeneration of the striatonigral pathways. Microscopically, the 
affected areas present with Lewy bodies and Lewy neurites, composed mainly 
of alpha-synuclein (Jellinger, 2011). Although the classical motor signs (rigidity, 
bradykinesia, tremor and postural instability) dominate the clinical picture, 
degeneration of other neuronal systems can result in a constellation of non-
motor symptoms (NMS). NMS can be the presenting symptom in PD, tend to 
become more common as the disease progresses and have a negative impact 
in the quality of life of individuals with PD (Fahn et al., 2011a). 
 
Most NMS can be classified as sensory symptoms, such as pain, restless legs 
syndrome (RLS) and hyposmia; or autonomic symptoms, like orthostatic 
hypotension, constipation, and urinary symptoms. Psychiatric and behavioural 
NMS include depression, anxiety, apathy, psychosis, cognitive impairment and 
impulsive compulsive behaviours (ICBs), poorly understood behavioural 
abnormalities associated with dopaminergic treatment (table 1 on page 17). 





Table 1. Common non-motor symptoms in Parkinson’s disease 
Sensory symptoms Pain, paraesthesia, numbness, burning sensation, 
akathisia, restless legs syndrome, hyposmia. 
Autonomic symptoms Urinary symptoms, sexual dysfunction, orthostatic 
hypotension, excessive salivation, constipation, 




Depression, anxiety, apathy, abulia, bradyphrenia, 
psychosis, hallucinations, personality changes, 
impulsive compulsive behaviours. 
Other symptoms Sleep fragmentation, sleep apnoea, REM sleep 
behaviour disorder, excessive daytime sleepiness, 
fatigue, cognitive impairment, confusion. 






















The absence of a curative treatment and disease modifying drugs means that 
PD treatment has traditionally focused on using medication to reduce the striatal 
dopaminergic deficit and alleviate motor symptoms. With disease progression, 
the majority of patients develop motor fluctuations and complications that can 
make the management of the condition challenging. Although treatments such 
as infusion therapies and deep brain stimulation can provide additional benefit 
at the advanced stage, disability invariably accumulates as disease progresses 
with most patients reaching end stage disease after approximately 15 years of 
onset (Poewe, 2006).  
 
1.2 Impulsive compulsive behaviours in Parkinson’s disease 
 
ICBs is an umbrella term used to describe behavioural abnormalities that can 
develop in PD patients in association with dopaminergic treatment. Some ICBs 
are characterised by high levels of impulsivity, i.e. failure to resist temptations 
and urges, such as compulsive sexual behaviour (CSB), pathological gambling, 
compulsive eating, and compulsive shopping; whereas others are associated 
with repetitive and/or compulsive behaviours, such as punding, a complex 
behavioural abnormality characterized by engagement in stereotyped non-goal 
oriented activities, hoarding behaviour, excessive hobbyism and the compulsive 
use of dopaminergic medication regardless of what is needed to achieve 
therapeutic benefit, also known as dopamine dysregulation syndrome (DDS)  
(Evans et al., 2004). Other less common ICBs that have been described in PD 
are: reckless generosity, compulsive smoking, reckless driving, aggression and 
walkabouts (Djamshidian et al., 2011a). 
 
Since the initial description of DDS by Giovannoni and colleagues in 2000 
(Giovannoni et al., 2000), clinical and scientific interest in ICBs has 
exponentially increased. Although in the past 18 years much has been learnt 
about the risk factors for ICBSs and its association with dopaminergic 
treatment, many questions remain unanswered, such as what causes ICBs, 
why some individuals are more susceptible than others, the prognosis and long-
term outcome, and whether reduction of dopaminergic treatment is associated 
with long term remission. 
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1.2.1 Epidemiology  
 
Since the initial description of DDS, reports from several authors have 
confirmed that ICBs are relatively common in PD. The largest study assessing 
the prevalence of ICBs was conducted in multiple centres across the US and 
Canada, whereby the authors analysed 3090 patients with PD receiving 
dopaminergic treatment and found that 14% had at least one of the following 
ICBs: CSB, pathological gambling, compulsive shopping and compulsive 
eating, with one quarter of them presenting with more than one behavioural 
addiction (Weintraub et al., 2010a). A similar prevalence had been reported in a 
previous study analysing 193 consecutive PD patients (Giladi et al., 2007). 
 
After these initial publications, researchers have assessed populations of PD 
patients from different countries suggesting a significant variability in the 
prevalence of ICBs. Low prevalence has been reported in China (3.53%) (Fan 
et al., 2009), Shanghai (4.15%) (Wang et al., 2016), and Turkey (5.9%) 
(Kenangil et al., 2010), whereas higher prevalence has been reported in Brazil 
(18.4%) (Valenca et al., 2013), Japan (21.5%) (Tanaka et al., 2013), Malaya 
(23.5%) (Lim et al., 2011), France (25%) (Perez-Lloret et al., 2012a), Norway 
(30.4%) (Erga et al., 2017), Finland (34.8%) (Joutsa et al., 2012), and Denmark 
(35.9%) (Callesen et al., 2014). Cultural factors, different laws regarding 
gambling availability and the different methods used to diagnose ICBs are 
possible explanations for the variation seen in these figures. It is also important 
to consider the possibility of under-reporting of ICBs by patients and their 
family/carers due to lack of insight, concealment associated with the sensitive 
nature of some ICBs, and failure to associate the behaviour with PD. 
 
The proportion of patients with ICBs in a specific population appears to remain 
stable over time as shown by a prospective observational study conducted in 
Italy. More than one thousand patients with PD were followed up for 2 years, 
showing that the prevalence of ICBs assessed by the Questionnaire for 
Impulsive-Compulsive Disorders in Parkinson’s Disease (QUIP) remained 
stable at baseline (34.2%), year 1 (34.8%) and year 2 (32.1%). The same was 
true for the proportion of patients with multiple ICBs, approximately 45%, which 
did not change between assessments (Antonini et al., 2017). 
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A few studies have assessed the occurrence of specific types of ICBs. 
Pathological gambling is defined as maladaptive gaming behaviour and its 
lifetime prevalence in PD patients on dopaminergic therapy varies between 
3.4% and 6%, with slightly higher rates reported on individuals using dopamine 
agonists (DA) (7.2%) and lower rates reported in China and Korea (0.32% and 
1.3% respectively) (Djamshidian et al., 2011b, Voon et al., 2006b). The lifetime 
prevalence of CSB in PD is estimated between 2 and 3.9% (Voon et al., 2006a, 
Weintraub et al., 2006, Weintraub et al., 2010a), and 7.4% of patients on DA 
(Nakum and Cavanna, 2016). Compulsive shopping can affect 0.7% (Voon et 
al., 2006a), 3.4% (Lee et al., 2010) and 5.7% (Weintraub et al., 2010a) of PD 
patients anytime during disease duration. Only one paper from the United 
States assessed the prevalence of compulsive eating, showing that it affects 
4.3% of American PD patients (Weintraub et al., 2010a). DDS affects between 
3.4 and 4.1% of PD patients on dopaminergic treatment (Djamshidian et al., 
2011a, Giovannoni et al., 2000). Punding affects from 1.4% (Miyasaki et al., 
2007) to 4.2% (Lee et al., 2010) of individuals with PD, up to 14% of patients on 
higher doses of dopamine replacement therapy (Evans et al., 2004). Hoarding 
behaviours is present in 28% of individuals with PD and ICBs and 3.5% of PD 
patients without ICBs (PD-ICB) (O'Sullivan et al., 2010b).  
 
1.2.2 Risk factors and associated clinical features 
 
Risk factors for developing ICBs include the use of dopaminergic medication, 
younger age at PD onset, higher novelty seeking personality trait, male sex, a 
personal or family history of addictive behaviours and a past or family history of 
depression (Averbeck et al., 2014). One study found a higher likelihood of 
developing ICBs in PD patients with preserved cognition, however the overall 
prevalence of ICBs reported was 8.1%, raising the possibility of underestimation 
(Poletti et al., 2013). Regarding the different types of ICBs, longer disease 
duration has been reported as a risk factor for DDS (Katzenschlager, 2011), 
and longer PD duration and the presence of dyskinesias as risk factors for 
punding (Yoo et al., 2015).  
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Dopaminergic therapy is the only modifiable risk factor for ICBs, after initiation 
of dopamine replacement therapy there is a cumulative increase in the risk of 
developing these behavioural abnormalities over time (Smith et al., 2015). 
Although levodopa has also been associated with the development of ICBs in 
PD, the most important risk factor is DA therapy (Weintraub et al., 2010a, Voon 
et al., 2007), as confirmed by several epidemiological studies assessing PD 
populations from different countries (Weintraub et al., 2010a, Giladi et al., 2007, 
Bastiaens et al., 2013, Weintraub et al., 2006). Hassan and colleagues 
assessed 321 PD patients on DA and found that 16% of them had ICBs, 
however if only patients on therapeutic doses of agonists were considered 
(defined by the authors as doses equal or higher than 2 mg of pramipexol or 6 
mg of ropinirole daily) the number of individuals affected reached 24% (Hassan 
et al., 2011). Garcia-Ruiz and colleagues studied PD patients using DA for at 
least 6 months and reported an even higher prevalence of ICBs: 39% (Garcia-
Ruiz et al., 2014). A similar prevalence was found in a prospective study that 
followed up PD patients for a maximum period of four years. Among 46 patients 
on DA, 39.1% developed ICBs after a mean period of 21 months (Bastiaens et 
al., 2013). Another study conducted with PD patients from three Latin American 
countries, Argentina, Colombia and Ecuador, reported an overall prevalence of 
ICBs of 27.45%, but among patients who received DA at some point, ICBs 
occurred in 34.7% (Ramirez Gomez et al., 2017). Two studies have reported an 
association between higher doses of DA and the development of ICBs in PD: a 
prospective study found a positive correlation between higher peak DA doses 
and ICBs (Bastiaens et al., 2013), and a recently published longitudinal study 
reported that larger doses and longer duration of DA use contributes to higher 
prevalence of ICBs (Corvol et al., 2018). 
 
Research with animal models support the association between DA and ICBs. 
Ropinirole has been shown to increase risky behaviours in a rodent model of 
gambling behaviour (Tremblay et al., 2016) and pramipexole has been 
associated with risky choices in a rodent model of PD (Rokosik and Napier, 
2012). The development of behavioural addictions in individuals using 
dopaminergic drugs for medical conditions other than PD is another factor 
corroborating this association. Among patients receiving treatment for RLS the 
prevalence of ICBs varies from 5 to 17% (Driver-Dunckley et al., 2007, 
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Pourcher et al., 2010, Cornelius et al., 2010), furthermore only RLS patients 
using dopaminergic medications develop behavioural addictions (Cornelius et 
al., 2010). ICBs have also been reported in patients using DA to treat pituitary 
adenomas (Martinkova et al., 2011), multiple system atrophy (Klos et al., 2005), 
progressive supranuclear palsy (O'Sullivan et al., 2010a) and 
tetrahydrobiopterin deficiency (Porta et al., 2016).  
 
Different types of DA may carry a lower risk of triggering ICBs. Apomorphine is 
a dopamine agonist which binds preferentially to dopamine D1 receptors (D1R) 
and dopamine D2 receptors (D2R), resembling more levodopa in its 
pharmacokinetic properties compared to other agonists. No randomized clinical 
trials have assessed apomorphine’s proclivity to induce ICBs, but initial reports 
point to a better risk profile compared to other DA (Todorova et al., 2015, 
Martinez-Martin et al., 2014). Rotigotine is a DA that is delivered through a 
cutaneous patch. Although some authors have reported a lower prevalence of 
ICBs on patients using this drug compared to pramipexole and ropinirole 
(Garcia-Ruiz et al., 2014, Todorova et al., 2013, Antonini et al., 2016), 
randomized clinical trials are needed to provide a definitive answer to this 
question. 
 
Specific types of ICBs might be associated with different types of dopaminergic 
medication. Pathological gambling and compulsive eating appear to be much 
more common with oral DA therapy (Djamshidian et al., 2011b), whereas DDS 
is more commonly seen with levodopa (Katzenschlager, 2011) and punding 
with drugs that stimulate D1R and D2R (Fasano and Petrovic, 2010). Data on 
the propensity of other PD medications to induce ICBs originate mainly from 
case reports and observational studies. Although both amantadine and 
monoamine oxidase inhibitors (MAOi) appear to be safer than DA, contradictory 
data is available on the propensity of amantadine to induce ICBs and case 
reports of ICBs in patients using MAOi have been published (Averbeck et al., 
2014).  
 
Most of the previously cited prevalence studies confirm previous findings that 
individuals who develop PD at an earlier age are at increased risk of developing 
ICBs (Weintraub et al., 2010a). In fact, ICBs have been reported to affect up to 
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58.3% of individuals with onset of PD before the age of 45 (Vela et al., 2016). 
Sex can influence the development of specific types of ICBs. CSB has been 
more frequently reported in males, whereas females more commonly develop 
compulsive shopping and compulsive eating (Djamshidian et al., 2011a). 
 
The data on the association between REM sleep behaviour disorder (RBD) and 
ICBs is contradictory, which could be a consequence of the different methods 
used by researchers to diagnose both conditions. Kim and colleagues studied 
994 patients for the presence of RBD and found a higher incidence of ICBs in 
these individuals, however the RBD group was on higher levodopa equivalent 
daily dosage (Kim et al., 2014). Whilst another group has also found a positive 
association between RBD and ICBs in PD patients (Fantini et al., 2015), two 
studies with smaller sample sizes have not found such association (Postuma et 
al., 2008, Romenets et al., 2012). Another study, the only one that used video-
polysomnography, found no association between RBD and ICBs (Bayard et al., 
2014). Nonetheless, sleep problems are common in patients with PD and ICBs 
and can be a consequence of increased impulsivity levels or the putative 
association between ICBs and RBD (Djamshidian et al., 2015). 
 
Impulsivity predating PD onset may be a risk factor for ICBs (Weintraub et al., 
2006) as shown by a study from Italy. The authors identified impulse control 
disorders in 17.5% of drug-naïve PD patients, similar to healthy controls, 
showing that subclinical impulsivity can be common in PD and could, 
theoretically, contribute to the development of ICBs (Antonini et al., 2011). The 
side of onset of PD symptoms has been shown to influence novelty seeking 
personality trait. Harris and colleagues found that patients with right-onset PD 
using DA exhibited higher levels of novelty seeking compared to patients with 
PD onset on the left side, suggesting that the former group is at higher risk of 
developing impulse control disorders. The authors postulated that higher 
premorbid dopamine levels in the left striatum could contribute to excessive 
stimulation of its ventral part by dopaminergic drugs and lead to the 





1.2.3 Cognitive, behavioural and neuropsychiatric features 
 
PD patients with ICBs (PD+ICB) have worse quality of life (Alvarado-Bolanos et 
al., 2015) and more functional impairment (Voon et al., 2011b) when compared 
to PD patients with no behavioural addictions. Moreover, carers of individuals 
with PD report greater burden of care when ICBs are present (Leroi et al., 
2012b). Not only do PD+ICB tend to suffer more from depression (Phu et al., 
2014) and anxiety (Voon et al., 2011b), but depression is more severe when 
multiple ICBs are present (Wu et al., 2015). Anxiety and worse autonomic and 
cognitive functions can be present in PD+ICB at the time of PD diagnosis, 
before the development of behavioural addictions (Ricciardi et al., 2018). 
Greater obsessive-compulsive symptoms have been reported in PD+ICB 
compared to PD-ICB (Voon et al., 2011b). Patients with PD and DDS display 
more neuropsychiatric symptoms such as depression, irritability, and 
disinhibition, when compared to PD without DDS (Cilia et al., 2014). 
Alexithymia, a personality trait characterised by difficulty in processing 
emotions, appears to be more common in PD compared to healthy individuals 
and may contribute to the development of ICBs (Ricciardi et al., 2015). 
 
Motor and reflection impulsivity, with consequences on decision making, have 
been reported in PD+ICB. In the beads task participants are asked to guess 
from which of two cups coloured beads are being drawn. The cups have 
different proportions of beads of two colours and participants are charged for 
each bead drawn. Rewards are given for correct guesses and wrong guesses 
are penalised (Averbeck et al., 2014). This task has been used by Djamshidian 
and colleagues to show that PD+ICB have reflection impulsivity. In essence, 
these individuals gather less information before making a decision, when 
compared to PD-ICB and healthy controls (Djamshidian et al., 2012b). 
Reflection impulsivity has also been described in PD patients being treated with 
DA that have not developed ICBs (Djamshidian et al., 2013). Other 
abnormalities on decision making have been reported, with PD+ICB showing 
decreased learning from negative feedback and increased learning to positive 
feedback in OFF medication, and increased learning to negative feedback when 
ON medication (Djamshidian et al., 2010, Djamshidian et al., 2012a), the 
opposite of what has been found in PD-ICB (Frank et al., 2004). 
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The Kirby questionnaire tests participants’ preference for immediate or delayed 
small, medium or large monetary rewards and has been used as a measure of 
impulsivity and delay discounting, preference for smaller rewards over delayed 
larger rewards. Housden and collaborators found that PD+ICB have highly 
elevated delay discounting, suggesting that ICBs are a consequence of 
stronger preference for immediate over future recompenses rather than an 
overvaluation of rewards (Housden et al., 2010), although inappropriate 
subjective estimation of rewards has also been demonstrated in PD+ICB 
(Pineau et al., 2016). Interestingly, delay discounting has also been reported in 
PD-ICB receiving treatment with DA (Milenkova et al., 2011) and in non-
medicated PD patients without overt ICBs, raising the question whether 
impulsive decision making occur as part of the disease or as a consequence of 
the use of DA (Al-Khaled et al., 2015). Risk taking behaviour has been 
associated with dopaminergic therapy in PD patients (Djamshidian et al., 2010), 
and has been reported in patients with pathological gambling (Djamshidian et 
al., 2010) and compulsive shopping using DA (Voon et al., 2011a). 
 
Contradictory data has been published on executive dysfunction in PD+ICB. 
While poor performance on working memory tasks has been described in 
comparison to PD-ICB (Djamshidian et al., 2010), comparable performance on 
the Stroop test has been reported (Djamshidian et al., 2011c). Cognitive 
function does not deteriorate faster in PD+ICB as shown by a prospective study 
assessing 40 individuals at baseline and 2 years later, whereby the authors did 
not report greater cognitive impairment or executive dysfunction in patients with 




ICBs appear to be associated with abnormalities of dopaminergic transmission 
and two main phenomena have been implicated in the genesis of these 
behavioural problems: excessive dopamine release in the ventral striatum and 
excessive dopamine D3 receptor (D3R) stimulation. 
 
The notion that ICBs are a consequence of excessive dopaminergic stimulation 
of the ventral striatum derives from knowledge about the normal functioning of 
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the dopaminergic reward system and observations from functional 
neuroimaging studies in drug addiction and PD+ICB. Under normal 
circumstances, there is tonic release of dopamine from the ventral tegmental 
area into the nucleus accumbens (NAc), in the ventral striatum. Changes in this 
tonic release occurs in response to stimuli, with rewarding activities resulting in 
an increase in dopamine release, and non-rewarding outcomes leading to a 
decrease. Dopaminergic connections between the ventral striatum and the 
orbitofrontal cortex are vital to the brain’s valuation process and influence 
decision making, i.e. a positive outcome means that the action will be 
associated with a higher probability of reward in the future, and in negative 
outcomes the ventral striatum signals to the orbitofrontal cortex that the stimulus 
has a higher future probability of negative outcome (Damier, 2015) (figure 1 on 
page 27).  
 
It has been postulated that in PD there is prominent loss of dopaminergic 
neurons in the dorsal striatum with relative preservation of the ventral striatum.  
The use of dopaminergic medication to treat PD symptoms could, therefore, 
overdose the ventral striatum and disrupt the decision making process, leading 
to the development of ICBs (Djamshidian et al., 2011b). This idea has been 
supported by functional neuroimaging studies. In PD patients with DDS, 
levodopa has been shown to induce excessive release of dopamine in the 
ventral striatum (Evans et al., 2006). The same finding has been reported in PD 
patients with other types of ICBs, including pathological gambling, CSB, 
compulsive shopping, compulsive eating and punding (O'Sullivan et al., 2011). 
Many authors have classified ICBs as behavioural addictions because similar 
phenomena have been observed in drug addiction. Functional neuroimaging 
has also been used to report greater decreases in binding potential in the 
ventral striatum of individuals with PD and pathological gambling, which could 
be a consequence of increased dopamine release or reduced D2R and D3R 
availability (Steeves et al., 2009). In PD patients with CSB the increased sexual 
desire and hedonic response has been correlated with activation of the ventral 




Figure 1. Important structures of the dopaminergic reward pathway.  
 
There is tonic release of dopamine from the ventral tegmental area (VTA, in 
dark red) into the nucleus accumbens (NAc, in purple) that changes according 
to the rewarding nature of a stimulus. Increases in dopamine release as a 
consequence of rewarding stimuli will reduce the prefrontal cortex (PFC, in 
blue) input via D2 inhibitory pathways and increase the hippocampal subiculum 
input (in dark grey) through D1 excitatory connections. Non-rewarding stimuli 
results in a reduction in dopamine release, removing the input from the 















Data from clinical observational studies showing that DA are the strongest risk 
factor for ICBs (Weintraub et al., 2010a) coupled with the fact that all DA are 
agonists of D3R is the basis to the theory that impulse control disorders in PD 
are a consequence of excessive D3R stimulation. In fact, most of the clinically 
available DA have higher affinity for D3R compared to D2R and the avidity with 
which a DA binds the D3R in comparison to the D2R has been correlated with 
increased risk of ICBs as displayed in figure 2 on page 29 (Seeman, 2015). 
Supporting this idea, stimulation of dopamine receptors by DA impair negative 
feedback signalling (van Eimeren et al., 2009) and PD+ICB using DA have a 
tendency to consider outcomes as “better than expected” (Voon et al., 2010). 
 
Other functional abnormalities have also been associated with ICBs in PD, such 
as a defective inhibitory network and a functional disconnection between brain 
structures involved in reward processing (van Eimeren et al., 2010, Premi et al., 
2016). Lower availability of the dopamine transporter in drug-naïve PD patients 
has been retrospectively associated with the development of IBCs (Vriend et al., 
2014) but similar findings have also been reported in PD+ICB and could mean 
either downregulation of the transporter or a pre-existing trait (Cilia et al., 2010). 
Other neurotransmitters might also be implicated in ICBs according to a recent 
publication where the authors reported a significant association between 
tryptophan hydroxylase type 2 gene variant, the severity of addictive behaviours 
and lower remission rates in PD patients (Cilia et al., 2016). 
 
Preliminary studies have suggested a role for genetic polymorphisms in the 
development of ICBs (table 2 on page 30). In healthy individuals, ropinirole can 
either increase or decrease impulsivity according to the expression of five 
genes: catechol-O-methyltransferase, dopamine transporter and genes 
encoding D1R, D2R and D3R (MacDonald et al., 2016). DRD1, DRD2 and 
GRIN2B gene variants have been associated with increased risk for ICBs in PD 
patients from Malaysia (Zainal Abidin et al., 2015). In Indian PD patients, one 
variant of the DRD3 gene has been positively correlated with ICBs 
(Krishnamoorthy et al., 2016). Variation in OPK1, HTR2A and DDC have also 
been reported to increase the risk for ICBs (Kraemmer et al., 2016). Genome-
wide association studies involving larger number of participants are needed to 
confirm these findings. 
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Figure 2. Dopamine D3 receptors and impulse control disorders.  
 
The image shows the proportion of patients who develop impulse control 
disorders (y axis) when using dopamine agonists with different levels of affinity 
to dopamine D3 receptor relative to D2 (x axis). There is a direct correlation 
between the development of impulse control disorders and dopamine agonist 
selectivity of dopamine D3 receptors relative to D2. Reproduced with 














Table 2. Genetic polymorphisms studies of PD patients with ICBs  
Study Country Participants Genes Results 
Zainal Abdin et 
al, 2015 
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Overview of previous studies investigating genetic polymorphisms in PD+ICB. 
PD+ICB – patients with Parkinson’s disease and impulsive compulsive 
behaviours; PD-ICB – patients with Parkinson’s disease without impulsive 
compulsive behaviours; DRD1 – dopamine D1 receptor; DRD2 – dopamine 
D2 receptor; DRD3 – dopamine D3 receptor; DRD4 – dopamine D4 receptor; 
DRD5 – dopamine D5 receptor; GRIN2B – N-methyl-D-aspartate 2B; HTR2A 
– serotonin receptor; COMT – catechol-O-methyltransferase; DAT – 
dopamine transporter;  DDC – dopa decarboxylase;  ADRA2C – adrenergic 






1.2.5 Diagnosis  
 
PD patients have a tendency to under-report adverse events from medication, 
which is more evident with neuropsychiatric symptoms, such as ICBs (Perez-
Lloret et al., 2012b). Additionally, lack of insight and deliberate concealment can 
further contribute to under-reporting of ICBs (Averbeck et al., 2014). This 
potentially leads to late diagnosis of behavioural addictions, bringing serious 
consequences to patients’ lives, such as debt and deterioration of personal 
relationships. Timely and accurate detection of ICBs is vital to avoid such 
complications. 
 
Although many screening instruments for ICBs have been developed, the most 
widely used is the QUIP (Weintraub et al., 2009). It is a sensitive instrument 
whether completed by the patient or carer with 100% negative predictive value, 
and a positive predictive value of approximately 37%. Agreement between 
patient and informant is higher for gambling and lower for buying, eating and 
CSB, which can be the result of lack of insight or that the latter behaviours are 
more likely to be concealed (Papay et al., 2011). Another version of the QUIP 
was developed subsequently, the QUIP-RS (Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease - Rating scale) (figure 3 on page 
32) which not only identifies ICBs but also measure their severity with good 
sensitivity and specificity values (Weintraub et al., 2012). However, relying 
solely on screening tools such as the QUIP to diagnose ICBs can result in a 
large number of false positives, meaning that the golden standard method for 
diagnosing ICBs is the clinical interview. Ideally the interview should include the 




Figure 3. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s 
Disease – Rating Scale (QUIP-RS). 
 
The QUIP-RS is a screening tool designed to detect and measure the severity 
of the following ICBs: pathological gambling, compulsive sexual behaviour, 
compulsive shopping, compulsive eating, punding/hobbyism and dopamine 
dysregulation syndrome. Four main questions assess how much each ICB 
interfere with patients’ daily lives. The higher the total score, the more severe 




Vigilance is required whenever a patient is started on DA. In the case of 
patients who have already developed ICBs, it is important to involve relatives, 
carer and general practitioner to provide adequate support and limit access to 
medication when needed, particularly in cases of DDS. It may also be 
necessary to limit access to finances in cases of compulsive shopping and 
pathological gambling. Poor or lacking caregiving/social support is associated 
with worse DDS outcome and relapses (Cilia et al., 2014). 
 
The main treatment strategy for ICBs is the reduction of dopaminergic 
medication (Averbeck et al., 2014). In patients with DDS, reduction of 
dopaminergic therapy is the most effective treatment with greater success rates 
seen when reductions of more than 55% of levodopa compared to baseline are 
achieved (Cilia et al., 2014). In PD+ICB using DA, reduction and withdrawal of 
this drug is the treatment of choice, as corroborated by several observational 
studies (Bastiaens et al., 2013, Sohtaoglu et al., 2010, Mamikonyan et al., 
2008, Macphee et al., 2009). When tapering a DA it is important to monitor 
patients for dopamine agonist withdrawal syndrome (DAWS), which causes 
distressing physical and psychological symptoms (Nirenberg, 2013). DAWS can 
affect 15 to 19% of individuals with PD on DA (Rabinak and Nirenberg, 2010, 
Pondal et al., 2013, Cunnington et al., 2012) and is defined by Rabinak and 
Nirenberg as ‘a severe, stereotyped cluster of physical and psychological 
symptoms that correlate with DA withdrawal in a dose dependent manner, 
cause clinically significant distress or social/occupational dysfunction, are 
refractory to levodopa and other PD medications, and cannot be accounted by 
other clinical factors’ (Rabinak and Nirenberg, 2010). Psychiatric symptoms 
such as depression, anxiety, agitation and dysphoria are common and can be 
accompanied by nausea, dizziness, generalised pain, diaphoresis and drug 
cravings. These symptoms do not respond to antidepressants, benzodiazepines 
or levodopa and usually subside when the DA is reinstated. Risk factors for 




Cognitive behavioural therapy can be useful in the treatment of PD+ICB. 
Individuals with lower burden from ICBs, better social input and on lower doses 
of antiparkinsonian medication are the ones with the greater potential to derive 
benefit from this intervention (Okai et al., 2015). 
 
A clinical trial of naltrexone involving 50 patients with PD and impulse control 
disorders failed to achieve its primary outcome measure, the clinician-rated 
global impression of change scale. However, there was a reduction in severity 
of symptoms leading the authors to conclude that further studies are needed 
(Papay et al., 2014). There are case reports of improvement of PD+ICB with 
diverse drugs: quetiapine in pathological gambling (Sevincok et al., 2007); 
clozapine for CSB with paraphilias (Fernandez and Durso, 1998) and 
pathological gambling (Rotondo et al., 2010); valproate for CSB, pathological 
gambling, walkabout behaviour and DDS (Hicks et al., 2011); carbamazepine 
for CSB (Bach et al., 2009); topiramate for CSB, pathological gambling, 
compulsive shopping and compulsive eating (Bermejo, 2008); zonisamide for 
CSB, pathological gambling, compulsive shopping and compulsive eating 
(Bermejo et al., 2010); finasteride for pathological gambling (Bortolato et al., 
2012); naltrexone for pathological gambling (Bosco et al., 2012); donepezil for 
CSB (Ivanco and Bohnen, 2005); and amantadine for pathological gambling 
(Thomas et al., 2010). Amantadine has also been assessed in larger studies 
with contradictory results. Whilst a randomized crossover study involving 17 PD 
patients with pathological gambling refractory to reduction or cessation of  DA 
showed resolution of the abnormal behaviour in 7 (Thomas et al., 2010), a 
retrospective analysis of the DOMINION study cohort showed that the use of 
amantadine was associated with impulse control disorders (Weintraub et al., 
2010b). Psychiatric complications of DDS such as psychosis and aggressive 
behaviour can be managed with clozapine (Cilia et al., 2014). 
 
Preliminary data available on infusion therapies for PD, apomorphine and 
levodopa intestinal gel, suggests a lower risk profile for triggering ICBs 
(Martinez-Martin et al., 2014, Todorova, 2013), with the exception of one study 
involving 15 patients on levodopa-carbidopa intestinal gel that reported 4 de 
novo cases of ICBs (Chang et al., 2016). 
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Deep brain stimulation (DBS) is a highly effective treatment for PD with 
evidence supporting its use in individuals with young onset PD and early in the 
course of the disease (Schuepbach et al., 2013). Several studies have 
addressed its safety in PD+ICB generating contradictory data. One study 
assessed 56 patients receiving DBS of the subthalamic nucleus (STN) for up to 
3 years. Thirteen patients had ICBs before surgery and, three years after, 11 of 
them had fully remitted and the remaining two improved partially. However, this 
effect can be explained by concomitant reduction of DA dose. Six patients 
developed new onset ICBs after surgery with spontaneous recovery afterwards 
(Amami et al., 2015). Ardouin and colleagues followed up 7 patients with 
pathological gambling after DBS of the STN. All cases resolved after an 
average period of 18 months concomitant with reduction of 74% of the 
dopaminergic treatment (Ardouin et al., 2006). One-hundred and fifty PD 
patients with STN DBS were assessed for pre and post-surgical prevalence of 
ICBs. The authors found that two thirds of the patients experienced remission 
with chronic DBS, with significant improvement in CSB, gambling and DDS. 
Eleven patients developed new-onset ICBs (Merola et al., 2016). A meta-
analysis showed that 27 studies with different methodologies addressed the risk 
profile of DBS for ICBs. Out of 226 patients reviewed, 88 de novo cases were 
reported, 138 had ICBs before surgery. One-hundred and thirty underwent 
bilateral STN DBS with 79% of the patients improving. Among these, de novo 
ICBs were reported in 15.11% (Kasemsuk et al., 2017). There is not enough 
data on the literature to assess if stimulation of the pallidus is safer than 
stimulation of the STN. Improvement of ICBs seen in some patients after STN 
DBS is likely a consequence of concomitant reduction of dopamine replacement 
therapy. A definitive answer to this questions could be provided by future 




Limited data is available on the long-term prognosis of ICBs. Cross-sectional 
and prospective studies have been published with the longest of them covering 
a period of four years. In common, these studies report that more than two 
thirds of patients improve and improvement is dependent on a significant 
reduction of DA dose (Mamikonyan et al., 2008, Sohtaoglu et al., 2010, 
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Bastiaens et al., 2013). However, QUIP scores may remain high even after 
improvement (Ramirez Gomez et al., 2017) and a significant proportion of 
patients fail to achieve remission. 
 
1.3 Aims of this thesis 
 
In chapter 2 the long-term prognosis of ICBs is examined. A population of 
PD+ICB was re-assessed after approximately 8 years of follow up. Data on 
remission rate, treatment strategies, neuropsychiatric and clinical features is 
provided. 
 
Chapter 3 describes clinical studies that have focused in specific types of ICBs. 
CSB was compared to other types of ICBs and its association with clinical and 
neuropsychiatric features and dopaminergic treatment investigated. The 
outcome of DDS until death was assessed in a population of patients who 
donated their brains for research. The clinical and neuropsychiatric features of 
punding were assessed in comparison to PD-ICB. The propensity of 
apomorphine continuous infusion to trigger ICBs was analysed in a population 
of individuals with advanced PD. 
 
Automatic and voluntary saccadic eye movements of PD+ICB were investigated 
for the first time in chapter 4. Results were compared to PD-ICB and healthy 
controls. Data on saccadic metrics obtained from both pro-saccades and anti-
saccades tasks are revealed as well as participant’s ability to suppress 
automatic saccades, measured by the proportion of anti-saccadic direction 
errors. 
 
Chapter 5 describes the first post mortem study of individuals with PD and DDS. 
Using immunohistochemistry techniques, the amount of alpha-synuclein 
pathology and tyrosine hydroxylase staining was assessed in the NAc, dorsal 
putamen and dorsal caudate of individuals with ICBs and compared to 
individuals who had PD but did not report ICBs in life. The levels of D2R and 
D3R in the NAc, putamen and frontal cortex were also compared using western 
immunoblotting.  
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Chapter 2: The long-term outcome of impulsive 




The main risk factors for developing ICBs are a younger age of PD onset, male 
sex and dopaminergic treatment, particularly DA (Weintraub et al., 2010a). 
Whilst 1 in 7 patients with PD will develop these behavioural abnormalities, the 
5-year cumulative incidence of ICBs was reported to be 46.1% in a recent 
longitudinal study (Corvol et al., 2018). Furthermore, up to 39% of PD patients 
on therapeutic doses of DA develop ICBs after 6 months of treatment (Garcia-
Ruiz et al., 2014).  
 
Few studies have assessed the outcome of ICBs. In one of them, 10 out of 15 
patients interviewed by phone after 29 months were completely free of ICBs 
(Mamikonyan et al., 2008). In another study, 22 patients were reassessed after 
43 months and only six were considered by their families and doctors to still 
have troublesome ICBs (Sohtaoglu et al., 2010). In both cases a significant 
proportion of patients successfully stopped or markedly reduced the dose of 
DA. In a prospective non-interventional study, 1069 PD patients were followed 
up for two years revealing that approximately one third had developed ICBs. 
The prevalence of behavioural addictions remained stable throughout the study 
period (Antonini et al., 2017). 
 
Longitudinal data on a large group of PD+ICB who were followed up for a mean 
period of 8.2 years is presented here, representing the largest and longest 
follow up study to date. Motor symptoms, neuropsychiatric complications, 








2.2 Materials and methods 
 
2.2.1 Study design and patient selection 
 
PD+ICB who participated in previous studies (visit 1 – V1) at the National 
Hospital for Neurology and Neurosurgery, Queen Square, London, from 2007 to 
2012 were invited to attend a new assessment between 2016 and 2017 (visit 2 
– V2). All patients had received a diagnosis of ICBs during an interview 
conducted by a movement disorders specialist. At V1, participants were 
assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS) part III 
and an interview to collect clinical and treatment data, focusing on ICBs, 
cognition, dopaminergic treatment, motor and neuropsychiatric symptoms. 
 
The study received approval by the Queen Square Ethics Committee and all 
patients gave informed consent. A few days before V2, patients received the 
following self-assessment questionnaires via post: The QUIP-RS, the Hospital 
Anxiety and Depression Scale (HADS) and the 36-Item Short Form Survey 
(SF36). Subsequently, patients were assessed during a hospital visit or at home 
(V2), if they were unable to make the journey to the hospital. During this 
assessment, demographic and clinical data were collected and the following 
scales/questionnaires used: the UPDRS parts I and III during ON period, the 
Abnormal Involuntary Movement Scale (AIMS), the Frontal Assessment Battery 
(FAB) and the Montreal Cognitive Assessment (MoCA). 
  
The diagnosis of ICBs at V2 was made based on the QUIP-RS scores using 
previously published cut-off values (Weintraub et al., 2009) and confirmed with 
a structured interview, conducted with the patient and spouse/carer when 
available. The interview contained questions that addressed each diagnostic 
criteria for impulse control disorders from the Diagnostic and Statistical Manual 
of Mental Disorders IV. Since specific diagnostic criteria for dopamine 
dysregulation syndrome and punding are not available in the DSM-IV, proposed 
criteria from Giovannini et al (Giovannoni et al., 2000) and O’Sullivan et al 
(O'Sullivan et al., 2007) were also included in the interview. When the results of 
the QUIP-RS and the interview were discordant, the definitive diagnosis of ICBs 
was based on the interview. 
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2.2.2 Statistical analysis 
 
Anonymised data was imported to SPSS 22 for statistical analysis. All variables 
were tested for normality and the appropriate statistical tests chosen 
accordingly. Parametric data was analysed using independent samples t-test 
and paired samples t-test. Non-parametric data was analysed using Mann-
Whitney U test and Wilcoxon matched pairs. Proportions were compared with 
the McNemar’s test and Pearson chi-square test; the latter was replaced with 
the Fisher’s exact test if the minimum expected cell count was less than five. A 
p value of less than 0.05 was considered significant, except for comparison 
between visits, when Bonferroni correction was applied and significance was 






Ninety individuals who were assessed at V1 were identified. Among these, 46 
were included in this study. Eight declined to participate, five were lost to follow 
up and 31 had died (figure 4 on page 40). Death certificates were available for 
26 patients. Respiratory conditions were the most common cause of death (13 
patients – 11 pneumonia and 2 pulmonary embolism), followed by PD (5 
deaths) and cancer (3 cases). Cardiac arrhythmia, old age, sepsis, stroke and 
gastro-intestinal bleed were the cause of death in one case each. No cases of 
suicide or traumatic fatality were reported. 
  
2.3.2 Demographic and clinical data of the entire cohort 
 
The study population consisted mostly of males with early onset PD and mean 
disease duration of 17 years. Mean follow up duration was just over 8 years. 
Three patients had been diagnosed with a genetic form of PD, all three carrying 
a bi-allelic PARKIN mutation. At V2, 3 patients were in residential care, and 4 
on atypical neuroleptic drugs. Deceased patients were older at disease onset 




Figure 4. The outcome of impulsive compulsive behaviours (ICBs) according to 
treatment strategies. 
 
Ninety patients were assessed at visit 1 and 46 were available for visit 2. Whilst 
27 patients were still being troubled by ICBs, 19 had experienced complete 
remission. The most used treatment strategies in both groups were: cessation 
of DA, reduction of DA and reduction of levodopa. 44 patients were unavailable 
















Visit 1 Visit 2 Treatment
90 patients with ICBs




10 Cessation of DA
6 Reduction of DA
3 Reduction of levodopa
19 Cessation of DA
7 reduction of DA
1 reduction of levodopa
44 unavailable
8 declined
5 lost to follow up
31 deceased
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Table 3. Demographic and clinical data of the entire cohort 
 N = 46 Deceased (N = 31) p value 
Male sex 37 (80.4%) 25 (80.6%) 0.982j 
Age at PD onset (years) 45.1 (± 9.6) 50.38 (± 10) 0.025* 
Disease duration (years) 17 (± 7.9) 20 (± 7.1) 0.036** 
Follow up duration (months) 98.3 (± 31.8)   
Genetic PD 3 (6.5%)   
In residential care 3 (6.5%)   
On neuroleptic drugs 4 (8.7%)   
Demographic and clinical data of the entire cohort. Demographic data from 
deceased patients was also included. Forty-six patients who were followed up 
for 8.2 years were available for reassessment. PD – Parkinson’s disease. 
Results expressed in total values and proportions or means and standard 
deviation. jchi-square test; *t-test for independent samples; **Mann-Whitney 






















2.3.3 Comparison between visit 1 and visit V2 
 
Participants’ average age was 54.7 years at V1 and 61.7 at V2. All 46 patients 
had received a diagnosis of ICBs at V1, among these 58.7% had multiple ICBs. 
At V2 more than half of the patients were still being troubled by ICBs, nearly 
60% of them had multiple ICBs. Details on the types of ICBs at each visit can 
be seen in table 4 on page 43. 
 
Apomorphine was considered separately from other DA in all comparisons. This 
decision was based on the different pharmacological profile of apomorphine 
compared to other DA. Initial treatment of ICBs consisted of cessation of 
oral/transcutaneous DA in 29 patients, reduction of DA dose in 13 and reduction 
of levodopa in 4. Among the patients who stopped or reduced 
oral/transcutaneous DA, seven (16.6%) developed DAWS. Of the 46 patients, 
19 improved completely and were asymptomatic at V2, 26 improved partially 
and 1 had no change of the addictive behaviour. None of the patients 
experienced worsening of ICBs over time. Five patients re-started 
oral/transcutaneous DA during disease course. Details on the outcome of ICBs 
according to treatment can be seen in figure 4.  
 
Average UPDRS part III scores and the prevalence of levodopa-induced 
dyskinesias increased significantly between the two assessments (table 4). The 
cognitive status of all 46 patients at V1 was available: four had been diagnosed 
with mild cognitive impairment, 2 had significant cognitive impairment and 40 
were cognitively intact. At V2, cognition was tested with the MoCA revealing 
that 32% of the patients scored below cut-off values and were considered to 
have cognitive impairment. There were no statistically significant differences on 
the prevalence of anxiety, depression and visual hallucinations between visits 
(table 4). 
 
Only five patients were not using levodopa at V1 and only two at V2. More 
participants were using MAOi and amantadine at V2. Total levodopa daily dose 
and total dopaminergic treatment dose measured in levodopa equivalent daily 
dose (LEDD) (Tomlinson et al., 2010) were significantly higher at V2 (table 4). 
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Table 4. Comparison between visits 
 Visit 1 (V1) Visit 2 (V2) p value 
Age (years) 54.7 (± 9.7) 61.7 (±10.2)  <0.001* 
ICBs 46 (100%) 27 (58.7%) <0.001l 
Multiple ICBs 27 (58.7%) 16 (59.2%) 0.754l 
DDS 6 3 0.508l 
CSB 23 13 0.052l 
Pathological gambling 13 5 0.008l 
Compulsive shopping 17 5 0.008l 
Compulsive eating 11 14 0.629l 
Punding 23 18 0.359l 
UPDRS III 16.2 (± 7.8)  34.65 (± 11)  <0.001* 
Dyskinesias 29 (63%) 38 (82.6%) 0.022l 
Cognitive impairment 2 (4.3%) 15 (32.6%) 0.001l 
Depression 14 (30.4%) 11 (23.9%) 0.629l 
Anxiety 8 (17.4%) 15 (32.6%) 0.118l 
Hallucinations 10 (21.7%) 12 (26.1%) 0.754l 
Levodopa use 41 (89.1%) 44 (95.6%) 0.375l 
DA use 42 (91.3%) 18 (39.1%) <0.001l 
MAOi use 8 (17.4%) 28 (60.9%) <0.001l 
Amantadine use 16 (34.8%) 37 (80.4%) <0.001l 
Levodopa dose 713.7 (± 487) N=41 1021 (± 437) N=44 0.001j 
DA LEDD 255.6 (± 113) N=42 153.4 (± 86.9) N=18 0.003j 
Total LEDD 979.6 (± 542.8) 1296.6 (± 457.7) <0.001j 
Infusion therapies Apomorphine: 
2.1% 
Apomorphine: 6.5%  
Duodopa: 2.1% 
 
Deep brain stimulation 0 11 (23.9%)  
Comparison between visits. ICBs – impulsive compulsive behaviours; DDS – 
dopamine dysregulation syndrome; CSB – compulsive sexual behaviour; 
UPDRS – Unified Parkinson’s Disease Rating Scale; DA – 
oral/transcutaneous dopamine agonists; MAOi – monoamine oxidase 
inhibitor; LEDD – levodopa equivalent daily dose. Results expressed in total 
values and proportions, or mean values and standard deviation. A p value of 
less than 0.025 was considered significant (in bold) after Bonferroni 
correction. *paired t-test; j Wilcoxon matched pairs; l McNemar’s test.  
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At V1, 42 patients were using oral/transcutaneous DA: 27 pramipexole, 12 
ropinirole, 1 rotigotine, 1 bromocriptine and 1 cabergoline. Eighteen patients 
were using DA at V2: 8 were using pramipexole, 3 ropinirole and 7 rotigotine. 
There was a significant reduction of oral/transcutaneous DA use at V2. 
Regarding advanced therapies, 1 patient was using apomorphine infusion at 
V1; at V2 3 patients were using apomorphine infusion and 1 duodopa intestinal 
gel. Eleven participants underwent DBS, 10 of the subthalamic nucleus and 1 of 
the globus pallidus (table 4). 
 
Additional scales and questionnaires were used at V2 to assess severity of 
ICBs, neuropsychiatric complications, quality of life, severity of PD, involuntary 
movements and cognitive status. Results can be seen in table 5 on page 45. 
 
2.3.4 Comparison between patients who experienced remission and patients 
with persistent ICBs  
 
Participants were divided into two groups based on the presence of ICBs at V2: 
PD patients with active ICBs (PD+V2ICB) and patients who experienced 
complete remission of ICBs (PD-V2ICB); and compared to identify any factors 
associated with long-term remission as detailed in table 6 on page 46. There 
were no differences in clinical and demographic data, marriage status and 
duration of follow up. Oral/transcutaneous DA LEDD and levodopa daily dose, 
as well as peak DA dose did not differ between groups. PD+V2ICB patients 
used DA for longer and were on higher total LEDD but the difference did not 
reach significance. 
 
The scores on the QUIP-RS, HADS total, HADS depression and UPDRS part I 
were higher on the PD+V2ICB group. Results of the other scales/questionnaires 
did not differ. Although patients with ICBs did not have higher burden of motor 
symptoms on the UPDRS III, Hoehn & Yahr results were different with more 






Table 5. Results of the scales/questionnaires used at visit 2 
 N = 46 
QUIP-RS 33.7 (± 19.2; 4 – 78) 
HADS depression 8 (± 3.5; 1 – 16) 
HADS anxiety 8.9 (± 4.2; 2 – 20) 
HADS total 16.5 (± 6.7; 3 – 35) 
SF36 general health 33.9 (± 17.9; 5 – 80) 
SF36 physical functioning 35.1 (± 28; 0 – 95) 
SF36 role limitations due to physical health 
problems 
10.3 (± 23.9; 0 – 100) 
SF36 role limitations due to personal or 
emotional problems 
40.5 (± 40.3; 0 – 100) 
SF36 energy/fatigue 36.8 (± 15.5; 10 – 65) 
SF36 emotional well being 58.5 (± 19.3; 2 – 92) 
SF36 social functioning 40.2 (± 25.6; 0 – 100) 
SF36 bodily pain 47.6 (± 30.6; 0 – 100) 
AIMS 7.8 (± 7.3; 0 – 24) 
UPDRS I 19.5 (± 8.3; 6 – 41) 
UPDRS III 34.6 (± 11; 12 – 61) 
Hoehn & Yahr 2: 52.1%  
3: 34.8%  
4: 13.1% 
FAB 15.2 (± 2.8; 6 – 18);  
MoCA 25.5 (± 4.8; 7 – 30);  
Results at visit 2. QUIP-RS – Questionnaire for Impulsive-Compulsive 
Disorders in Parkinson’s Disease – Rating Scale; HADS – the Hospital 
Anxiety and Depression Scale; SF36 – the 36-Item Short Form Survey; 
UPDRS – Unified Parkinson’s Disease Rating Scale; AIMS – Abnormal 
Involuntary Movement Scale; FAB – the Frontal Assessment Battery; MoCA – 
the Montreal Cognitive Assessment. Results expressed in mean values with 






Table 6. Comparison between patients with and without ICBs at V2 
 PD-V2ICB (N = 19)  PD+V2ICB (N = 27)  p value 
Male sex 15 (78.9%) 22 (81.4%) 1.000† 
Married 12 (63.1%) 18 (66.6%) 0.806j 
Age 61.1 (± 10.4) 62 (± 10.2) 0.769* 
Age at PD onset 45.9 (± 8.9) 44.6 (± 10.2) 0.644* 
Disease duration 15.2 (± 5.4) 18.2 (± 9.1) 0.214* 
Months of DA use 70.3 (± 41) 89.7 (± 47.5) 0.157* 
DA use (V1) 16 (84.2%) 26 (96.2%) 0.292† 
DA use (V2) 7 (36.8%) 11 (40.7%) 0.790j 
DA LEDD (V1) 227.1 (± 97.6)         
N = 16 
273.1 (± 120)         
N = 26 
0.205* 
DA LEDD (V2) 135.4 (± 69.9)        
N = 7 
164.9 (± 97.6)        
N = 11 
0.500* 
Peak DA dose 312.8 (± 104)         
N = 17 
311.6 (± 139)         
N = 27 
0.468** 
Levodopa use (V1) 17 (89.4%) 24 (88.8%) 0.950† 
Levodopa use (V2) 18 (94.7%) 26 (96.3%) 1.000† 
Levodopa daily dose 
(V1) 
622.6 (± 302)         
N = 17 
778.3 (± 582)         
N = 24 
0.320* 
Levodopa daily dose 
(V2) 
959.8 (± 450)         
N = 18 
1064.9 (±432)        
N = 26 
0.440* 
Total LEDD (V1) 907 (± 436.1) 1030.7 (± 609.7) 0.453* 
Total LEDD (V2) 1197.6 (± 438.5) 1366.2 (± 496.4) 0.241* 
MAOi (V2) 11 (68.7%) 17 (62.9%) 0.729j 
Amantadine (V2) 15 (78.9%) 22 (81.4%) 1.000† 
Dyskinesias 16 (84.2%) 22 (81.4%) 1.000† 
DBS 4 (21%) 7 (25.9%) 1.000† 
QUIP-RS 23.3 (± 16.8) 41 (± 17.5) 0.001* 
HADS depression 6.7 (± 3.3) 9 (± 3.3) 0.029* 
HADS anxiety 7.7 (± 4.1) 9.7 (± 4.1) 0.117* 
HADS total 14 (± 5.4) 18.4 (± 7) 0.026* 
AIMS 6.7 (± 6.9) 8.7 (± 7.6) 0.378* 
UPDRS I 15. (± 6) 22.3 (± 8.7) 0.003* 
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 PD-V2ICB (N = 19)  PD+V2ICB (N = 27)  p value 
UPDRS III 33.5 (± 10.4) 35.4 (± 11.5) 0.567* 







FAB 15.5 (± 2.7) 14.9 (± 2.9) 0.448* 
MoCA 26.3 (± 3.3) 24.9 (± 5.6) 0.324* 
Comparison between patients with active ICBs (PD+V2ICB) and patients who 
improved completely (PD-V2ICB) at visit 2 (V2). V1 – Visit 1; PD – 
Parkinson’s disease; DA – oral or transcutaneous dopamine agonists; LEDD 
– levodopa equivalent daily dose; MAOi – monoamine oxidase inhibitors; 
DBS – deep brain stimulation; QUIP-RS – Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease – Rating Scale; HADS – the 
Hospital Anxiety and Depression Scale; SF36 – the 36-Item Short Form 
Survey; UPDRS – Unified Parkinson’s Disease Rating Scale; AIMS – 
Abnormal Involuntary Movement Scale; FAB – the Frontal Assessment 
Battery; MoCA – the Montreal Cognitive Assessment. Results expressed in 
total values and proportion, or mean values and standard deviation. 
Significant results in bold. †Fisher’s exact test; *independent samples t-test; j 

















To investigate whether different types of ICBs were associated with different 
dopaminergic drugs, patients were again sub-divided into two groups, but this 
time based on the type of ICB present at V1: patients with DDS and/or punding 
(PD+V1DDS/pu) and PD patients with other ICBs (PD-V1DDS/pu). Statistical 
analysis showed that there were no significant differences in any of the 
variables tested as seen in table 7 on page 49. Further comparison between 
PD+V1DDS/pu and PD-V1DDS/pu according to remission status also failed to 
reveal significant differences. PD+V1DDS/pu, who were no longer actively 
demonstrating addictive behaviours at V2, still had a 40% increase in levodopa 
intake during the interval (607mg up to 1046mg/day). This compared to an 
approximately 25% increase in levodopa intake amongst patients with 

























Table 7. Comparison between patients with DDS/punding and other ICBs 
 PD+V1DDS/pu         
(N = 26)  
PD-V1DDS/pu     
(N = 20)  
p value 
Male sex 22 (84.6%) 15 (75%) 0.472† 
Age 61.7 (± 9.9) 61.6 (± 10.8) 0.956* 
Age at PD onset 44.7 (± 9.4) 45.6 (± 10.1) 0.763* 
DA use (V1) 23 (88.4%) 19 (95%) 0.622† 
DA use (V2) 13 (50 %) 8 (40%) 0.500j 
DA LEDD (V1) 264.6 (± 97.3)           
N = 23 
244.6 (± 131.5)        
N = 19 
0.574* 
DA LEDD (V2) 143.8 (± 93)             N 
= 11 
168.5 (± 79.6)            
N = 7 
0.572* 
Peak DA dose 295.3 (± 102)           N 
= 24 
332.2 (± 149)         
N= 20 
0.493** 
Levodopa use (V1) 22 (84.6%) 19 (95%) 0.369† 
Levodopa use (V2) 24 (92.3%) 20 (100%) 0.498† 
Levodopa daily dose 
(V1) 
797.1 (± 526.5)        N 
= 22 
617.2 (± 431.2)    
N = 19 
0.243* 
Levodopa daily dose 
(V2) 
1085.8 (± 461.1)       
N = 24 
945.1 (± 405.5)    
N = 20 
0.294* 
Total LEDD (V1) 1018.8 (± 599.2) 928.7 (± 469.6) 0.583* 
Total LEDD (V2) 1329.5 (± 488.1) 1253.7 (± 468.2) 0.598* 
iMAO (V2) 14 (53.8%) 14 (70%) 0.266j 
Amantadine (V2) 21 (80.7%) 16 (80%) 1.000† 
Comparison between patients with DDS and/or punding (PD+V1DDS/pu) and 
patients with other ICBs (PD-V1DDS/pu) at visit 1. PD – Parkinson’s disease; 
ICBs – impulsive compulsive behaviours; DDS – dopamine dysregulation 
syndrome; DA – oral or transcutaneous dopamine agonists; LEDD – levodopa 
equivalent daily dose; MAOi – monoamine oxidase inhibitors; Results 
expressed in total values with proportion, or mean values with standard 
deviation and range. Significant results in bold. †Fisher’s exact test; 







The long-term outcome of ICBs in a large cohort of patients with PD is 
presented in this chapter, the longest follow up study of PD+ICB to date. 
Analysis offers new insights into treatment strategies, associated clinical 
features and prognosis of this disabling condition. 
 
The treatment of choice for ICBs is reduction of dopaminergic treatment (Mestre 
et al., 2013). The literature shows that, in DDS, greater remission rates are 
seen among patients who have managed to achieve higher reduction in 
dopaminergic treatment dose (Cilia et al., 2014). In this study, all but one 
patient improved after reduction of PD treatment, confirming the strong 
association between ICBs and dopaminergic medication (Weintraub et al., 
2010a). 
 
In patients using DA, ICBs commonly improve after reduction or removal of the 
drug (Evans et al., 2009, Bastiaens et al., 2013). In line with this, previous 
reports on the outcome of ICBs found that remission is associated with 
reduction or discontinuation of DA. A retrospective study assessed 15 patients 
with PD and pathological gambling that experienced complete remission of the 
abnormal behaviour 21 months after cessation of DA (Macphee et al., 2009). In 
another study 15 PD+ICB were assessed by telephone after 29.2 months. 
Twelve participants either discontinued or significantly decreased DA and ten 
participants no longer met diagnostic criteria for ICBs (Mamikonyan et al., 
2008), however there is a possibility of under-reporting of ICBs associated with 
the telephone assessment (Mamikonyan et al., 2008). Sohtaoglu and 
collaborators reported on 22 PD+ICB after 43.2 months. Sixteen patients were 
free of addictive behaviours after a significant reduction in DA dose (Sohtaoglu 
et al., 2010). Finally, a recently published longitudinal study designed to assess 
the influence of DA in the development of impulse control disorders found a 
50% remission rate in patients who completely stopped DA (Corvol et al., 2018). 
 
The remission rate of ICBs reported here was lower than that reported by the 
aforementioned studies (Mamikonyan et al., 2008, Sohtaoglu et al., 2010), 
despite a similar proportion of patients using DA at V2 and a significant 
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reduction in DA dose between visits. Continued use of DA by a significant 
proportion of the patients is a possible explanation for the lower remission rate. 
DAWS prevented reduction of oral/transcutaneous DA in at least seven 
patients, a similar proportion to previously reported figures (Rabinak and 
Nirenberg, 2010). Undocumented DAWS may have been a factor in why other 
patients remained on DA, but this may not have been elaborated on by patients 
who (anecdotally) may simply describe “feeling better on the DA”. Another 
possibility is that following initial reduction of dopaminergic treatment and 
improvement, some patients may have experienced relapse of ICBs after 
additional increases in treatment required for disease progression as levodopa 
has also been associated with ICBs (Weintraub et al., 2010a). This is supported 
by the increase in total LEDD seen at V2 and the fact that 5 patients resumed 
use of DA later in the disease course. Finally, it is possible that the lower 
remission rate found is a consequence of the inclusion of more severe cases at 
V1 compared to other studies as a structured interview has greater sensitivity 
than the QUIP-RS for detection of clinically relevant ICBs, and all patients were 
seen at a tertiary centre (Papay et al., 2011).  
 
Although ICBs have been associated with DA use in a dose-dependent fashion 
in a longitudinal study (Corvol et al., 2018), according to our results neither 
duration of DA use, peak DA dose, DA dose at V1 and DA dose at V2 
influenced the long-term remission of ICBs. This was also true after patients 
were compared according to the presence of DDS/punding. This is compatible 
with other studies showing similar dose of levodopa, DA and total dopaminergic 
treatment between PD+V2ICB and PD-V2ICB at follow up (Sohtaoglu et al., 
2010, Siri et al., 2015). Long term ICB remission appears to be associated with 
diverse factors. It has been postulated that drug addiction is perpetuated by 
brain plasticity that forms long-lasting maladaptive changes (Dong and Nestler, 
2014). Considering the shared pathophysiological mechanisms between drug 
addiction and ICBs (O'Sullivan et al., 2011), it is possible that similar changes 
are contributing to the low long-term remission of ICBs. 
 
DDS and punding are more commonly associated with drugs that preferentially  
stimulate dopamine receptors D1 and D2, such as levodopa (Katzenschlager, 
2011, Fasano and Petrovic, 2010), whereas other ICBs are more commonly 
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seen with oral/transcutaneous DA use (Weintraub et al., 2010a). The 
comparison between patients with DDS/punding and other ICBs did not reveal 
any association with specific types of dopaminergic medication. One possible 
explanation is that patients were seen after diagnosis when initial reduction of 
dopaminergic treatment had already started. The outcome of DDS/punding was 
also not influenced by dopaminergic treatment at V2, similar to the analysis 
grouping all ICBs together. 
 
A higher prevalence of multiple ICBs than previously reported was found 
(Antonini et al., 2017, Weintraub et al., 2010a, Garcia-Ruiz et al., 2014). 
Selection bias towards more severe cases is a possible explanation as 
previously explained. Despite more than 40% of the patients experiencing 
remission and nearly all of the remaining cases showing reduction in ICB 
severity, the proportion of patients having multiple ICBs remained stable at V2, 
in line with the literature. One prospective study assessed the prevalence of 
ICBs over a two-year period and found that the proportion of patients with 
multiple ICBs assessed by the QUIP (45%) remained stable over time (Antonini 
et al., 2017).  
 
Compared to V1, fewer patients were using DA and more patients were using 
MAOi and amantadine at V2. This likely reflects the clinical practice of using 
MAOi to compensate for motor deterioration after the reduction in DA. The 
increase in amantadine use is likely an attempt to control levodopa induced 
dyskinesias, a common comorbidity of PD+ICB (Voon et al., 2009). Although 
both these classes of drugs appear to be safer than DA in patients with ICBs, 
contradictory data has been published on the propensity of amantadine to 
induce ICBs and case reports of ICBs on patients with MAOi have been 
published (Averbeck et al., 2014). 
 
More patients were using rotigotine and apomorphine at V2. Some studies have 
reported a lower proclivity of both these drugs to induce ICBs (Antonini et al., 
2016, Magennis, 2012, Todorova et al., 2013), possibly because of reduced 
D3R stimulation (Seeman, 2015) and, in the case of apomorphine, less 
reinforcing properties associated with continuous infusion as drugs that 
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stimulate faster clearance and re-uptake of dopamine (pulsatile stimulation) 
have more reinforcing properties (Volkow et al., 2004). 
 
The risk of dementia in PD increases with age and disease duration. Nineteen 
percent of PD patients with an average age at disease onset of 34 develop 
cognitive impairment after 18 years of disease progression (Schrag et al., 
1998). Whereas in PD patients with later disease onset (mean age 67) the 
prevalence of dementia after 10 years of disease is 46%. In the present study, a 
third of patients exhibited cognitive impairment at V2, suggesting that ICBs do 
not increase to any significant degree the risk for PD dementia, in line with a 
previous study that assessed the cognitive outcome in 40 PD+ICB after two 
years. The authors did not find greater cognitive impairment or executive 
dysfunction in PD+ICB when compared to PD-ICB (Siri et al., 2015). 
 
Prevalence of depression at V1 was higher compared to published data from 
PD-ICB (Reijnders et al., 2008) confirming previous reports that PD+ICB are 
more likely to suffer from depression (Phu et al., 2014). Corroborating this 
association, the HADS depression scores were higher among PD+V2ICB. 
Quality of life measured by the SF36 was lower than the normative values 
published for patients with PD (Banks and Martin, 2009), particularly the general 
health, physical functioning, role limitations due to physical health and social 
functioning subscales, confirming previous data that ICBs are associated with 
worse quality of life (Phu et al., 2014). 
 
Dyskinesias can affect up to 60% of PD patients after 10 years of disease 
progression (Van Gerpen et al., 2006), in line with our findings at V1. However, 
this was lower than the figure at V2, after approximately 17 years of disease 
progression. Younger age at PD onset, longer disease duration and longer 
exposure to levodopa are risk factors for the development of dyskinesias and 
could explain the higher prevalence at V2 (Zesiewicz et al., 2007). 
 
A lower proportion of patients were using neuroleptic drugs at V2 compared 
with the results reported by Sohtaoglu and colleagues (Sohtaoglu et al., 2010). 
In their study, neuroleptics were used routinely if patients did not improve after 
initial treatment with reduction of DA, which was not our practice. However, the 
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fact that data from deceased patients was not available may have contributed to 
the exclusion of patients with more advanced disease and more likely to be 
using neuroleptic drugs.  
 
Approximately one quarter of the patients underwent DBS. The literature 
suggests that DBS is safe in patients with previous ICBs, although a transient 
increase in impulsivity can occur after surgery (Amami et al., 2015). In the 
present study, seven patients were still symptomatic after DBS, but none 
experienced worsening of ICBs. The reduction in dopaminergic treatment that 
usually follows the procedure is a possible explanation for the low risk profile 
associated with DBS (Ardouin et al., 2006). 
 
The comparison between PD-V2ICB and PD+V2ICB, showed that the latter 
scored higher on the UPDRS part I. The higher severity of NMS could explain 
this finding and has been reported before (Antonini et al., 2017). A higher 
proportion of patients with more advanced disease was also seen among 
PD+V2ICB patients. This contradicts other findings that ICBs are not associated 
with disease severity (Antonini et al., 2017, Antonini et al., 2011). One possible 
explanation is that patients with more advanced disease require higher doses of 
dopaminergic treatment and are, therefore, at increased risk of recurrence of 
ICBs.  
 
Increased carer burden has been associated with behavioural abnormalities in 
PD (Leroi et al., 2012a) but it is unclear whether ICBs could lead to a higher 
divorce rate. The unchanged proportion of married individuals between 
PD+V2ICB and PD-V2ICB coupled with published data showing a similar 
number of married individuals in PD with and without ICBs (Leroi et al., 2012a) 
suggest that ICBs do not increase divorce rate in PD. However, larger studies 
are needed to answer this question. 
 
One limitation of this study is that only half of the patients were available for re-
assessment. The main reason for this is that approximately one third of the 
initial cohort had died at the time of reassessment. Although the mortality rate 
found here was lower than in a PD population after 10 years of disease 
progression (Williams-Gray et al., 2013), it is similar to what has been described 
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among patients with disease onset between the ages of 50 and 54 (Ishihara et 
al., 2007). Data currently being prepared by our group for publication on 
patients with PD without ICBs from the Queen Square Brain Bank shows a 
disease duration of 21.5 years when onset of the disease is around the age of 
51, similar to the disease duration of the deceased group from this cohort. This 
suggests that patients with ICBs do not have a more aggressive phenotype of 
PD. However, it is important to acknowledge that ICBs are more prevalent in 
individuals with young onset PD, a population known to have slower disease 
progression and less cognitive impairment (Schrag et al., 1998). 
 
Another potential caveat is the lack of a control group limiting the generalisation 
of our findings. Diagnostic accuracy can also be a problem in research with 
ICBs. On the one hand, patients and relatives commonly under-report ICBs, 
either because of lack of insight or concealment (Averbeck et al., 2014). On the 
other hand, using only screening tools such as the QUIP can result in a large 
number of false positive cases (Papay et al., 2011). The approach to diagnose 
ICBs used in this study, interviews at both visits aided by screening 
questionnaires, likely contributed to accurate detection of ICBs. Furthermore, 
spouses/carers were interviewed when available and all patients were seen by 
movement disorders specialists with research interest in ICBs. 
 
2.5 Conclusion  
 
In this eight-year follow up study of ICBs in PD, a lower rate of remission than 
previously reported and higher proportion of multiple ICBs were found. ICBs can 
remain troublesome for many in the long term and are associated with 
significant reduction in quality of life and increased prevalence of depression. 
Despite this, all but one patient showed some improvement after reduction of 
dopaminergic treatment. The most used treatment strategy was cessation of 
oral/transcutaneous DA, but approximately half of the patients were still using 
these drugs at follow up. Even when reduction or discontinuation of 




Chapter 3: Expanding the clinical knowledge on 
impulsive compulsive behaviours in Parkinson’s 
disease 
 
3.1 Compulsive sexual behaviour in Parkinson’s disease is 




ICBs are a significant source of distress for patients with PD and their families. 
Among the different types of ICBs, CSB is particularly difficult to diagnose, 
considering the obvious sensitive and personal nature of sexual behaviour, and 
it is likely that prevalence numbers are under reported. While the prevalence of 
CSB in the general population is 3 to 6% (Nakum and Cavanna, 2016), 
previous research estimates the lifetime prevalence of this abnormal behaviour 
in individuals with PD between 2 and 3.9% (Weintraub et al., 2010a, Voon et 
al., 2006a, Weintraub et al., 2006). Similar to what has been found for other 
ICBs, the prevalence of CSB is higher among PD patients on DA, reaching 
7.4% (Nakum and Cavanna, 2016). CSB has also been associated with male 
gender and earlier onset of PD (Nakum and Cavanna, 2016). Whilst the use of 
DA has been linked to development of CSB, and levodopa has been associated 
with ICBs in general (Weintraub et al., 2010a), it is still unclear whether higher 
doses of levodopa are a risk factor for the development of CSB in PD patients. 
 
3.1.2 Materials and methods 
 
Patients were identified from a database of individuals with PD and ICBs who 
were seen at the National Hospital for Neurology and Neurosurgery, Queen 
Square, London, UK, and who had participated in 3 previous research projects 
over an eight-year period (from 2008 to 2016). Each project received approval 
by the local ethics committee. All the ICB cases were recruited to research 
studies from PD clinics at the National Hospital and selected due to the 
reporting of ICBS. All the 46 patients who participated in the study described in 
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chapter 2 (The long-term outcome of impulsive compulsive behaviours in 
Parkinson’s disease) were included. 
 
All cases underwent a thorough clinical investigation as well as a detailed semi-
structured interview conducted by a movement disorders specialist. Hospital 
notes were reviewed for clinical and demographic data, with particular interest 
in dopaminergic treatment when ICBs were diagnosed. LEDD was calculated 
according to previously published guidelines (Tomlinson et al., 2010). Data was 
analysed using the software SPSS 22, all variables were tested for normality 




In total, 128 PD+ICB were identified. Seventeen cases were excluded because 
data on dopaminergic treatment when the ICB was most active was incomplete. 
The remaining 111 patients were included in the analysis. Just over 75% of the 
patients were males. The average age of PD onset for the entire cohort was 
46.3 years, mean PD duration 11.3 years and mean age at ICBs 56.9 years. DA 
were used by 91% of the patients (table 8 on page 58). 
 
Only 9 patients were not exposed to DA: 2 with isolated DDS; 1 with isolated 
compulsive eating; 1 with isolated pathological gambling; 1 with DDS 
associated with compulsive shopping and punding; 1 with DDS, CSB and 
punding; 1 with CSB and pathological gambling; 1 with pathological gambling 
and compulsive shopping; and 1 with CSB and compulsive shopping. 
 
CSB was the most frequently identified ICB, present in 49.5% of the patients. 
Details on the prevalence of other types of ICBs can be seen in table 8. Multiple 








Table 8. Clinical and demographic data 
N 111 
Proportion of males 76.8% 
Mean age of PD onset in years  46.3 (± 10.2; 21 – 66) 
Mean PD duration at onset of ICBs in years 11.3 (± 6.8; 1 – 43)  
Mean age at ICBs onset in years 56.9 (± 9.5; 33 – 75) 
Patients using a dopamine agonist 91% 
Total LEDD in mg 1280.8 (± 630; 120 – 3460) 
   
Types of ICBs  
55 (49.5%) 









Dopamine dysregulation syndrome 
Compulsive eating 
Clinical and demographic data of the entire cohort. PD – Parkinson’s disease; 
LEDD – levodopa equivalent daily dose; ICBs – impulsive compulsive 
behaviours. Results expressed in total values and/or proportions or mean 

















For statistical analysis, the cohort was divided into two groups based on the 
presence of CSB: PD+CSB (N = 55) and PD-CSB (N = 56). The proportion of 
male individuals was higher in the PD+CSB group and these individuals 
developed ICBs at a younger age (table 9 on page 60). 
 
There were no differences between groups in the proportion of patients using 
levodopa, DA, MAOi, amantadine or COMT inhibitors (COMTi). Nine patients 
had not been exposed to DA, 3 with CSB and 6 without. The PD+CSB group 
was using a higher dose of dopaminergic treatment and levodopa as measured 
by total LEDD, levodopa daily dose, combined levodopa and COMTi LEDD, and 
isolated COMTi LEDD. DA LEDD and MAOi LEDD were similar between 
groups. Multiple ICBs were present in 48.2% of individuals without and 76.3% 
of individuals with CSB (p = 0.002) (table 9). 
 
There was no difference in the number of patients with DDS between groups, 
showing that the higher dose of levodopa in the PD+CSB group was not being 
driven by a higher proportion of dysregulators. The prevalence of other ICBs 



















Table 9. Comparison of clinical and demographic characteristics  
 PD+CSB PD-CSB p 
N = 111 55 56  
Proportion of males (%) 94.5 60.7 <0.001* 
Age of PD onset (years) 44.6 48.0 0.079** 
PD duration (years) 11.8 13.2 0.344** 
PD duration at ICB onset (years)  10.8 11.8 0.471** 
Age at ICB onset (years) 54.6 59.1 0.020** 
Multiple ICBs (%) 76.3 48.2 0.002* 
Patients using levodopa (%) 98.1 91 0.206* 
Patients using DA (%) 94.5 89.2 0.48* 
Patients using MAOi (%) 36.3 26.7 0.312* 
Patients using amantadine (%) 49 44.6 0.705* 
Patients using COMTi (%) 49  53.5 0.706* 
Levodopa daily dose (mg) 994.5 704.9 0.043** 
DA LEDD (mg) 385 357.8 0.802** 
MAOi LEDD (mg) 97.5 (N=20) 96.67 (N=15) 0.934** 
Levodopa + MAOi LEDD (mg) 911.5 (N=20) 696.7 (N=15) 0.114*** 
COMTi LEDD (mg) 265.2 (N=27) 215.6 (N=30) 0.026** 
Levodopa + COMTi LEDD (mg) 1068.5 (N=27) 874.5 (N=30) 0.039** 
Total LEDD (mg) 1400.1 1163.6 0.014** 
    
Types of ICBs    
Punding 38.1  48.2 0.340* 
Compulsive shopping 43.6 33.9 0.333* 
Pathological gambling 30.9 33.9 0.840* 
Dopamine dysregulation 
syndrome 
21.8 26.7 0.659* 
Compulsive eating 14.5 25 0.234* 
Comparison of clinical and demographic characteristics between groups. PD – 
Parkinson’s disease; ICBs – impulsive compulsive behaviours; DA – 
dopamine agonist; MAOi – monoamine oxidase inhibitor; COMTi – COMT 
inhibitor; LEDD – levodopa equivalent daily dose. *Chi-square test. Results 
expressed in total values or proportions. **Mann-Whitney U test. Significant 




Most of the patients in this cohort comprised men, which is in keeping with 
previous studies (Weintraub et al., 2010a). CSB was the most frequently 
identified ICB in our cohort, affecting almost 50% of individuals with PD-
associated ICBs. A novel finding was that PD+CSB tend to develop this 
abnormal behaviour at an earlier age and are more likely to develop multiple 
ICBs compared to PD patients with other ICBs. This finding has important 
clinical implications as individuals with multiple ICBs are more likely to develop 
depression (Wu et al., 2015) and higher levels of impulsivity have been 
associated with worse quality of life in PD (Leroi et al., 2012a). Furthermore, 
considering the high prevalence of CSB found and the possibility of under-
reporting, clinicians should specifically enquire PD patients about this 
behaviour, particularly if other ICBs are present.  
 
The prevalence of multiple ICBs in this cohort was nearly two thirds, higher than 
the 28.7% of PD+ICB found by Weintraub and colleagues (Weintraub et al., 
2010a), similar to the prevalence found by Garcia-Ruiz analysing PD patients 
on DA (Garcia-Ruiz et al., 2014), and lower than the 80% found by Poletti and 
collaborators (Poletti et al., 2013). The different numbers reported might be a 
consequence of the different instruments used to diagnose ICBs, as it has been 
reported that the QUIP can be positive in up to 40% of patients without a 
diagnosis of ICB (Papay et al., 2011). The figures reported here seem accurate 
as all patients were seen in a research setting and diagnosed by a movement 
disorders specialist with the aid of a semi-structured interview in combination 
with the QUIP, after it became available. Furthermore, all patients seen in this 
study had significant impairment in social or occupational functioning from the 
abnormal behaviours. 
 
Between group analysis showed that the two groups had similar age at PD 
onset and disease duration, however the proportion of male patients was 
significantly higher in the PD+CSB group. This is in line with the literature as 
other authors have also found that CSB is more likely to develop in male PD 
patients (Weintraub et al., 2010a, Voon et al., 2006a). The menopause is 
responsible for a decline in the sexual function of healthy women (Avis et al., 
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2017) and could theoretically contribute to the lower prevalence of CSB in 
women with PD, but larger studies are needed to answer this question. Cultural 
bias could also make women less likely to report CSB. Younger age of PD 
onset is a well-known risk factor for the development of ICBs and many authors 
have published data on this positive association (Djamshidian et al., 2011a). 
However, this is the first study to report that patients with PD and CSB tend to 
develop this abnormal behaviour at an earlier age compared to patients with 
other ICBs.  
 
Another novel finding is that PD+CSB were on higher doses of dopaminergic 
treatment. The majority of patients were using a dopamine agonist, in keeping 
with previously published data that shows that DA are the main risk factor for 
the development of ICBs (Weintraub et al., 2010a, Giladi et al., 2007, Voon et 
al., 2007). DA and MAOi dose, measured in LEDD, and the proportion of 
patients using DA, amantadine and MAOi did not differ. However, patients with 
CSB were using higher levodopa daily dose and higher COMTi doses than 
patients without CSB, although the proportion of patients using COMTi did not 
differ between groups. This suggests that higher dopaminergic stimulation, 
particularly higher doses of levodopa are a risk factor for the development of 
CSB. It is likely that higher doses of COMTi are not directly related to ICBs but, 
rather, are contributing to excessive dopaminergic stimulation by increasing the 
bioavailability of levodopa. This is corroborated by the fact that only half of the 
patients were using COMTi. 
 
The association of abnormal sexual behaviour and levodopa was reported in 
the early days of levodopa use, years before DA started being used for PD. 
Barbeau and colleagues treated 80 patients with PD with an average dose of 
4.8 g of levodopa per day and reported that at least 4 males developed an 
increase in libido (Barbeau, 1969). Corroborating this finding, levodopa has 
been shown to increase mounting behaviour in male rats. Dopamine’s 
facilitatory role in the sexual behaviour of male rats, which appears to also be 
present in male primates, can explain these findings and the association of CSB 
with higher doses of levodopa (Melis and Argiolas, 1995). 
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Although the main risk factor for the development of impulse controls disorders 
in PD is the use of DA (Weintraub et al., 2010a), levodopa has been found to be 
an important contributor to the development of ICBs in patients already 
receiving treatment with DA (Hassan et al., 2011). Higher doses of levodopa are 
the most important risk factor for the development of DDS in PD patients 
(O'Sullivan et al., 2009). Punding has also been associated with higher doses of 
levodopa (Evans et al., 2004), although it is also significantly associated with 
DA use (Pettorruso et al., 2016). This is in contrast to pathological gambling, 
which rarely occurs on levodopa monotherapy (Djamshidian et al., 2011b). Data 
from animal models have shown that chronic levodopa use can result in ectopic 
expression of D3R that could theoretically facilitate appearance of behavioural 
problems through sensitization (Luquin-Piudo and Sanz, 2011). More data is 
needed to answer whether levodopa is the direct cause for the development of 
CSB or is acting through behavioural sensitization. 
 
Interestingly, despite finding that patients with CSB were on higher doses of 
levodopa, the proportion of other types of ICBs was similar between groups, 
indicating that even though higher levodopa doses are associated with both 
CSB and DDS, these abnormal behaviours are not more likely to occur 
together. This finding also suggests that the higher doses of levodopa being 
used by PD+CSB were not being driven by patients with DDS. Another 
important clinical implication from this study is that clinicians that are confronted 
with patients with CSB must be aware that increasing levodopa (to compensate 
for reducing the DA dose) may also be associated with increased risk of CSB.  
 
By including only patients who participated in previous research projects, it is 
possible that patients with ICBs that were diagnosed during a regular 
outpatient’s appointment were not included. However, since the idea was to 
assess the prevalence of CSB among patients with established ICBs, it is likely 
that this approach minimised the possibility of including false positives.  
 
It is possible that the association of CSB with higher doses of levodopa was 
found by chance, and more studies are needed to confirm this finding. In 
addition, this retrospective case control study does not allow causality 
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correlations. Nonetheless, this study highlights the potential behavioural 




The data from this study confirms that CSB is more frequent in males and tends 
to appear earlier than other ICBs. CSB may be the most frequent ICB 
associated with PD. Furthermore, patients with CSB are more likely to develop 
multiple ICBs. When compared to other types of ICBs, this behavioural 
addiction appears to be driven by higher doses of levodopa. Data from larger 
studies are needed to confirm these novel findings. 
 
3.2 The outcome of dopamine dysregulation syndrome in 




DDS is characterised by compulsive dopaminergic medication use markedly 
exceeding the amount required for adequate control of PD symptoms 
(O'Sullivan et al., 2009). The main risk factors for the development of DDS are 
male sex, younger age at PD onset and dopaminergic treatment (Djamshidian 
et al., 2011a, Giovannoni et al., 2000, Katzenschlager, 2011). Patients with 
DDS also commonly develop concomitant ICBs, depression and an altered 
perception of ON state (Giovannoni et al., 2000, Cilia et al., 2014). Some 
patients describe ‘a high’ from each dose of levodopa initially but go on to crave 
and want higher and higher doses without any liking or enjoyment from their 
therapy. The behavioural sequelae closely resemble those experienced by 
chronic cocaine and amphetamine addicts (Volkow et al., 2004). 
 
A carefully supervised slow reduction in the daily dose of levodopa can lead to 
improvement or resolution in some patients. However, despite adequate 
treatment, a follow up study over several years has previously reported that 
more than a third of patients remain symptomatic (Cilia et al., 2014). 
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Considering that DDS is an uncommon complication of dopaminergic treatment 
and the relative paucity of literature on this topic, more data is needed to guide 
clinical care. This section describes a retrospective analysis to assess the 
prevalence, association with medication, clinical characteristics and outcome of 
DDS in a population of pathologically proven PD patients from the Queen 
Square Brain Bank for Neurological Disorders (QSBB), London, UK.   
 
3.2.2 Materials and methods 
 
A QSBB database search for consecutive donations from 2005 to 2016 with a 
diagnosis of PD was performed. Thirty-two cases from the cohort described in 
chapter 5 (Impulsive compulsive behaviours in Parkinson’s disease are 
associated with lower alpha-synuclein load and dopamine D3 receptor levels in 
the nucleus accumbens) were included: 15 PD+ICB and 17 PD-ICB. All cases 
of PD who developed DDS according to previously published diagnostic criteria 
(Giovannoni et al., 2000) underwent detailed review of GP and hospital records. 
Sex, age at PD onset, PD duration and age at death were collated, as well as 
presence of dementia, depression and dyskinesias. For those with DDS, 
additional data was collected, particularly duration, medications associated with 
the development of DDS, dose of dopaminergic treatment at DDS onset and 
death, use of DA and the outcome of DDS.  
 
All variables were tested for normality and statistical tests chosen accordingly. 
Data was analysed using SPSS 22. The QSBB has a license from the Human 
Tissue Authority to store brain tissue and its brain donation protocols were 
approved by a London Multi-Centre Research Ethics Committee. Written 




A total of 193 cases with a pathological diagnosis of idiopathic PD among brain 
donations received from 2005 to 2016 were identified (124 males and 69 
females). The average age at disease onset was 60.2 years, the average age 
at death was 77.5 years and average disease duration 17.3 years. Dementia 
occurred in 46% of the patients, depression in 24.4% and levodopa-induced 
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dyskinesias in 42%. Seventeen patients developed DDS. Of these, 10 died of 
pneumonia, 2 of myocardial infarction, 2 of PD, 1 from heart failure, 1 from 
dissecting aortic aneurysm and 1 from malnutrition. 
 
For statistical analysis, patients were divided into two groups based on the 
presence of DDS: PD+DDS (patients with PD and DDS) and PD-DDS (patients 
with PD without DDS). Eleven PD-DDS had ICBs other than DDS: 8 CSB, 1 
compulsive shopping, 1 pathological gambling and 1 CSB and punding. 
PD+DDS had younger age at PD onset, higher prevalence of dyskinesias, 
longer disease duration, and died at an earlier age compared to PD-DDS (table 
10 on page 67). The majority of patients who developed dyskinesias (78%) did 
so before DDS. 
 
A few observations from patients’ notes are included to illustrate the 
phenomenology of DDS: “daughter noticed that her mother was taking sinemet 
like ‘smarties’”; “patient is using more levodopa than necessary but prefers to 
run high with some dyskinesia”; “patient is stockpiling medication, taking 2125 
mg of levodopa per day but stated he was on 1350 mg”; “phoned because he 
had used all levodopa, confessed he was using excessive medication that was 
making him feel disturbed, agitated and dyskinetic”’; “when ON patient was 
hyperactive and slightly maniac and when OFF depressed, during admission 
was clearly ON but claimed to be OFF”; “patient’s assessment of OFF-periods 
were rather inaccurate”; “grossly dyskinetic due to the fact that he takes his 
drugs at will, took own discharge during hospitalisation to reduce levodopa and 
went back to previous doses”. 
 
All patients with DDS received neurological and psychiatric care and 8 of them 
were seen at the National Hospital for Neurology and Neurosurgery, Queen 
Square. The average duration of DDS was 53.5 months. One patient in the 
PD+DDS group had undergone implantation of embryonic mesencephalic 






Table 10. Comparison between groups 
 PD+DDS (N = 17) PD-DDS (N = 176) P 
Males (%) 14 (82.3%) 110 (62.5%) 0.119* 
Age at PD onset (years) 50.8 (± 9) 61.2 (± 10.7) <0.001** 
Disease duration (years) 22.5 (± 5.7) 16.7 (± 8) 0.003*** 
Age at death (years) 73.4 (± 8) 77.9 (± 7.6) 0.020*** 
Dementia (%) 7 (41.1%) 82 (46.5%) 0.669* 
Depression (%) 7 (41.1%) 40 (22.7%) 0.134* 
Dyskinesias (%) 14 (82.3%) 67 (38%) 0.001* 
Comparison between PD patients with (PD+DDS) and without DDS (PD-
DDS). PD – Parkinson’s disease; DDS – dopamine dysregulation syndrome. 
Results expressed in mean values and standard deviation or total values and 
proportions. Significant results in bold. *Chi-square test; **unpaired t-test; 























Five of the patients with DDS had concomitant ICBs (4 CSB and 1 pathological 
gambling). All PD+DDS were using levodopa at onset, albeit only 3 (17.6%) as 
monotherapy. Details of other anti-parkinsonian medications are shown in table 
11 on page 69. The amount of dopamine replacement therapy in LEDD was 
calculated as previously described (Tomlinson et al., 2010). Although patients 
were using less medication at the time of death in comparison to peak usage, 
this did not reach statistical significance (p = 0.356; Wilcoxon matched pairs). 
 
Nine out of seventeen patients (52.9%) improved completely, 7 (41.1%) partially 
and in 1 patient (5.8%) DDS remained unchanged until death. All patients had 
alteration of their dopaminergic medication as a therapeutic measure. Levodopa 
dose was reduced in 10 cases; cessation of DA was done in 4 cases and 
reduction of DA dose in 3. 
 
Further statistical tests comparing patients who achieved remission with 
patients who remained symptomatic until death demonstrated a trend for higher 
levodopa lifetime cumulative dose (calculated as described elsewhere 
(Parkkinen et al., 2011)) in the latter group but this failed to reach statistical 
significance. LEDD at DDS onset and at death, as well as duration of DA 
treatment, did not differ between groups. However, patients who failed to 
















Table 11. Characteristics of the patients who developed DDS 
 PD+DDS (N = 17)   
Average duration of 
DDS (months) 
53.5 (± 65.6)   
Medications at DDS onset   
   Levodopa 17 (100%)   
   Oral/transdermal DA 10 (58.8%)   
   Selegiline 5 (29.4%)   
   Amantadine 3 (17.6%)   
   Apomorphine infusion 2 (11.7%)   
LEDD at DDS onset 1411 (± 579)   
LEDD at death 1196 (± 636)   
    
Outcome Remission         
(N = 9) 
Partial improvement 




3643 kg (± 3517) 5837 kg (± 3468) 0.083* 
LEDD at DDS onset 1468 (± 595) 1346 (± 595) 0.680* 
LEDD at death 1225 (± 797) 1164 (± 444) 0.564* 
DA peak LEDD 229.4 (± 94) N = 7 429.1 (± 224.7) N = 7 0.035* 
DA duration in months 86 (± 26.2) N = 7 83.7 (± 55.5) N = 7 0.620* 
Characteristics of the patients who developed DDS and comparison according 
to remission status. DDS – dopamine dysregulation syndrome; DA – dopamine 
agonist; LEDD – levodopa equivalent daily dose. Results expressed in mean 
values and standard deviation or total values and proportions. Significant 













This is the longest follow up study of DDS in pathologically proven PD patients 
who received specialist care during life. The overall prevalence of DDS was 
8.8%, which is higher than previously reported (Katzenschlager, 2011, 
Giovannoni et al., 2000). No particular effort was made at the QSBB to seek 
donation from patients known to have DDS in life. The longer length of follow up 
in this group of patients raises the possibility that the lifetime prevalence of DDS 
may be higher than has hitherto been recognised. An alternative explanation is 
that patients with DDS were more likely to donate their brains because of 
increased impulsivity levels (Averbeck et al., 2014). 
 
Patients with DDS had earlier disease onset (Warren et al., 2017) and longer 
disease duration. This likely reflects the predominance of younger patients, who 
tend to experience slower progression of PD (van Rooden et al., 2010). 
However, DDS patients died at a younger age than patients without DDS, 
probably reflecting the earlier age of onset. Pneumonia was the main cause of 
death among PD+DDS and there were no suicides (Pennington et al., 2010). 
 
A total of 41% of patients developed dementia after DDS, in line with a recent 
study (Williams-Gray et al., 2013) and confirming previous findings that patients 
with DDS are not more likely to develop dementia (Cilia et al., 2014). 
Depression was present in approximately 24%, also consistent with the 
literature (Reijnders et al., 2008). The retrospective data collection, the small 
sample size and the fact that most patients were not formally assessed for 
depression might have contributed to a lower prevalence of depression than 
expected from clinical observation. 
 
As expected, dyskinesias were more prevalent in PD+DDS in part reflecting the 
higher levodopa dosage. A recently published study found that patients with PD 
and dyskinesias have a higher prevalence of ICBs than a general PD 
population, raising the possibility of dopaminergic sensitisation as a shared 
mechanism between both phenomena (Biundo et al., 2017, Voon et al., 2009). 
The fact that dyskinesias tended to predate DDS suggests that PD patients at 
risk who develop dyskinesias should be carefully screened for DDS. Only about 
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a  third of the patients with DDS had other ICBs, which is lower than in a recent 
systematic review (Warren et al., 2017). 
 
At the time of DDS diagnosis all patients were using levodopa, but only 3 as 
monotherapy. Levodopa is believed to be the main risk factor for the 
development of DDS (O'Sullivan et al., 2009). DA were used as an add on 
therapy by more than 50% of the patients with DDS, in line with a recent review 
(Warren et al., 2017). Apomorphine infusion was used by 2 patients at DDS 
onset. Apomorphine is a dopamine agonist with a different pharmacological 
profile than other DA, as it stimulates mainly D1R and D2R (Fahn et al., 2011b), 
akin to levodopa. Studies of PD patients on apomorphine infusion suggest a 
lower prevalence of ICBs compared to oral DA (Magennis, 2012, Martinez-
Martin et al., 2014, Todorova et al., 2015) but it is still unclear whether 
apomorphine use is associated with increased risk of DDS. Continuous delivery 
of dopaminergic drugs may have less reinforcing properties resulting in a lower 
risk for triggering DDS (Katzenschlager, 2011). In this study, 3 patients used 
infusion therapies, 2 apomorphine infusion and 1 duodopa, and in all DDS 
resolved. 
 
Although nearly all the patients showed some improvement after phased 
reduction in dopaminergic treatment, nearly half of them remained symptomatic 
until death. This is a similar remission rate to a systematic review on DDS 
(Warren et al., 2017) and higher than a long term retrospective study (Cilia et 
al., 2014). Interestingly, patients who remained symptomatic were exposed to 
higher maximum doses of DA. It is possible that excessive stimulation of D3R 
might act to sensitise the ventral striatum to the reinforcing properties of 
levodopa. It is important to note that peak DA dose was calculated based on 
doctor’s notes, and there is a possibility that doses were understated. 
Nonetheless, the association of peak DA dose with persistent DDS has not 
been reported previously and further studies are needed to confirm this finding. 
  
The main disadvantage of this study is that, as with many brain bank studies, 
the clinical information was analysed retrospectively, making quality of data 
heavily dependent on the details provided in the hospital records. However, all 
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patients were seen by consultant neurologists regularly and the clinical detail 
provided in the notes was substantial.    
 
3.2.5 Conclusion  
 
The prevalence of DDS in a brain bank study of Parkinson’s disease raises the 
possibility that one in eleven patients may develop DDS. Treatment success 
depends critically on the ability to achieve concordance in dopaminergic drug 
dose reduction. 
 





Punding is a stereotyped non-goal orientated behaviour, characterized by 
repetitive manipulations of technical equipment, the continual handling, 
examining, and sorting of common objects, grooming, hoarding, pointless 
driving or aimless walkabouts (Evans et al., 2004). Initially described among 
amphetamine and cocaine users, punding was first reported in a levodopa 
treated patient with PD by Friedman in 1994 (Friedman, 1994). The prevalence 
of punding in PD varies between 1.4% (Miyasaki et al., 2007) up to 14% of 
patients (Evans et al., 2004).  
 
There is an idiosyncratic quality to punding, with previous occupations and pre-
morbid hobbies influencing the type of abnormal behaviour (Evans et al., 2004). 
Patients with punding have more psychiatric symptoms, greater impulsivity and 
are more likely to have other ICBs (Pettorruso et al., 2016). Punding has also 
been linked with DDS (Evans et al., 2004) and levodopa peak dose dyskinesias 
(Silveira-Moriyama et al., 2006). 
 
Little is known about the neuropsychiatric profile of patients with punding. In this 
study, clinical and neuropsychiatric features of PD patients with 
punding/hobbyism were compared to PD-ICB. 
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3.3.2 Materials and methods 
 
A total of 47 PD patients diagnosed with punding and/or hobbyism and 25 PD 
patients without punding or other ICBs were recruited from a movement 
disorders outpatient clinic at the National Hospital for Neurology and 
Neurosurgery, Queen Square, London, UK. Eighteen patients with punding 
described in chapter 2 (The long-term outcome of impulsive compulsive 
behaviours in Parkinson’s disease) were included in this study, as well as 9 
PD+ICB and 15 PD-ICB from chapter 4 (Impaired saccadic suppression in 
patients with Parkinson’s disease and impulsive compulsive behaviours). 
 
A diagnosis of punding/hobbyism was made based on the QUIP-RS using 
previously published cut-off scores (Weintraub et al., 2012) and confirmed with 
a structured interview. PD-ICB also completed the QUIP-RS and structured 
interview to confirm the absence of punding or other ICBs. Participants self-
completed the following questionnaires: the HADS, the SF36, the Barratt 
Impulsiveness Scale (BIS11), the REM Sleep Behaviour Disorder Screening 
Questionnaire (RBDq) and the Apathy Scale (AS). The UPDRS parts I and III, 
AIMS, FAB, MoCA, and the Stroop test (EncephalApp Stroop Test (Bajaj et al., 
2013)) were completed with the investigating physician.  
 
The study received approval by the local ethics committee. All variables were 
tested for normality. Parametric data was analysed using independent samples 
t-test and non-parametric data Mann-Whitney U test. Proportions were 
compared with the Pearson chi-square test, except if the minimum expected cell 
count was less than five, when the Fisher’s exact test was used. A p value of 
less than 0.05 was considered significant. Data was analysed using SPSS 22. 
 
3.3.3 Results  
 
Forty-seven patients with PD and punding (PD+pu) as the dominant 
behavioural phenotype were included in the study and compared to 25 PD-ICB. 
There were no differences in age, duration of illness or medication use, 
including amantadine and MAOi (Table 12 on page 75), as well as current total 
dose of levodopa or of DA. As punding has been shown to be related to high 
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DA doses, the current DA dose was compared to the peak DA dose and found 
to be 62% lower among patients with punding (Wilcoxon matched pairs; p = 
0.016). In comparison, there had been a smaller non-significant reduction in DA 
dose in the PD-ICB group (Wilcoxon matched pairs; p = 0.176). 
 
Among the 47 patients with punding and hobbyism, 25 had comorbid ICBs: 
DDS was present in 4 individuals; CSB in 16; pathological gambling in 6; 
compulsive shopping in 8; and compulsive eating in 13. A comparison between 
patients with isolated punding and punding associated with co-morbid ICBs 
showed no significant differences, except for HADS and UPDRS part I scores, 
which were significantly higher in patients with punding and other ICBs 
compared to isolated punding.  
 
Table 12 shows the neuropsychiatric and cognitive characteristics of the two 
groups. Compared to PD-ICB, PD+Pu reported significantly higher scores on 
the HADS anxiety subscale. Motor fluctuations, defined as wearing-off of 
levodopa, absence of ON, ON-OFF phenomenon and unpredictable OFF 
periods, were more frequent in patients with punding. There was a trend for 
higher prevalence of levodopa-induced dyskinesias and RBD in the PD+pu 
group. None of the SF36 subscales differed between groups. 
 
The UPDRS part I scores were significantly higher in PD patients with punding, 
but the UPDRS part III scores did not differ. The difference seen for UPDRS 
part I remained significant after correcting for the dopamine dysregulation 
syndrome score (unpaired samples t-test; p = 0.034) and the anxiety score 
(unpaired samples t-test; p = 0.015). PD+pu also showed significantly higher 
impulsivity levels in the BIS11 questionnaire and lower (worse) FAB scores. 
Patients with punding had slower reaction times on the Stroop test but made a 
similar number of errors compared to the control group. The MoCA scores did 







Table 12. Comparison of demographic and clinical characteristics 
 PD+pu (N = 47) PD-ICB (N = 25) p value 
Male sex 38 (80.8%) 18 (72%) 0.390* 
Age 57.5 (± 14) 59.8 (± 9) 0.640† 
Age at PD onset (years) 44.7 (± 10.5) 47.56 (± 7.9) 0.238¥ 
Disease duration (years) 14.5 (± 8.5) 12.4 (± 6.7) 0.352† 
Depression 22 (46.8%) 11 (44%) 0.820* 
Dyskinesias 37 (78.7%) 15 (60%) 0.063* 
Deep brain stimulation 5 (10.6%) 4 (16%) 0.513* 
DA use 22 (46.8%) 13 (52%) 0.675* 
MAOi use 9 (19.1%) 3 (12%) 0.532** 
Motor fluctuations 43 (91.4%) 18 (72%) 0.041** 
LEDD9 1090.8 (± 426) 893.8 (± 526) 0.090¥ 
DA dose in LEDD 197 (± 148) N=22  257 (±127) N=13 0.132† 
HADS total 17 (± 6) 13.1 (± 6) 0.016¥ 
HADS anxiety 9.3 (±3) 6.8 (± 4) 0.014¥ 
HADS depression 7.6 (± 3) 6.6 (± 3) 0.270¥ 
UPDRS part I 19.2 (± 8) N=44 13.2 (± 5) N=18 0.010¥ 
UPDRS part III 29 (± 11) 24.4 (± 14) 0.138¥ 
BIS11 67.8 (± 7) N=42 64.1 (± 6) N= 22 0.049¥ 
AIMS 7.3 (± 6) 4.8 (± 6) 0.070† 
FAB 15.6 (± 2) 16.6 (± 2) 0.017† 
MoCA 25.7 (± 5) 27.1 (± 2) 0.324† 
RBD 78% N=41 50% N=20 0.064* 
Apathy Scale 14.5 (± 6) N=40 13 (± 5) N=18 0.320† 
Stroop reaction time (s) 19.1 (± 5.2) N=21 16.34 (± 2.3) N=12 0.040¥ 
Stroop errors 1.4 (± 2.2) 0.42 (± 0.5) 0.321† 
Comparison between groups. PD – Parkinson’s disease; PD+pu – patients 
with PD and punding; PD-ICB – PD patients without ICBs; DA – dopamine 
agonist; MAOi – monoamine oxidase inhibitors; LEDD – levodopa equivalent 
daily dose; HADS – Hospital Anxiety and Depression Scale; UPDRS – Unified 
Parkinson’s Disease Rating Scale; BIS11 – Barratt Impulsiveness Scale; 
AIMS - Abnormal Involuntary Movement Scale; FAB - Frontal Assessment 
Battery; MoCA - Montreal Cognitive Assessment; RBD – Rem Sleep 
Behaviour Disorder; Results expressed in mean values and standard 
deviation or total values with proportions. Significant results in bold. *Chi-




Our findings support previous data showing that PD+pu have higher impulsivity 
(Pettorruso et al., 2016, Evans et al., 2004). Furthermore, punding was 
associated with increased anxiety and NMS, frontal lobe abnormalities on 
neuropsychological testing and higher prevalence of PD motor fluctuations. 
 
Punding is more common in males who develop PD at an earlier age (Spencer 
et al., 2011), compatible with our findings. There were no differences in quality 
of life between groups, contradicting previous data (Lawrence et al., 2007). 
Considering that the SF36 is a self-assessment questionnaire it is possible that 
patients with punding failed to report difficulties due to lack of insight. Another 
possible explanation is that the SF36 is less sensitive to changes in PD patients 
as it has been designed as a general quality of life questionnaire. 
 
PD+pu had higher levels of anxiety, which is in line with a previous study in 
PD+ICB (Leroi et al., 2011) but in disagreement with another study (Pettorruso 
et al., 2016). Although punding is not driven by anxiety per se, anxiety can 
develop when patients are forced to stop their behaviour against their will 
(Fasano and Petrovic, 2010).This may explain the higher anxiety scores at 
assessment. The depression scores did not differ between groups, in keeping 
with previous reports (Fasano and Petrovic, 2010). 
 
The Stroop task revealed that patients with punding had longer reaction times 
before making a decision in line with a previous study (Yoo et al., 2015). 
However, error rates did not differ between the two groups, compatible with 
previously published data assessing PD+ICB (Djamshidian et al., 2011c). The 
longer reaction time may reflect delayed decision making and frontal lobe 
dysfunction. Interestingly, prefrontal cortical thinning on neuroimaging has been 
described in PD+pu (Yoo et al., 2015, Markovic et al., 2017). 
 
Supporting the evidence for frontal lobe dysfunction, patients with punding 
scored lower than controls on the FAB. Contradictory data from PD+ICB have 
been published (Averbeck et al., 2014) but no previous studies have specifically 
assessed frontal function in PD+pu. It has been postulated that the abnormal 
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expression of stereotypic behaviours is associated with frontal lobe dysfunction 
(Fasano and Petrovic, 2010), which could explain the lower FAB scores. 
Furthermore, punding also occurs among individuals addicted to cocaine and 
methamphetamine (Rusyniak, 2011), conditions that have been associated with 
frontal dysfunction (Koob and Volkow, 2010). 
 
Higher doses of dopaminergic therapy have been consistently associated with 
punding (Evans et al., 2004, Spencer et al., 2011) but data on the use of DA is 
less clear with different groups publishing contradictory findings (Pettorruso et 
al., 2016, Silveira-Moriyama et al., 2006). PD+pu were not using higher doses 
of DA, suggesting that D3R stimulation associated with the use of DA is not the 
main mechanism underlying punding. Previous data shows that punding is 
more commonly seen in patients using drugs that stimulates dopamine D1 and 
D2 receptors (Fasano and Petrovic, 2010) such as levodopa. However, patients 
with punding had been submitted to a significant reduction in DA dose as 
shown by a post hoc analysis and it is possible that an assessment conducted 
in an earlier time point could have revealed significant differences in total dose 
of dopaminergic therapy and higher DA dose in the punding group.  
 
Complex interactions between pharmacological and non-pharmacological 
factors (such as personal habits, personality and PD degeneration) are likely 
contributing to the development of punding (Fasano and Petrovic, 2010). The 
idiosyncratic nature of this behavioural condition and its association with 
compulsive symptoms (Evans et al., 2004) are arguments in favour of this idea. 
   
Our sample size is relatively small. This is because stringent criteria were used 
and only PD patients who had either no evidence of punding or any other ICBs 
or had punding or hobbyism as the dominant phenotype were included. 
Nonetheless, this is one of the largest studies looking into cognitive and 









Higher self-rated impulsivity associated with clinician-assessed impaired frontal 
function in patients with punding was reported. Peak DA doses were 
significantly higher than current DA dose in the PD+pu group due to physician 
driven dose reduction in order to manage drug induced complications. Higher 
dopaminergic stimulation in individuals with reduced inhibitory control could be 
the mechanism behind punding behaviour.  
 
3.4 Retrospective study of impulsive compulsive behaviours in 





ICBs can have devastating consequences on the lives of patients with PD and 
their families. The greatest risk factor for triggering these addictive behaviours is 
DA therapy (Weintraub et al., 2010a, Voon et al., 2007). Immediate release 
orally active agonists appear to carry increased risk for ICBs when compared to 
transdermal or prolonged release oral agonists (Garcia-Ruiz et al., 2014, Rizos 
et al., 2016). 
 
The association of ICBs with oral dopamine D2/D3 agonists is well documented 
but the potential of apomorphine to induce them is unclear, with conflicting 
results reported. One study showed that in five out of seven patients, pre-
existing ICBs improved after apomorphine pump therapy (5 partially and 2 
completely). However, there was onset of de novo ICBs in six other cases 
(CSB, compulsive eating, compulsive shopping and internet use) using 
apomorphine pump therapy. Only two patients with new onset ICBs were using 
a DA, in both cases rotigotine (Todorova, 2013). Other studies, of 15 and 30 
individuals respectively, reported no ICBs or improvement of ICBs after 
treatment with apomorphine (Todorova et al., 2013, Magennis, 2012). In the 
present study, a detailed review of clinical notes was performed to assess 
whether apomorphine can trigger or improve ICBs in PD.  
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3.4.2 Materials and methods 
 
A retrospective audit of PD patients treated with apomorphine pumps at the 
National Hospital for Neurology and Neurosurgery, Queen Square, London, UK, 
was conducted. Only patients who were registered using the apomorphine 
pump in the years of 2013 and 2014 were included to ensure complete data 
acquisition and importantly covering a period when all patients would have been 
questioned carefully about ICBs. Two patients described in chapter 2 (The long-
term outcome of impulsive compulsive behaviours in Parkinson’s disease) were 
included.  
 
All files were reviewed and screened for ICBs and other neuropsychiatric 
disorders, including depression, anxiety, psychosis and cognitive impairment. 
Clinical indications for apomorphine, the daily dosage, side effects, pre-existing 
ICBs and therapies were noted as well as the therapeutic outcome. Data was 




A total of 28 patients (18 males) were included in this study. Demographic 
characteristics are summarised in table 13 on page 80. All patients started 
apomorphine because of refractory motor fluctuations with significant off periods 
for at least 2 hours per day. Five patients (17.9%) discontinued the pump for the 
following reasons: technical problems with the pump (3 patients); 
hypersomnolence (1 patient); and deteriorating cognition (1 patient). The data 











Table 13. Demographic characteristics and side effects from apomorphine 
 N Range or % SD 
Number of patients 28   
Male/Female  18/10   
Mean age at PD onset (years) 51 35 - 76 ± 8.8 
Mean disease duration (years) 18.6 8 - 35 ± 6.2 
Mean disease duration when starting 
apomorphine (years) 
15.2 6 - 28 ± 5.4 
Mean duration of apomorphine 
treatment (months) 
43.3 2 - 120 ± 34.6 
Mean hours per day on apomorphine 13.9 12 - 24 ± 3 
Mean maximum apomorphine dosage 
(mg) 
56.3 24 - 96 ± 23.4 
Patients who stopped apomorphine (n) 5  (17.9%)  
Patient experiencing side effects  25 (89.3%)  
Skin nodules 13 (46.4%)  
Hypersomnolence 10 (35.7%)  
Cognitive impairment 8 (28.5%)  
Visual Hallucinations 6 (21.4%)  
Dizziness 5 (17.8%)  
Postural hypotension 5 (17.8%)  
Bruising injection site 4 (14.3%)  
Nausea 2 (7.1%)  
Excessive sweating 2 (7.1%)  
Dry mouth 1 (3.6%)  
Itching injection site 1 (3.6%)  
Demographic data and side effects from apomorphine infusion. PD – 









Patients were divided into two groups based on the presence or absence of 
ICBs prior to the start of apomorphine and were followed up for a mean period 
of 43 months. ICBs were diagnosed by a movement disorder specialist. Follow-
up visits were conducted in the same clinical setting. Twelve patients had 
experienced ICBs prior to apomorphine use, with more men affected than 
women. Eight patients had more than one ICB. Furthermore, PD+ICB had a 
younger onset of PD compared to PD-ICB. Both groups had similar disease 
duration and duration of apomorphine treatment. There was no significant 
difference in apomorphine dosage between the two groups, as well as 
occurrence of side effects. Four PD-ICB patients and one PD+ICB patient 
stopped apomorphine prematurely (p = 0.25) (Table 14 on page 82). 
 
In total, 19 out of the 28 patients (67.8%) were treated with a DA prior to 
apomorphine. Five PD-ICB patients were still using a DA after initiation of 
apomorphine pump treatment. Six out of 12 PD+ICB patients experienced 
complete resolution of their ICBs and/or addictive behaviours after reduction (N 
= 2) or withdrawal (N = 4) of the DA (see Figure 5 on page 83), meaning that 2 
PD+ICB were still using a DA after apomorphine was introduced, albeit in a 
smaller dose. There was no recurrence of ICBs in this group of individuals. The 
remaining six patients had active ICBs at the time apomorphine was started. 
After initiation of apomorphine pump treatment, one patient with CSB improved 
completely, three patients showed complete resolution of DDS and partial 
improvement of impulsivity (one with DDS and CSB, one with pathological 
gambling, and one with DDS, CSB and pathological gambling) and two patients 
experienced no change in their symptoms (one with hoarding behaviour and 
one with DDS, CSB and punding). Details on the ICBs are described in table 15 
on page 84 and figure 5. One patient who had no previous history of ICBs and 
no previous exposure to a DA developed new onset compulsive eating 








Table 14. Comparison between PD patients with and without ICBs 
 PD+ICB (N = 12) PD-ICB (N = 16) p value 
Male/female 11/1 7/9 0.009* 
Mean age at PD onset 
(years) 
46.5 (± 8.1) 54.3 (± 8) 0.018** 
Mean disease duration 
(years) 
19 (±7.8) 18.3 (± 5) 0.75** 
Mean disease duration 
when starting apomorphine 
(years) 
16.1 (± 6.8) 14.5 (± 4.1) 0.43** 
Mean duration of 
apomorphine treatment 
(months) 
39.4 (± 32.5) 46.2 (±36.9) 0.61** 
Mean maximum 
apomorphine dosage (mg) 
57.4 (± 19.9) 55.5 (± 26.4) 0.84** 
Patients experiencing side 
effects (N) 
10 (83.3%) 15 (93.7%) 0.37* 
Patients who stopped 
apomorphine (N) 
1 (8.3%) 4 (22.2%) 0.25* 
Comparison between groups. PD – Parkinson’s disease; PD+ICB – PD 
patients with ICBs; PD-ICB – PD patients without ICBs. Results expressed in 
total number and proportion or mean values and standard deviation. 















Figure 5. Outcome of patients with ICBs.  
 
Twelve individuals had developed ICBs (PD+ICB). Six patients improved prior 
to apomorphine and six remained with active ICBs. After apomorphine 3 
patients had partial improvement (1 with CSB, DDS and compulsive shopping, 1 
with pathological gambling and 1 DDS, CSB and pathological gambling), 1 
patient with CSB improved completely, 2 patients remained unchanged (1 with 
hoarding and 1 with DDS, CSB and punding) and 1 patient developed de novo 
compulsive eating. PD-ICB – PD patients without ICBs; PD+ICB – PD patients 
with ICBs; CS – compulsive shopping; HS – hypersexuality; DDS – dopamine 
dysregulation syndrome; PG – pathological gambling; Ho – hoarding behaviour; 
Pu – punding; CE – compulsive eating; RG – reckless generosity. * 1 patient 
was also using the pen formulation. ** 2 patients were also using pen 




Table 15. Impulsive compulsive behaviours outcomes 
Case ICBs prior to apomorphine ICBs after apomorphine LEDD 
2 DDS and CSB ICBs resolved and did not 
occur. 
1220 
3 CSB and CS ICBs resolved and did not 
occur. 
1750 
4 CSB, CS and punding ICBs resolved and did not 
occur. 
1310 
5* CSB, DDS and CS Improved partially.  1738.5 
10* CSB Improved completely. 1020 
11* PG Improved partially. 1330 
18 CSB and PG ICBs resolved and did not 
occur. 
1787.5 
20* Hoarding ICB unchanged. 1550 
24 None Compulsive eating.  1500 
27 CSB, CS and punding ICBs resolved and did not 
occur. 
1738.5 
31* DDS, CSB and PG Improved partially. PG 
persisted. 
1587 
35* DDS, CSB and punding ICBs unchanged. 1510 
41 CSB and PG ICBs resolved and did not 
occur. 
860 
ICBs outcome displayed by individual cases. In bold the only case who 
developed de novo ICB after apomorphine infusion. ICBs – impulsive 
compulsive behaviours; DDS – dopamine dysregulation syndrome; CSB – 
compulsive sexual behaviour; CS – compulsive shopping; PG – pathological 






LEDD was calculated as previously described (Tomlinson et al., 2010). 
Considering all participants (N = 28), total LEDD was lower before apomorphine 
(before 1241.53; after 1414.71) (p = 0.062; Wilcoxon matched pairs test). 
Oral/transdermal DA LEDD for the total cohort was also calculated, which was 
significantly lower after apomorphine (159.2; 45.14; p = 0.01). A similar analysis 
in the group of patients with ICBs before apomorphine was conducted (N = 12). 
Although there was no difference in total LEDD before (1407.19; ±473.17) and 
after (1450.12; ±304.90) apomorphine treatment (p = 0.75), there was a 
statistically significant difference in DA LEDD before (188.98; ±170.19) and after 
(10.83; ±25.39) apomorphine (Wilcoxon matched pairs test; p = 0.008). 
 
The majority of the patients (85%) had levodopa induced dyskinesias. A total of 
25 patients (89.3%), experienced side effects from apomorphine, with 16 of 
them (57.14%) experiencing 2 or more side effects. The most common side 
effects were skin nodules, which occurred in 46.4% of the patients, and 




This study suggests that apomorphine pump therapy has a lower risk of 
generating ICBs than oral DA treatment. All 12 patients who had ICBs prior to 
apomorphine had been treated with an oral DA and six of them showed 
complete remission of their abnormal behaviour after reducing or stopping the 
agonist. None of these patients experienced recurrence of ICBs after the 
introduction of apomorphine infusion. 
 
Six patients still had ongoing ICBs despite reduction of DA at the time of starting 
the apomorphine pump. In one of these, damaging impulsivity disappeared, 
three more had considerable improvement so that it no longer represented a 
problem for the patient and to the family, and two did not experience any 
change in severity of their ICBs. None of these patients was still using a DA 
after apomorphine was started. Oral DA may induce long-term 
pharmacodynamic changes (van Eimeren et al., 2010), which may explain 
persistence of some of the pathological behaviours seen after discontinuation of 
treatment. 
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It seems probable that the reduction in DA dose was primarily responsible for 
the improvement seen. The fact that ICBs did not recur after apomorphine 
treatment initiation suggests that this drug has a lower tendency to trigger 
behavioural addictions in PD as previous studies have shown that attempts to 
reinstate oral DA, even at lower dosage, commonly lead to a recurrence of ICBs 
(Rabinak and Nirenberg, 2010). There are a number of potential reasons for 
this. There is evidence from imaging studies that large and rapid increases in 
extracellular dopamine may be the encoding mechanism through which 
dopamine attributes salience to an event in normal conditions. Dopaminergic 
drugs with fast brain uptake and clearance closely mimic this natural process 
and tend to be more implicated in the experience of “high” and drug-induced 
reinforcement (Volkow et al., 2004). A continuous steady state delivery of 
apomorphine to the dopamine receptor would have the opposite effect and may 
explain its low proclivity to induce addictive behaviours. Corroborating this, a 
recent study has shown that continuous jejunal infusion of levodopa improved 
DDS and other ICBs (Catalan et al., 2013). Further evidence to support this 
idea comes from a three-year observational study showing that infusion 
therapies, apomorphine and intrajejunal levodopa, carry a reduced risk for the 
development of ICBs in individuals with PD (Todorova et al., 2015). 
 
Differences in affinity to dopamine receptors may also contribute to the 
occurrence of ICBs. Apomorphine has a receptor profile similar to dopamine 
with higher affinity for D1R and D2R (Fahn et al., 2011a) in contrast to other DA 
which have a more marked affinity for D3R. It has been suggested that this D3R 
selectivity may be linked to the occurrence of ICBs (Seeman, 2015, Samuel et 
al., 2015). 
 
Apomorphine has also been claimed to possess sedative and anti-psychotic 
effects and its molecular structure includes a piperidine moiety similar to that of 
the major tranquiliser thioridazine (Chase and Tamminga, 1980). Historically, 
repeated hourly injections of apomorphine for 5 days have been used as a 
treatment for alcohol and other forms of substance dependence (Dent, 1952, 
Scheel-Kruger et al., 1977, Beil and Trojan, 1977). Neuropsychiatric symptoms 
have been reported to improve in some PD patients after the introduction of 
apomorphine pump therapy (Ellis et al., 1997), although it is unclear whether 
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this improvement can be a consequence of the aforementioned neuroleptic 
effect. 
 
It has been suggested that ICBs and punding may be the ventral striatal 
equivalent to levodopa-induced dyskinesias and that both phenomena are due 
to dopaminergic sensitisation (Voon et al., 2009). Rodriguez-Oroz and 
collaborators identified a pattern of oscillatory activity in the STN in both 
conditions albeit in a different topography (Rodriguez-Oroz et al., 2011). The 
similarity between levodopa-induced dyskinesias and ICBs, coupled with the 
evidence that apomorphine infusion has been shown to be effective in reducing 
PD dyskinesias (Katzenschlager et al., 2005) may explain why none of our 
patients with pre-existent ICBs relapsed. 
 
In the present study, the mean apomorphine pump dosage was 56.3 mg per 
day, which is lower than the 69.8 mg reported by Tyne and collaborators and 
the 98 mg per day reported in an earlier era from our own centre by Manson et 
al (Tyne et al., 2004, Manson et al., 2002). Apomorphine infusion was delivered 
for an average period of 13.94 hours, which is similar to the data from Tyne and 
collaborators, but significantly less than the 16.5 hours found by Manson et al 
(Tyne et al., 2004, Manson et al., 2002). It is possible that higher doses and 
longer duration of  apomorphine may be an independent risk factor for ICBs 
(Antonini, 2007), therefore the lower doses used in this cohort might be another 
factor contributing to reduced occurrence of ICBs.  
 
Although apomorphine appears to be safer than other DA, previous studies 
have shown that de novo cases of ICBs can occasionally occur in patients 
using apomorphine pump therapy (Martinez-Martin et al., 2014, Samuel et al., 
2015, Garcia Ruiz et al., 2008). One of the patients in this cohort who had no 
previous history of addictive behaviours developed compulsive eating 15 
months after treatment with apomorphine pump. This behaviour was mild and 
did not lead to a premature cessation of therapy.  
 
The limitations of this study are that it is descriptive and retrospective and has 
been carried out on a relatively small number of patients, the variable follow-up 
period after initiation of apomorphine treatment and the relative high rate of 
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discontinuation of the pump. In addition, it is believed that DDS and other types 
of ICBs may have different pathophysiological origins. Moreover, grouping 
these behavioural abnormalities together limits the generalisability of these 
results to a wider PD population. 
 
Considering that PD+ICB have lower insight and therefore a tendency to under-
report their symptoms (Averbeck et al., 2014), it is possible that ICBs, despite 
being present in 46% of the cases, were still under-reported. So far, only 
retrospective and open-label studies have addressed the issue of apomorphine 
and ICBs (Samuel et al., 2015, Garcia Ruiz et al., 2008, Magennis, 2012, 
Todorova, 2013, Todorova et al., 2013) and the data linking DA is largely based 




Based on the full case notes from these patients and the research interest in 
dopamine dysregulation going back to 2000, apomorphine pump seems to have 
lower tendency to worsen or trigger ICBs. Continuous infusion of apomorphine, 
therefore, appears to be a valid treatment option for patients with ICBs and DDS 
when other treatment options have failed. Further prospective studies are 













Chapter 4: Impaired saccadic suppression in patients 





Eye movement abnormalities have been described in many neurodegenerative 
conditions including PD. Previous studies have included diverse methods of 
assessment, from physical examination by a neurologist to more sophisticated 
approaches, such as dedicated eye tracking devices. The known motor 
abnormalities characteristic of PD are reflected in saccadic movements in the 
form of hypometric saccades and longer fixation periods. Whilst these 
abnormalities have been reported in several studies, little is known about the 
oculomotor function of individuals with PD+ICB. 
 
Increased reaction time (latency) and reduced gain (hypometria) of eye 
movements occur commonly in PD (Munoz and Everling, 2004, Matsumoto et 
al., 2011). Increased anti-saccadic direction errors have also been reported, 
even among drug-naïve patients (Antoniades et al., 2015). Although most 
studies have shown that voluntary (memory guided) saccades tend to be more 
impaired than automatic saccades (visually guided or reflexive) in PD patients 
(Chan et al., 2005, Hood et al., 2007, Chambers and Prescott, 2010), similar 
performance between PD patients and healthy individuals in a visually guided 
saccadic task, and inferior performance on a voluntary saccades task have 
been described (Briand et al., 1999). 
 
Levodopa can improve the performance of PD patients on tests of voluntary 
saccades but not to the level of healthy individuals. Levodopa can also slow 
reaction time (saccadic latency) of reflexive saccades in PD patients but it does 
not improve hypometric saccades (Hood et al., 2007).  
 
Saccades can be facilitated by the striatum via its inhibitory effect on the 
substantia nigra pars reticulata which results in liberation of the superior 
colliculus (SC); or supressed by its indirect effect of increasing tonic inhibition 
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via external globus pallidus or STN (Hikosaka et al., 2014). The eye movement 
abnormalities seen in PD can be explained in terms of excessive SC inhibition 
by the basal ganglia output nuclei and decreased activity of the basal ganglia-
frontal cortex circuit (Terao et al., 2011). Supporting this theory, electrical 
stimulation of the substantia nigra pars reticulata can affect negatively both 
automatic and voluntary saccades in primates (Liu and Basso, 2008). 
Furthermore, DBS of the STN in PD patients has been shown to improve 
parameters of both memory and visually guided saccades (Yugeta et al., 2010). 
 
The anti-saccades task is a relatively simple way to test an individual’s own 
control over voluntary action. It consists of suppression of the urge to look to a 
target in the visual field and instead, look to the opposite direction of the target. 
Evidence from studies with primates and humans supports the notion that 
correct performance in the anti-saccades test requires top-down inhibition of 
saccade neurons in the SC and frontal eye field before the target appears 
(Munoz and Everling, 2004). This test has been used extensively to prove that 
voluntary saccades are affected in PD (Antoniades et al., 2015, Crevits et al., 
2000, Briand et al., 1999, van Stockum et al., 2012, Hood et al., 2007). 
 
Motor and reflection impulsivity, with jumping to conclusions and decisions, has 
been shown to occur in PD+ICB (Averbeck et al., 2014). The number of 
direction errors in the anti-saccades task has been positively correlated with 
impulsivity levels in healthy individuals (Spinella, 2004), but until the present 
date no studies assessing saccadic movements in patients with PD and ICBs 
have been published.  
 
Automatic and voluntary saccades of PD+ICB were tested and compared to 
PD-ICB and healthy controls (HC). It was hypothesized that PD+ICB would 
make more premature saccades in both the pro and anti-saccades tasks and 







4.2 Materials and methods 
 
4.2.1 Study design and patient selection 
 
Individuals with PD fulfilling the QSBB diagnostic criteria (Hughes et al., 1992) 
and active ICBs were recruited from PD clinics at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London and matched by age, 
sex, PD duration and age at PD onset with PD patients without ICBs, and by 
age with healthy individuals recruited among relatives/spouses of PD patients. 
Patients with a diagnosis of Parkinson’s disease dementia or with MoCA score 
of less than 26 were excluded. The research protocol was approved by the 
Queen Square Ethics Committee. 
 
 All participants were assessed with the MoCA and the FAB. Individuals with PD 
were also assessed with the QUIP-RS, the UPDRS part III and the AIMS. 
Diagnosis of ICBs was confirmed with a structured interview. 
 
4.2.2 Saccadic assessment 
 
To ensure PD patients were tested in the ON state, patients using levodopa 
were assessed one hour after intake. Eye movements assessments were 
conducted with an e(ye) BRAINÓ T2 device. Details of the eyetracker setup can 
be seen in figure 6 on page 92. Before each task a twelve-point calibration of 









Figure 6. The e(ye)BRAIN T2 apparatus.  
 
The helmet contains infrared cameras positioned below the line of sight to track 
pupils. The screen is maintained 60 cm away from the participant and head 
movements are tracked by another camera positioned on the top of the screen 
that detects light emitted by the helmet. Suricog™: e(ye)BRAIN T2 User’s 






















Two research paradigms were created specifically for this research: 
 
- A pro-saccades task to test automatic saccades.  
 
Participants started by focusing on a grey dot measuring 0.32 degrees of visual 
angle on the centre of the screen. They were then instructed to make a saccade 
to a blue dot appearing eccentrically (15 degrees horizontally from centre) on 
the screen, displayed for 1500 milliseconds (ms). The central grey dot remained 
on display throughout the assessment. After 1500 ms, the blue dot 
disappeared, and patients had to return their eyes to the central fixation dot. 
Forty randomized trials were conducted to each side for each participant, 
totalling eighty trials. The 15 degrees amplitude was chosen based on previous 
publications showing normative values and that saccades to larger amplitudes 
are frequently inaccurate (Becker and Fuchs, 1969). 
 
- An anti-saccades task to test voluntary saccades. 
 
Participants were instructed to focus on a central grey dot measuring 0.32 
degrees of visual angle that was displayed for 1500 ms. In this task a step 
paradigm was used, meaning that immediately after the grey dot disappeared, 
without delay, a red dot appeared randomly on either side of the screen 15 
degrees horizontally away from the centre. Participants were instructed to look 
to the opposite side of the screen from the red dot and return their eyes to the 
central fixation point as soon as it reappeared, 1500 ms later. Forty randomized 
trials of the same amplitude (15 degrees) were conducted to each side for each 
participant, totalling eighty trials. 
 
4.2.3 Statistical analysis 
 
Data analysis was conducted initially with the e(ye)BRAIN software me(ye) 
analysisã. The computer was programmed to identify the first saccadic 
movement occurring after target onset that exceeded a speed of 30 degrees 
per second. The quality of the recording from both eyes was inspected visually 
and the channel with best recording chosen for data analysis. A poor-quality 
signal was identified when there was too much interference to prevent accurate 
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detection of saccades and/or when the computer failed to identify more than 
75% of the expected saccadic movements, in both cases recordings were 
excluded from analysis.  
 
All variables were exported to SPSS version 22 for data analysis. Data points 
outside the interquartile ranges were excluded from the analysis. All variables 
were tested for normality and statistical tests chosen accordingly. Due to the 
possibility that saccades with latency greater than 900 ms or lower than 120 ms 
were not related to stimulus presentation, these were excluded from the 
calculation of saccadic parameters. Considering that normal subjects generate 
a saccade within approximately 200 ms (Kveraga et al., 2002), saccades with 
latencies between 120 and 180 ms were classified as premature and included 
in the analysis. Latency and gain were calculated for each detected saccade 
and mean values used for comparison. The number of direction errors in the 
anti-saccades task was calculated for each participant and mean values used 
for comparison. A p value of less than 0.05 was considered significant. 
    
4.3 Results 
 
4.3.1 Demographic and clinical characteristics 
 
There were 52 participants in the trial. Six patients with PD were excluded: two 
because of low MoCA scores, three because of poor quality of recording and 
one because of a technical fault with the computer processing unit. One healthy 
individual was excluded because of poor quality of the recording. Fifteen 
patients were included in each group: PD+ICB, PD-ICB and HC.  
 
The groups were well matched for age but there was a higher proportion of 
females in the HC group. PD+ICB and PD-ICB had similar disease duration and 
age at PD onset. A similar proportion of PD patients were using DA and 
receiving a similar amount of dopaminergic treatment, measured as LEDD 
(Tomlinson et al., 2010). PD+ICB scored higher on the QUIP-RS, AIMS and 
UPDRS III. The scores on the MoCA and FAB did not differ between groups. 
Demographic and clinical data are detailed in table 16 on page 95. 
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Table 16. Demographic and clinical characteristics divided by group 
 PD+ICB PD-ICB HC p value 
N 15 15 15  
Females (%) 2 (13.3) 3 (20) 8 (53.3) 0.035* 
Age (years) 53.6 (± 9.8) 54.6 (± 7.3) 53 (± 9.1) 0.880 ƒ 
Average age at 
PD onset (years) 
42.7 (± 10.3) 45.9 (± 7.5) - 0.344† 
Average PD 
duration (years) 
11.1 (± 4.3) 8.7 (± 4.5)  - 0.152† 
Hoehn & Yahr 2 1.8 - 0.057* 
Current use of 
DA (%) 
9 (60) 9 (60)  1.000* 
Total DA LEDD    
(N = 9) 
164.7 (± 133.3) 242.4 (± 96.6) - 0.178† 
Total LEDD 895.8 (± 397.5) 744.5 (± 466) - 0.347† 
QUIP-RS 39.9 (± 11.1) 10 (± 7.4) - <0.001ƒ 
AIMS 7.4 (± 4.6) 2.8 (± 3.3) - 0.005 ƒ 
UPDRS III 24.6 (± 6.9) 13.7 (± 5.6) - <0.001ƒ 
MoCA (median, 
IQR) 





17.5 (16; 18) 18 (17; 18)  18 (18; 18) 0.089 Ø 
Demographic and clinical characteristics divided by group. PD – Parkinson’s 
disease. DA – dopamine agonist; LEDD – levodopa equivalent daily dose; 
QUIP-RS – Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s 
Disease - Rating Scale; UPDRS III – Unified Parkinson’s Disease Rating 
Scale part III; AIMS – Abnormal Involuntary Movements Scale; MoCA – 
Montreal Cognitive Assessment; FAB – Frontal Assessment Battery; *Chi-
square test; ƒ ANOVA; † Independent samples t-test; Ø Kruskal-Wallis test. 
Significant results in bold. Results expressed in mean values and standard 
deviation for variables with normal distribution or median values and 





In the PD+ICB group there were seven patients with singe ICBs (3 with CSB, 3 
with punding and 1 with compulsive shopping) and eight with multiple ICBs 
(punding was present in 6 individuals, CSB in 5, compulsive eating in 4, 
compulsive shopping in 4 and pathological gambling in 1).  
 
4.3.2 Pro-saccades task 
 
The number of outlying data points excluded did not differ between groups as 
compared with the Kruskal-Wallis test in both the pro and anti-saccades tasks. 
Automatic saccades, tested with the pro-saccades task, did not differ between 
groups as displayed in table 17 on page 97. 
 
4.3.3 Anti-saccades task 
 
Voluntary saccades were assessed with the anti-saccades task. There was no 
difference in the number of premature saccades and saccadic latency between 
groups. Reaction time immediately after a direction error, however, was longer 
in PD+ICB.  
 
Amplitude of anti-saccades differed between groups (table 18 on page 98), a 
post hoc analysis showed that PD+ICB made smaller amplitude saccades than 
HC (p = 0.021, Mann-Whitney U test). There was no difference between 
PD+ICB and PD-ICB (p = 0.110) and between PD-ICB and HC (p = 0.097). 
 
The number of direction errors also differed between groups. A post hoc 
analysis revealed that PD+ICB made more direction errors than PD-ICB (p = 
0.006) and HC (p = 0.001). The number of direction errors did not differ 
between PD-ICB and HC (p = 0.802). The anti-saccades test data is 








Table 17. Pro-saccades task  
 PD+ICB PD-ICB HC p value 
N 15 15 15  
Premature saccades 
(median, IQR) 
9 (4; 13) 8 (2; 12) 7 (2; 10) 0.545* 
Latency in ms 








Amplitude (°) 14.8 (± 2.2) 15.1 (± 2.6) 16.1 (± 2.3) 0.324** 
Comparison of the pro-saccades task results. Ms – milliseconds. *Kruskal-
Wallis test; **ANOVA. Results expressed in mean values and standard 
deviation for variables with normal distribution or median values and 

























Table 18. Anti-saccades task  
 PD+ICB PD-ICB HC p value 




1 (0; 1) 0 (0; 2) 0 (0; 1) 0.310* 









Latency after a 
















Direction errors (N) 31.1 (± 13.1)  18.9 (± 12) 15.2 (± 13.9) 0.005** 
Direction errors (%) 48.6 (± 22) 25.2 (± 16) 20.7 (± 19.5) 0.001** 
Comparison of the anti-saccades task results. Ms – milliseconds. *Kruskal-
Wallis test; **ANOVA. Significant results in bold. Results expressed in mean 
values and standard deviation for variables with normal distribution or median 




















This study is the first to assess saccadic eye movements of PD+ICB. 
Performance was similar between PD patients with and without ICBs and 
healthy controls in all parameters of the pro-saccades task, suggesting that 
automatic saccades are preserved in PD. While most, but not all, published 
studies have found preserved automatic saccades in individuals with PD 
(Briand et al., 1999, Chan et al., 2005, Hood et al., 2007, Chambers and 
Prescott, 2010) corroborating our findings, one study reported reduced 
amplitude of automatic saccades which was correlated with disease severity, 
measured by motor and cognitive impairment (Macaskill et al., 2012). 
 
The SC is the point of convergence for cortical and subcortical structures that 
influence saccadic control (Munoz and Everling, 2004), and is modulated by the 
basal ganglia (Hikosaka et al., 2014). This structure in under tonic inhibition 
from the substantia nigra pars reticulata. Cortical visual signals are initially 
directed to the caudate, which connects to the nigra pars reticulata via direct 
and indirect pathways. The former inhibits the nigra and releases the SC to 
perform a saccade, whereas the latter increase the SC inhibition preventing the 
generation of saccades towards ‘valueless objects’ (Hikosaka et al., 2014, Kim 
et al., 2017). The nigra pars reticulata tends to be affected later in PD (Jellinger, 
2011), therefore integrity of such pathways in the early stages of the disease 
could explain the preservation of pro-saccades.  
 
It is interesting to note that more premature saccades were made in the pro-
saccades task compared to the anti-saccades task. It has been shown that 
anticipatory saccadic movements can occur with predictable tasks, similar to 
our pro-saccades paradigm (Holmqvist et al., 2011).  
 
Contradictory data on anti-saccadic reaction time in PD has been published, 
presumably relating to medication status and different paradigms (Briand et al., 
1999). Here, all patients were tested during ON stage which may explain the 
lack of differences in anti-saccadic latencies between groups. The amplitude of 
anti-saccades, however, was lower in PD+ICB compared to HC. Previous 
reports have shown that PD patients without impulsivity have hypometric 
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saccades but here this finding was only replicated in PD+ICB (Briand et al., 
1999), possibly due to the small sample size, as a trend for shorter saccades in 
PD-ICB compared to HC was identified. As previously described in a general 
PD population, saccadic hypometria of PD+ICB did not improve with levodopa 
(Hood et al., 2007). 
 
PD+ICB exhibited longer anti-saccadic latencies immediately after a direction 
error. This could be explained by the fact that they were tested on medication 
as previous studies have shown that PD+ICB on dopaminergic treatment are 
more sensitive to negative feedback (Djamshidian et al., 2010, Djamshidian et 
al., 2012a). 
 
Increased anti-saccadic error rate has been reported in drug naïve PD patients 
early in the course of the disease (Antoniades et al., 2015). The error rate found 
by Antoniades and colleagues in PD patients (15%) and controls (8.7%) 
(Antoniades et al., 2015) was less than the 25% and 20%, respectively, found in 
the present study. Considering that patients were assessed for 4 minutes in 
each task, without interruption, one has to consider the possibility that fatigue 
contributed to the higher error rate described here. However, another group has 
found higher error rates in healthy young adults (Li et al., 2012) than both 
Antoniades et al and the present study suggesting that PD-ICB and HC did not 
have an increased rate of anti-saccadic direction errors. 
 
The similar error rate between PD-ICB and HC could be attributed to levodopa, 
as this medication has been shown to reduce anti-saccadic error rate in PD 
(Hood et al., 2007). The use of levodopa, however, was not enough to reduce 
the error rate of PD+ICB (nearly 50%). Patients with ICBs have a bias towards 
risky choices in decision making tasks (Djamshidian et al., 2010), reflection 
impulsivity (Djamshidian et al., 2012b) and temporal discounting (Milenkova et 
al., 2011). However, considering the short time between target onset and 
saccadic movement and the low number of premature saccades, it is unlikely 
that decision making abnormalities are responsible for the higher anti-saccadic 
error rate in PD+ICB. Previous studies show that correct performance in the 
anti-saccades task requires top-down inhibition of saccadic neurons in the SC 
before target onset (Munoz and Everling, 2004). PD-related dopaminergic 
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depletion in the dorsolateral prefrontal cortex coupled with deficits in cortical 
inhibitory circuits in PD+ICB (Djamshidian et al., 2011a) could be the 
mechanism behind the failure to suppress automatic saccades in individuals 
with ICBs (Pretegiani and Optican, 2017).  
 
An important caveat is the higher UPDRS scores in PD+ICB, which could have 
contributed to an increase in the number of anti-saccadic direction errors. It has 
been described that anti-saccadic error rate and reaction time tend to increase 
as PD progresses (Terao et al., 2011, Kitagawa et al., 1994). However, there 
are important differences between the present study and previous research 
reporting saccadic abnormalities in advanced PD. Firstly, PD+ICB exhibited a 
very high error rate (48.62%), significantly higher than what has been described 
before by Kitagawa et al (36.2%). Secondly, the anti-saccadic reaction time 
reported here was shorter (318.6 ms) than what has been described previously 
(410 ms) (Kitagawa et al., 1994). Lastly, severity of bradykinesia has been 
correlated with longer anti-saccadic latencies (Kitagawa et al., 1994) but no 
differences in anti-saccadic latencies between PD+ICB and PD-ICB were found. 
Therefore, although the UPDRS III suggests that PD+ICB patients have more 
advanced PD, the findings from the anti-saccades task do not corroborate this. 
Although the UPDRS III motor score influences performance in PD-ICB 
(Kitagawa et al., 1994) it is likely that cognitive impulsivity is contributing to the 
poor performance in PD+ICB. Further studies with a larger sample size 
including patients with similar UPDRS III scores are needed to definitively 
answer this question. 
 
One limitation of this study is the small sample size. This was addressed by 
sampling 80 saccades in each task, however this could have contributed to a 
lengthy testing procedure and fatigue that could have negatively affected 
performance of participants. To reduce fatigability, the eye movements 
assessment was conducted before the other tests and patients were offered 
breaks between tasks. 
 
There were more female volunteers among HC. Previously published data 
suggests that saccadic velocity, accuracy and latency does not differ greatly 
between sexes (Wilson et al., 1993), although one study reported that women 
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tend to make more errors than men in the anti-saccades task (Li et al., 2012). 
However, the HC error rate of 20% is lower than the rates previously reported 




This is the first study to assess saccadic parameters in patients with PD and 
ICBs. PD+ICB made hypometric voluntary saccades. Longer anti-saccades 
latencies after an error in PD+ICB suggest higher sensitivity to their negative 
performance. PD+ICB made a high number of direction errors in the anti-
saccades task and this finding may have important clinical implications. If anti-
saccadic error rate could be confirmed as a marker for ICBs in PD this could be 
used to inform choice of initial treatment in a particular individual. It may be 
appropriate that patients with early PD and a high rate of anti-saccades 




















Chapter 5: Dopamine dysregulation syndrome in 
Parkinson’s disease is associated with lower alpha-




5.1.1 The dopaminergic reward pathway 
 
The dopaminergic (or mesocorticolimbic) reward system consists of a series of 
structures located mainly in the midbrain and basal ganglia that attribute value 
to different stimuli in order to generate an appropriate behavioural response 
(figure 1). This system is of paramount importance to maintain an organism’s 
homeostasis and the main neurotransmitter used is dopamine, albeit not the 
only one. Changes in the tonic release of dopamine from the ventral tegmental 
area in the midbrain to the NAc are the way the brain encodes the nature of a 
stimulus, with rewarding stimuli resulting in a fast and temporary increase and 
non-rewarding stimuli leading to the opposite, a sudden decrease in dopamine 
release (Damier, 2015). Stimuli that generate a sensation of pleasure or liking 
(hedonic response) are classified as rewarding. The hedonic response to 
sensory stimuli is facilitated by the NAc and the ventral pallidum through 
reciprocal connections. Within these structures there are areas rich in opioid 
receptors, called hedonic hotspots, that can amplify the hedonic response to 
sweet taste stimuli (Pecina et al., 2006, Smith and Berridge, 2007). 
 
The NAc is also responsible for originating an appropriate behavioural response 
to different stimuli. Connections between this structure and other brain areas, 
like the amygdala and the prefrontal cortex, contribute to creating an 
association between stimulus and related events, facilitating future engagement 
(Kalivas and Volkow, 2005). Motivation to pursue determinate activity is 
modulated by the prefrontal cortex and the hippocampal subiculum via 
projections from the ventral striatum. Activation of the mesocorticolimbic 
pathway with consequent dopamine release results in two major simultaneous 
changes: stimulation of D1R will increase subiculum input keeping a subject 
focused on a task; and stimulation of D2R will inhibit the prefrontal cortex and 
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free the subject to engage with the task. Conversely, if a reward is not elicited 
dopamine levels drop removing the input from the subiculum and reducing 
prefrontal cortex inhibition, freeing the subject to shift task focus (figure 1) (Goto 
and Grace, 2005, Napier et al., 2015). 
 
There are common brain areas that respond to rewards regardless of the type, 
supporting the idea of a general hedonic representation in the brain. These 
areas are the ventral striatum, anterior insula, anterior cingulate cortex and 
midbrain (Sescousse et al., 2010).  
 
5.1.2 Structures implicated in impulsivity and drug abuse 
 
In healthy individuals, impulsivity has been inversely correlated with D2R and 
D3R availability in the midbrain and positively correlated with the magnitude of 
amphetamine-induced dopamine release in the striatum (Buckholtz et al., 
2010). Pathophysiological similarities between drug addiction and ICBs in PD 
suggest shared pathways between the two conditions. Evidence from imaging 
studies in drug addiction shows that large and rapid increases in extracellular 
dopamine may be the encoding mechanism through which dopamine attributes 
salience to an event in normal conditions. Therefore, dopaminergic drugs with 
fast brain uptake and clearance more closely mimic this natural process and 
tend to be more implicated in the experience of “high” and drug-induced 
reinforcement (Volkow et al., 2004). Recreational drugs have the ability to 
increase dopamine in the basal ganglia to a supra-physiological level, and this 
is believed to be an important step in the promotion of addiction (Wise and 
Rompre, 1989). With repeated drug use the hedonic response is lost in favour 
of habitual automatic responses (Everitt and Robbins, 2005). 
 
In the molecular level, the transcription factor Delta-FosB has been shown to 
increase in the striatum after exposure to drugs of abuse and to enhance 
sensitivity to rewards in rats (McClung et al., 2004). PD patients with 
dyskinesias also have increased expression of this molecule in the posterior 
putamen suggesting its involvement in maladaptive neuroplasticity (Lindgren et 
al., 2011). Studies are needed to investigate whether similar changes are 
present in PD+ICB. 
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5.1.3 Parkinson’s disease and Impulsive compulsive behaviours  
 
A similar pattern of excessive release of dopamine in the ventral striatum to that 
described in drug abusers has been reported in PD+ICB. Using 11C-Raclopride 
positron emission tomography (PET) in patients with PD, Evans and colleagues 
showed that individuals with DDS have enhanced dopamine release in the 
ventral striatum induced by levodopa (Evans et al., 2006). Similar changes in 
dopamine transmission also occur in non-substance addicted PD patients with 
other types of ICBs. O’Sullivan and colleagues demonstrated that medicated 
PD+ICB (including CSB, binge eating, punding, compulsive shopping, DDS, 
pathological gambling and reckless generosity) have increased dopamine 
release in the ventral striatum after exposure to reward-related cues. In that 
study, different ICBs elicited the same dopaminergic response providing further 
evidence to the theory that there is a general hedonic representation system in 
the brain (O'Sullivan et al., 2011).  
 
In PD patients with pathological gambling, not only increased dopamine release 
in the ventral striatum has been demonstrated (Steeves et al., 2009), but these 
patients also exhibit hyperactivity of structures of the dopaminergic reward 
system. This suggests that pathological gambling in PD is a consequence of 
overstimulation of a relatively preserved mesocorticolimbic pathway (Cilia et al., 
2008). However, a defective inhibitory network can also play a part, as PD 
patients with pathological gambling exhibit reduced blood flow to brain areas 
associated with response inhibition after receiving apomorphine (van Eimeren 
et al., 2010). 
 
Structural abnormalities have also been described in PD+ICB, such as: cortical 
thinning in areas of the frontal cortex and corpus callosum, alongside volume 
reduction of the right NAc and volume increase of the amygdala (Biundo et al., 
2015); volume loss in the NAc, caudate, hippocampus and amygdala, and 
increased thickening of anterior cingulate and frontal pole cortices, which could 
be attributed to either dopaminergic stimulation or a pre-existent vulnerability to 
addiction (Pellicano et al., 2015); and cortical thinning of the dorsolateral 
prefrontal and orbitofrontal areas in patients with punding (Yoo et al., 2015). 
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D3R are widely expressed in the limbic system of the human brain, particularly 
in cell cluster populations within the NAc (Suzuki et al., 1998) and have higher 
affinity for dopamine compared to D1R and D2R, making them more sensitive 
to changes in dopamine levels (Payer et al., 2014). It has been postulated that 
ICBs are a consequence of overstimulation of D3R by DA. Data supporting this 
connection comes mainly from observational clinical studies showing that the 
higher the selectivity of a dopamine agonist to D3R the greater the risk of ICBs 
as detailed in figure 2 (Seeman, 2015). Furthermore, tonic stimulation of 
dopamine receptors associated with the use of DA may impair negative 
feedback signalling by preventing drops in dopaminergic tonic stimulation, 
reducing negative reinforcement (van Eimeren et al., 2009). Despite previous 
findings that D3R expression is upregulated in drug addiction (Payer et al., 
2014), in PD+ICB, no changes in D2R levels and no evidence of upregulation of 
D3R in the limbic striatum were found in a PET study (Payer et al., 2015). 
 
Over the last decade our understanding of the pathophysiology of ICBs has 
markedly improved in parallel with increased scientific interest in this stimulating 
topic. Although data from animal models and imaging studies have shed some 
light on the associated structural and functional abnormalities encountered in 
PD patients with behavioural addictions, the cause of ICBs remains elusive. To 
the present date no post mortem study involving PD+ICB has been conducted. 
The QSBB has received donations from patients with PD who were troubled in 
life by DDS. This study was designed to identify cellular and molecular insights 
into the mechanisms of DDS that could translate into better clinical care and the 
development of novel pharmacological treatments. 
 
5.2 Materials and methods 
 
5.2.1 Study design and patient selection 
 
Cases with pathologically proven PD who developed DDS in life were identified 
from the archives of the QSBB. Using the same database, cases with PD who 
had not exhibited ICBs matched by sex, age at PD onset, disease duration and 
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age at death were selected in a consecutive fashion, starting with more recent 
cases, to act as controls. 
 
The medical records were systematically reviewed including primary and 
specialist care medical notes, correspondence between doctors and data 
collected from the QSBB prior to donation. Demographic and clinical data were 
collated, as well as information on ICBs and detailed medication history. 
Symptoms that were not mentioned in the notes were considered absent. 
Written consent for donation was obtained from all cases. 
 
The decision to study the NAc was based on previous reports showing 
excessive dopaminergic release in the ventral striatum of PD+ICB (Evans et al., 
2006, O'Sullivan et al., 2011) and a connection between excessive stimulation 
of D3R, which are mainly expressed in the NAc, and ICBs (Seeman, 2015). 
Two methods were selected based on the QSBB expertise and availability of 
antibodies with specific binding to the chosen targets: immunohistochemistry to 
analyse alpha-synuclein load and tyrosine hydroxylase (TH) levels; and western 
immunoblotting to quantify D2R and D3R protein levels. Additional western 
blotting to confirm alpha-synuclein levels was conducted. Additional brain 
regions were chosen to confirm whether any differences found were restricted 
to the NAc. For immunohistochemistry, the dorsal putamen and dorsal caudate 
were selected because these areas have not been implicated in the 
development of ICBs. For western blotting, one area with high levels of D2R 
and D3R (the dorsal putamen) and another with low levels (the inferior frontal 
cortex) were chosen (Luquin-Piudo and Sanz, 2011). 
 
5.2.2 Sample preparation 
 
Brain donations were processed according to QSBB standard operating 
procedures. After post-mortem, the brain was hemi-dissected and one half of 
the brain (usually the right) was frozen and stored at -80°C while the other half 
was fixed in 10% formalin for 3 weeks until neuropathological assessment. 
Paraffin-embedded blocks containing the anterior striatum including the NAc are 
routinely obtained during neuropathological examination of all PD cases 
donated to the QSBB. Initially, a case by case macroscopic review of the 
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paraffin-fixed blocks was conducted to confirm the presence of the NAc, 
putamen and caudate.  
 
Subsequently, three 8 µm sections and one 12 µm section were cut and 
mounted on glass slides and left to dry in a 60°C oven over night. One 8 µm 
section was stained with haematoxylin and eosin and one 12 µm section with 
luxol fast blue according to QSBB standard operating procedures. After 
confirmation of adequate sampling of the NAc using microscopy, the remaining 
8 µm sections were stained with alpha-synuclein and TH as described in the 
following section. 
 
When flash frozen brain tissue was available, samples from the NAc, dorsal 
putamen and the frontal inferior gyrus were obtained by micro-dissection and 




Eight µm sections were stained for TH and alpha-synuclein using similar 
immunohistochemistry techniques as described below. 
 
Sample preparation  
 
Initially, the samples were dewaxed using several changes of xylene of few 
minutes each. Sections were then washed in changes of 100% industrial 
methylated spirit (IMS) for several minutes each change and placed into a 
solution of hydrogen peroxide and methanol for 10 minutes at room 




Pre-treatment of the samples was conducted as follows: sections were treated 
in 98% formic acid for 10 minutes at room temperature and washed in running 
tap water for 10 minutes; sections were subsequently pressure cooked in the 
citrate buffer for 10 minutes and rinsed in running tap water and tris buffered 
saline (TBS); finally, sections were rinsed with de-ionised water and proteinase 
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K solution (Dako) was applied for 10 minutes at room temperature. Sections 
were transferred to TBS and placed into 10% powered milk solution for 30 




The primary antibody was applied to the tissue section for one hour at room 
temperature and then rinsed off with TBS. This was followed by 3 five-minute 
washes in TBS. The secondary antibody was applied for 30 minutes at room 
temperature and then rinsed off in TBS. This was also followed by three five-
minute washes in TBS. The ABC working solution was applied to all sections for 
30 minutes at room temperature and rinsed off with TBS. This was followed by 
3 five-minute washes, also in TBS. Sections were immersed in DAB solution 
(activated with the addition of hydrogen peroxide) for 5 minutes at room 
temperature. Subsequently, the sections were rinsed in TBS followed by 
running tap water for 10 minutes. Sections were then counterstained in Mayer’s 
haematoxylin for 1 minute and washed in warm running tap water for 10 
minutes before being dehydrated in ascending grade of IMS (70%, 90% and 
100%), cleared in xylene and mounted. 
 
Image analysis of alpha-synuclein and TH immunoreactivity 
 
Digital images of TH and alpha-synuclein stained slides were captured using a 
high-resolution digital scanner (Leica SCN400). The NAc, putamen and caudate 
were extracted from the original image using Aperio ImageScope software 
(Leica Biosystems) and the obtained image processed with ImageJ software. 
To optimise the sampling of the regions of interest, a Bland-Altman plot (Bland 
and Altman, 1999) was used to identify the ideal number of random squares to 
be sampled from each brain region: 5 random squares of 1000 pixels each for 
the NAc and caudate, and 10 for the putamen. The threshold was adjusted to 
correctly identify the two-dimensional area of alpha-synuclein (Lewy bodies and 
neurites) and TH immunoreactivity. Aereal fraction was calculated as a ratio of 
immunostained pixels to the total number of pixels in the whole field and 
expressed as percentage. Mean values for the random squares were obtained 
and exported to SPSS 22 for statistical analysis. All the analysis was conducted 
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blinded to the presence of ICBs. To account for learning effect, all cases were 
analysed twice and only the second round of analysis was used for comparison. 
 
The core and the shell of the NAc exhibit different immunoreactivity profiles. 
Considering that the core expresses calbindin and the shell calretinin 
immunoreactivity, an attempt to identify these structures was conducted using 
these two substances as markers. Despite previous reports showing good 
differentiation of these structures in humans using a selection of chemical 
markers (Prensa et al., 2003), clear boundaries between the shell and the core 
were not identified using only calbindin and calretinin. 
 




- 0.45g citric acid 
- 5.8g tri-sodium citrate 
- 2L deionised water 
Tris-buffered saline (1x TBS) 
- 10% 10x TBS in sterile deionized water (final formulation: 50mM Tris-Cl, 
pH 7.5, 150 mM NaCl) 
ABC working solution  
- Avidin/Biotin complex, for every 5 ml of TBS 2 drops of solution A and 2 
drops of solution B were used 
DAB solution 
- 1 ml 5% DAB (3,3'-diaminobenzidine) in 100 ml TBS 
 
Antibodies: 








Table 19. Antibodies used for immunohistochemistry 
Protein 
detected 















Rabbit polyclonal 1:1000 
Secondary antibody 
Rabbit IgG Anti-rabbit IgG 
E0353 
Dako Swine 1:200 
in TBS 























5.2.4 Western immunoblotting 
 
As none of the commercially available D3R antibodies were suitable for 
immunohistochemistry, analysis of protein levels was conducted using Western 
immunoblotting. However, as western blot analysis requires flash frozen brain 
tissue, only 25 QSBB cases were available: 10 PD+ICB and 15 PD-ICB. 
 
Protein preparation from brain tissue 
 
Samples from the NAc, dorsal putamen and inferior frontal gyrus were obtained 
by micro-dissection performed by an experienced QSBB technician. Samples 
were stored at -80°C and maintained on dry ice prior to the homogenization. 
Frozen tissue samples were weighed and ice cold RIPA buffer (50 mM Tris-HCl, 
pH 8.0 containing 150 mM sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS (sodium dodecyl sulphate)) added at a 5:1 
(v/v) ratio of buffer to tissue. The RIPA buffer was supplemented with 1% 
protease inhibitor cocktail and phosphatase inhibitor (both Sigma-Aldrich). 
Subsequently, 500 μL of RIPA buffer was added to each. Samples were then 
homogenized with a Qiagen Tissueruptor homogeniser. Homogenates were 
centrifuged in a microcentrifuge for 20 minutes at 12000 rpm at 4°C. Lastly, the 
supernatants were collected and stored at -80°C. 
 
Protein concentration determination 
 
Due to variable protein concentrations of brain tissue homogenates, protein 
concentrations were determined using the BioRad DC Protein Assay. This 
ensured that equal amounts of protein per sample were loaded into each well of 
SDS-polyacrylamide gels for electrophoretic separation prior to immunoblotting. 
A quantification of sample protein was made using a standard curve derived 
from known concentrations of bovine serum albumin (BSA). 
 
Using a 2.0 mg/mL solution of BSA, a set of 800µL standard dilutions were 
made in deionized water with a range of 0 to 150 µg/mL. Samples were diluted 
1:25 by mixing 1 µL with 24 µL of deionized water. Five μl of standards and 
brain samples were pipetted in triplicate into individual wells of a 96-well plate. 
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Twenty-five μl of Reagent A were added into each well. Next, 200 μl of Reagent 
B were added into each well, mixed and incubated at room temperature for 10 
minutes. Absorbance at 750 nm was measured using the Tecan Spark 10M 
plate reader. The absorbance values for the BSA standards were plotted on a 
graph using Microsoft Excel, and the formula for a straight line was determined 
using the linear section of the graph (normally 0 to 150 µg/mL). This formula 
and the dilution factor were then used to calculate the concentration of the 
protein samples using their absorbance values. 
 
Western immunoblot analysis of proteins 
 
Immunoblot analysis of proteins is a routine method used for studying complex 
protein mixtures. Firstly, the proteins are separated according to molecular 
weight using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (Laemmli, 
1970) followed by immobilisation by transfer to a nitrocellulose membrane and 
detection of specific proteins by antibodies. 
 
Equal masses of protein samples were prepared by mixing with 10% v/v 
reducing agent (Invitrogen) and 6x loading dye (BioRad Criterion) and 
denaturated at 100°C for 10 minutes. For SDS-PAGE, the BioRad Criterion 
system was used, which comprises pre-cast Bis-Tris polyacrylamide 4-12% 
gradient gels. Thirty µL samples were loaded into the wells of the gel alongside 
5 µL of SeeBlue (Invitrogen) pre-stained protein size markers. Electrophoresis 
was performed in running buffer containing 3-(N-morpholino) propanesulphonic 
acid (MOPS) at 200 V until the dye front reached the bottom of the gel, normally 
within 50 minutes in MOPS buffer. The apparatus was then disassembled, and 
the separated proteins were transferred to a nitrocellulose membrane using the 
semi-dry Trans-Blot Turbo machine (BioRad). Briefly, this entails the 200 V 
electrophoresis for 10 minutes of the protein from the gel onto the membrane in 
semi-dry transfer buffer. 
 
Excess protein binding sites of the membranes were blocked by incubation for 1 
hour with 5% BSA (Sigma-Aldrich) in TBS. Primary antibodies against the 
proteins of interest were diluted at defined rations in TBS containing 0.05% (v/v) 
Tween-20 (TBSt) and incubated with the membranes for a defined period. 
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Typically, this was overnight incubation at 4°C. Membranes were then washed 
with TBSt, firstly, followed by 3 x 10-minute washes with shaking. The 
membrane was then incubated for 1 hour at room temperature with secondary 
fluorescently-labelled detection antibody (Li-Cor) against the primary antibody 
diluted 1:20000 in TBSt. This was followed by two washes with TBSt and a final 
wash in TBS. Membranes were scanned on a Li-Cor Odyssey 3000 for 
fluorescence detection of immunolabelled protein bands.  
 
Densitometry of immunoblots 
 
Considering the total number of samples, two gels were required for each 
comparison. To allow statistical comparison between gels, clinical data was 
used to choose an optimal control that was included in every gel (internal 
control). Immunoblot scans were analysed by densitometry using Image Studio 
Lite software (Li-Cor). A region of interest (ROI) was drawn around the 
largest/brightest band, and ROIs of the same dimensions drawn around protein 
bands for all other samples to be quantified. Mean intensities of each ROI were 
then analysed in Microsoft Excel. In order to calculate net band intensity, 
background readings were subtracted from band intensity readings. Signal 
intensity values of each band were normalised for beta-actin and, subsequently, 
for the optimal internal control. All comparisons were run three times and mean 
values used for statistical analysis. Immunoblot results were expressed as 
proportional/fold change in intensity between cases and controls. 
 
Materials for western blotting 
 
Reagents: 
Radioimmunoprecipitation (RIPA) buffer 
- 150 mM NaCl (Sigma-Aldrich) 
- 5 mM EDTA, pH 8.0 (Life technologies) 
- 50 mM Tris-HCL, pH 8.0 (Sigma-Aldrich) 
- 1 mL 1.0% NP-40 (IGEPAL CA-630) 
- 5 mL 0.5% 10% sodium deoxycholate (Sigma-Aldrich) 
- 1 mL 1.0% 10% SDS (Sigma-Aldrich) 
- 84 mL dH20 
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- 1x complete mini protease inhibitor cocktail (Sigma-Aldrich) 
- 1x PhosSTOP phosphatase inhibitor cocktail (Sigma-Aldrich) 
 
Running buffer 
- 100 mL 20x MOPS (BioRad) 
- 1900 mL ultra-pure water 
 
Tris buffered saline (1X TBS) 
- 10% 10x TBS on sterile deionized water 
 
Blocking buffer 
- 5 g BSA (Sigma-Aldrich) 
- 100 mL 1x TBS 
 
TBSt    
- TBS supplemented with 0.1% vol/vol Tween 20 (Sigma-Aldrich) 
 
Antibodies: 


















Table 20. Antibodies used for western immunoblotting 









EPR10148 Abcam Rabbit 
monoclonal 
1:100 
Beta-Actin A2228 Sigma-Aldrich Mouse 
monoclonal 
1:1000 





Rabbit IgG IRDye 800 CW Li-Cor Donkey 1 µg/mL 
Mouse IgG IRDye 680 RD Li-Cor Donkey 1 µg/mL 





















5.2.5 Lewy pathology and Alzheimer’s disease neuropathological changes 
analysis 
 
All cases were quantified for Lewy pathology and Alzheimer’s disease 
neuropathological changes. PD pathology was investigated using the Braak 
staging system, which is able to determine disease progression by assessing 
the presence of Lewy pathology in different structures of the central nervous 
system: the lower brain stem (stage 1), pontine nuclei (stage 2), midbrain (stage 
3), basal prosencephalon and mesocortex (stage 4), neocortex (stage 5), and 
primary areas of the neocortex (stage 6) (Braak et al., 2003). Cortical Lewy 
pathology was quantified with the McKeith criteria, whereby a semi-quantitative 
analysis of the presence of Lewy bodies in five regions of the cortex 
(transentorhinal, cingulate, temporal, frontal and parietal) is used to classify 
each case as brain-stem predominant, limbic (transitional) or neocortical 
(McKeith et al., 1996).  
 
Alzheimer’s disease pathology was also quantified. The Braak and Braak 
staging system was used to compute tau neurofibrillary deposits. This staging 
system assesses the spread of neurofibrillary tangles and neuropil threads 
through cortical areas: the transentorhinal cortex (stages I and II), limbic areas 
(stages III and IV) and isocortical areas (stages V and VI) (Braak and Braak, 
1991). Amyloid beta was accounted for with the Thal staging of amyloid beta 
deposition, which assesses the evolution of amyloid beta deposition in the brain 
in five stages. Stage 1 is characterized by involvement of the neocortex, stage 2 
allocortex, stage 3 diencephalic nuclei, stage 4 brainstem nuclei and stage 5 
the cerebellum (Thal et al., 2002). 
 
We have also used the Consortium to Establish a Registry for Alzheimer’s 
Disease (CERAD) score (Mirra et al., 1991), a semi-quantitative measure of 
neuritic plaques that takes into account patients’ age and plaque frequency in 
the most affected neocortical area to give a probability of Alzheimer’s disease 
diagnosis; and The National Institute of Aging-Alzheimer’s Association (NIA-AA) 
score. The latter assesses beta amyloid plaques, neurofibrillary tangles and 
neuritic plaques to identify one of four levels of Alzheimer’s disease 
neuropathological changes: not, low, intermediate or high (Hyman et al., 2012).  
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5.2.6 Statistical analysis 
 
All variables were tested for normality. Parametric data was analysed using 
independent samples t-test and non-parametric data Mann-Whitney U and 
Wilcoxon matched pairs. Mann-Whitney U test was used for all variables 
obtained from western blotting. Proportions were compared with the Pearson 
chi-square test, except if the minimum expected cell count was less than five, 
when the Fisher’s exact test was used. A p-value of less than 0.05 was 
considered significant. Data was analysed using SPSS 22. 
 
5.3 Results  
 
5.3.1 Clinical and demographic data 
 
Twenty-three PD+DDS were identified from the QSBB archives and matched by 
sex, age at PD onset, age at death and PD duration with thirty PD-ICB. All 
patients had been assessed by specialists throughout disease course. One 
patient in the control group had DDS, therefore 24 patients were included in the 
PD+DDS group and 29 in the control group (PD-ICB). Among PD+DDS, ten 
individuals (41.6%) had multiple behavioural addictions. Details on the types of 
ICBs can be seen in table 21 on page 119. 
 
The most common cause of death was pneumonia (8 PD+DDS and 12 PD-
ICB), followed by end stage PD (5 PD+DDS and 7 PD-ICB) and septicaemia (3 
PD+DDS and 5 PD-ICB). Causes of death according to group are displayed in 










Table 21. Types of impulsive compulsive behaviours 
N ICBs 
16 Isolated DDS 
2 DDS and CSB 
1 DDS and punding 
1 DDS and pathological gambling 
2 DDS, CSB and compulsive shopping 
1 DDS, CSB and punding 
1 DDS, CSB, compulsive eating and punding 
The different types of ICBs diagnosed in the study population. ICBs – 
impulsive compulsive behaviours; DDS – dopamine dysregulation syndrome; 

























Table 22. Causes of death divided by group 
 PD+DDS (N = 24) PD-ICB (N =29) 
Pneumonia 8 12 
Parkinson’s disease 5 7 
Septicaemia 3 5 
Ischaemic heart disease 1 1 
Heart failure 2 0 
Respiratory failure 1 0 
Pulmonary embolism 1 0 
Asthma attack 1 0 
Malnutrition 1 0 
Dissecting aortic aneurysm 1 0 
Sudden death 0 1 
Metastatic carcinoma 0 1 
Aortic aneurysm 0 1 
Urinary tract infection 0 1 
Causes of death separated by group. PD+DDS – Patients with Parkinson’s 
disease and dopamine dysregulation syndrome; PD-ICB – Patients with 

















The proportion of males, age at PD onset, PD duration, age at death and 
prevalence of dyskinesias did not differ between groups (table 23 on page 122). 
A similar proportion of patients used DA anytime during disease progression 
and a non-significant higher proportion of PD+DDS were using DA at death. 
There was a trend for higher DA peak dose, measured in LEDD as previously 
described (Tomlinson et al., 2010). Duration of DA use, DA end dose and 
proportion of patients using MAOi anytime during disease course did not differ 
between groups. Lifetime cumulative dose of levodopa was calculated as 
described elsewhere (Parkkinen et al., 2011) and was statistically similar 
between groups. The dose of all PD medications at death was calculated in 
LEDD revealing that PD+DDS used more medication than controls. 
 
5.3.2 Alpha-synuclein  
 
Alpha-synuclein pathology was initially identified by immunohistochemistry. One 
NAc sample from a patient with DDS was damaged and removed from data 
analysis. Dorsal caudate from 21 PD+DDS and 27 controls were available for 
analysis, as well as dorsal putamen from 22 PD+DDS and 29 controls. Lewy 
bodies and neurites were seen in all three regions as displayed in figure 7 on 
page 123. 
 
Aereal fraction analysis revealed significant differences in the NAc analysis, 
with PD+DDS showing lower alpha-synuclein load compared to PD-ICB. No 
differences were seen between groups in the putamen and caudate. Total 
alpha-synuclein load was calculated as the sum of alpha-synuclein stained area 
from all three structures and was non-significantly lower in the PD+DDS group 











Table 23. Demographic and clinical data 
 PD+DDS PD-ICB p value 
Male sex 79.2% 75.8% 0.775* 
Age at PD onset (years) 50 (± 10) 51.8 (± 5) 0.480‡ 
PD duration (years) 20.6 (± 5.5) 21.4 (± 3.6) 0.481Þ 
Age at death (years) 70.5 (± 9.4) 73.2 (± 4.7) 0.342‡ 
Dyskinesias (%) 95.8% 75.8% 0.059§ 
LEDD at death 1202.6 (± 653.2) 777.3 (± 448.5) 0.007Þ 
Levodopa lifetime 
cumulative dose (kg) 
5301.5 (± 4221) 3475.1 (± 2651) 0.077‡ 
DA use anytime (%) 91.3%  86.2% 0.682§ 
DA at death (%) 45.8% 34.4% 0.400* 
DA peak dose in LEDD 623.5 (± 644)       
N = 21 
317.6 (± 255)     
N = 25 
0.050‡ 
DA end dose in LEDD 213.14 (± 234)       
N = 11 
173.8 (± 105)     
N = 18 
0.057‡ 
DA duration (years) 8.65 (± 5.6) 6.91 (± 5.5) 0.360‡ 
MAOi anytime (%) 79.2% 89.6% 0.444§ 
Comparison of demographic and clinical data. PD – Parkinson’s disease;; 
PD+DDS – patients with PD and DDS; PD-ICB – PD patients without ICBs; 
LEDD – levodopa equivalent daily dose; DA – dopamine agonists; MAOi – 
monoamine oxidase inhibitors. Results expressed in mean values and 
standard deviation or proportions. Significant results in bold. *Chi-square; ‡ 











Figure 7. Lewy pathology.  
 
Lewy bodies and neurites (black arrows) were seen in the dorsal putamen 
(panel A), the nucleus accumbens (panel B) and the dorsal caudate. Anti-alpha 
synuclein antibody manufactured by Abcam (Ab15530). On the left scale bar 






















Table 24. Alpha-synuclein quantification by aereal fraction analysis 
 PD+DDS (N = 24) PD-ICB (N = 29) p value 
Nucleus 
accumbens 
0.0828 (0.099) N = 23 0.2330 (0.406) N = 29 0.006* 
Caudate 0.0526 (0.169) N = 21 0.1108 (0.217) N = 27 0.066* 
Putamen 0.1276 (0.276) N = 22 0.1343 (0.210) N = 29 0.669* 
Total alpha-
synuclein load 
0.4069 (0.558) 0.6022 (0.616) 0.072* 
Alpha-synuclein quantified by aereal fraction analysis. PD+DDS – patients 
with PD and DDS; PD-ICB – PD patients without ICBs. Results expressed in 
median values and interquartile ranges. Significant results in bold. *Mann-


























Figure 8. Quantification of alpha-synuclein load by aereal fraction analysis. 
 
Lower alpha-synuclein load was detected in the nucleus accumbens (NAc) of 
PD+DDS. No differences were seen in the caudate and putamen. The y axis 
represents the ratio of immune-stained pixels to the total number of pixels in the 
whole field expressed as percentage. PD+DDS – patients with PD and DDS; 
PD-ICB – patients with PD without ICBs. Results expressed in median and 





















A comparison of alpha-synuclein load between the three regions was 
conducted. When all cases were assessed together no differences were found 
as seen in figure 9 on page 127 (Friedman test; p = 0.646). A post hoc analysis 
revealed that PD-ICB had higher levels of alpha-synuclein in the NAc compared 
to the putamen (Wilcoxon matched pairs; p = 0.002) and the caudate (Wilcoxon 
matched pairs; p 0.039). 
 
Western blot analysis of alpha-synuclein confirmed the finding obtained by 
immunohistochemistry. Samples from 10 PD+DDS and 15 PD-ICB cases were 
available for comparison. Alpha-synuclein was identified as a single band 
immediately above the 17 KDa marker as displayed in figure 10 on page 128 
(predicted molecular weight 19 KDa). Comparison between groups revealed 
that alpha-synuclein levels in the NAc of PD+DDS were 79% of PD-ICB, 
significantly lower. Alpha-synuclein levels of PD+DDS were 110% of PD-ICB in 
the frontal cortex and 107% of PD-DDS in the dorsal putamen, which did not 






















Figure 9. Comparison of alpha-synuclein load in different structures.  
 
There were no differences in alpha-synuclein levels between the studied brain 
regions in PD+DDS and when all cases were analysed together. PD-ICB 
exhibited higher alpha-synuclein load in the NAc compared to the caudate and 
the putamen. The y axis represents the ratio of immune-stained pixels to the 
total number of pixels in the whole field expressed as percentage. PD+DDS  – 
patients with PD and DDS; PD-ICB – patients with PD without ICBs; NAc – 
nucleus accumbens. Results expressed in median and interquartile ranges. 



















Figure 10. Alpha-synuclein immunoblotting of the nucleus accumbens (NAc), 
inferior frontal cortex and dorsal putamen.  
 
Alpha-synuclein was identified as a single band immediately above the 17 KDa 
marker (predicted molecular weight 19 KDa). Two gels were required for each 
comparison and an internal control (without ICBs) was used to allow 
comparison between gels. PD+DDS had lower alpha-synuclein load in the NAc, 
no differences were seen in the other brain regions. ICB – patients with 
Parkinson’s disease and dopamine dysregulation syndrome; CTRL – Patients 
with Parkinson’s disease without impulsive compulsive behaviours; IC – internal 





Table 25. Alpha-synuclein quantification by western immunoblotting 
 PD+DDS (N = 10) PD-ICB (N = 15) p value 
Nucleus accumbens 0.9244 (0.527) 1.1673 (0.679) 0.031* 
Frontal cortex 0.7177 (0.488) 0.6550 (0.310) 0.496* 
Putamen 1.416 (0.486) 1.324 (0.450) 0.531* 
Alpha-synuclein assessed by western immunoblotting. PD+DDS – patients 
with PD and DDS; PD-ICB – PD patients without ICBs. Results expressed in 
median values and interquartile ranges. Significant results in bold. *Mann-





























Figure 11. Quantification of alpha-synuclein by western immunoblotting.  
 
Lower alpha-synuclein load was seen in the nucleus accumbens in the 
PD+DDS group, corroborating the immunohistochemistry analysis. The y axis 
represents signal intensity normalised for beta-acting and for the optimal 
internal control. PD+DDS – patients with PD and DDS; PD-ICB – patients with 
PD without ICBs. Results expressed in median and interquartile ranges. 






















5.3.3 Tyrosine hydroxylase 
 
Similar to the alpha-synuclein analysis, one NAc sample from a patient with 
DDS had been damaged and was removed from data analysis. Caudate 
samples from 21 PD+DDS and 27 PD-ICBs and putamen from 22 cases and 29 
controls were available for comparison. Quantification of TH immunoreactivity 
showed similar TH levels in both groups and in all three structures as displayed 
in table 26 on page 132 and figure 12 on page 133. Total TH level, calculated 
as the sum of TH levels from all three regions, was also similar between 
PD+DDS and PD-ICB. 
 
A comparison of TH immunoreactivity in the different brain regions was 
conducted. When all cases were analysed together TH levels were significantly 
different (Friedman test; p < 0.001), revealing a gradient of staining between the 
three structures as displayed in figure 13 on page 134. Post hoc analysis 
revealed higher TH levels in the NAc compared to the caudate (Wilcoxon 
matched pairs; p < 0.001) and in the caudate compared to the putamen 
(Wilcoxon matched pairs; p < 0.001) (figure 14 on page 135). The same 


















Table 26. Tyrosine hydroxylase quantification by aereal fraction analysis  
 PD+DDS (N = 24) PD-ICB (N = 29) p value 
Nucleus accumbens 12.98 (14.98) N=23 12.18 (11.32) 0.949* 
Caudate 4.04 (7.02) N = 21 3.80 (8.21) N = 27 0.484* 
Putamen 1.53 (3.02) N = 22 1.00 (1.45) N=29 0.250* 
Total TH  18.94 (27.47)  17.87 (24.39) 0.665* 
Tyrosine hydroxylase levels assessed by aereal fraction analysis. PD+DDS – 
patients with Parkinson’s disease and dopamine dysregulation syndrome; 
PD-ICB – Parkinson’s disease patients without impulsive compulsive 
behaviours. Results expressed in median values and interquartile ranges. 



























Figure 12. Quantification of tyrosine hydroxylase levels by aereal fraction 
analysis. 
 
Similar levels of TH were seen in all three brain regions. The y axis represents 
the ratio of immune-stained pixels to the total number of pixels in the whole field 
expressed as percentage. PD+DDS – patients with Parkinson’s disease and 
dopamine dysregulation syndrome; PD-ICB – patients with Parkinson’s disease 
without impulsive compulsive behaviours. Results expressed in median and 
















Figure 13. Tyrosine hydroxylase staining in different regions.  
 
A - nucleus accumbens (NAc); B – dorsal caudate; C – dorsal putamen. TH 
immunoreactivity was higher in the NAc, followed by the caudate and the 
putamen with no differences between patients with and without dopamine 
dysregulation syndrome. Anti-tyrosine hydroxylase antibody manufactured by 
























Figure 14. Comparison of tyrosine hydroxylase levels in different regions.  
 
Higher TH levels were seen in the NAc, followed by the caudate and the 
putamen. Similar results were achieved when cases were analysed separately, 
according to the presence of ICBs. The y axis represents the ratio of immune-
stained pixels to the total number of pixels in the whole field expressed as 
percentage. NAc – nucleus accumbens. Results expressed in median and 






















5.3.4 Dopamine D2 and D3 receptors  
 
Frozen tissue samples from 10 PD+DDS and 15 PD-ICB were available. The 
expected molecular weight of D2R is 49 KDa. Immunoblot analysis of D2R 
revealed a single band of 49 KDa of molecular weight as displayed in figure 15 
on page 137.  
 
D2R levels of PD+DDS were 81% of PD-ICB in the NAc, 92% in the frontal 
cortex and 96% in the putamen but the differences did not reach statistical 
significance as seen in table 27 on page 138 and figure 16 on page 139. 
 
D3R predicted molecular weight is 44 KDa. Immunoblot analysis of D3R 
revealed a single band immediately below the 49 KDa marker as detailed in 
figure 17 on page 140. 
 
Table 28 on page 141 and figure 18 on page 142 shows D3R levels in different 
brain regions separated by groups. Signal intensity of PD+DDS was 66% of PD-
ICB in the NAc, 102% in the frontal cortex and 118% in the dorsal putamen. 
Lower D3R levels were detected in the NAc of PD+DDS, but the difference did 



















Figure 15. Dopamine D2 receptor (D2R) immunoblotting of the nucleus 
accumbens (NAc), inferior frontal cortex and dorsal putamen.  
 
D2R identified as a single band with 49 KDa of molecular weight. Two gels were 
required for each comparison, an internal control (without ICBs) was used to 
allow comparison between gels. No differences in D2R protein levels were 
seen. ICB – patients with Parkinson’s disease and dopamine dysregulation 
syndrome; CTRL – Patients with Parkinson’s disease without impulsive 






Table 27. Dopamine D2 receptor protein levels 
 PD+DDS (N = 10) PD-ICB (N = 15) p value 
Nucleus accumbens 1.23 (1.51) 1.52 (1.63) 0.395* 
Frontal cortex 0.99 (0.22) 1.07 (0.28) 0.428* 
Putamen 0.96 (0.48) 1.00 (0.49) 0.567* 
Dopamine D2 receptor signal intensity assessed by western immunoblotting. 
D2R levels of PD+DDS were lower in the NAc, but the difference did not 
reach significance. PD+DDS – patients with PD and DDS; PD-ICB – PD 
patients without ICBs. Results expressed in median values and interquartile 




























Figure 16. Comparison of D2 receptor (D2R) signal intensity between PD 
patients with DDS (PD+DDS) and PD controls (PD-ICB). 
 
No significant differences were found in D2R levels. The y axis represents 
signal intensity normalised for beta-acting and for the optimal internal control. 
Results expressed in median and interquartile ranges. No significant differences 
























Figure 17. Dopamine D3 receptor (D3R) immunoblotting of the nucleus 
accumbens (NAc), inferior frontal cortex and dorsal putamen.  
 
D3R identified as a single band immediately below the 49 KDa marker 
(expected molecular weight of 44 KDa). Two gels were required for each 
comparison, an internal control (without ICBs) was used to allow comparison 
between gels. No differences were seen. ICB – patients with Parkinson’s 
disease dopamine dysregulation syndrome; CTRL – Patients with Parkinson’s 







Table 28. Dopamine D3 receptor protein levels 
 PD+DDS (N = 10) PD-ICB (N = 15) p value 
Nucleus accumbens 0.669 (0.77) 1.000 (0.48) 0.091* 
Frontal cortex 1.238 (0.62) 1.204 (0.56) 0.683* 
Putamen 1.26 (3.21) 1.06 (0.28) 0.567* 
Dopamine D3 receptor signal intensity assessed by western immunoblotting. 
Non-significantly lower D3R protein levels were seen in the NAc of PD+DDS. 
PD+DDS – patients with PD and DDS; PD-ICB – PD patients without ICBs. 
Significant results in bold. Results expressed in median values and 




























Figure 18. Comparison of D3 receptor signal intensity between PD patients with 
DDS (PD+DDS) and PD controls (PD-ICB). 
 
No differences were seen. The y axis represents signal intensity normalised for 
beta-acting and for the optimal internal control. Results expressed in median 
























5.3.5 Assessment of Lewy pathology and Alzheimer’s disease 
neuropathological changes 
 
Lewy pathology and Alzheimer’s disease neuropathological changes were 
assessed in 22 PD+DDS and 29 PD-ICB. The majority of patients were 
classified as Braak stage 6 (Lewy pathology reaching neocortex and premotor 
areas with mild changes in primary sensory and motor cortex) and the 
remaining as stage 5 (Lewy pathology reaching high order sensory association 
areas of the neocortex and prefrontal neocortex) with no significant differences 
between groups. Cortical Lewy pathology assessment using the McKeith criteria 
revealed that all cases had either limbic or neocortical pathology with no 
differences according to the presence of DDS (table 29 on page 144). 
 
Alzheimer’s disease pathology was also analysed. No differences were seen in 
the Braak and Braak and Thal staging systems. Similarly, the CERAD and NIA-
AA scores did not differ between groups, showing absent or low levels of 




















Table 29. Assessment of Lewy pathology and Alzheimer’s disease 
neuropathological changes 


































































Assessment of Lewy pathology and Alzheimer’s disease neuropathological 
changes. PD+DDS – patients with PD and DDS; PD-ICB – PD patients 








This is the first post mortem study of alpha-synuclein, D2R and D3R levels in 
PD+DDS. In line with previous research in ICBs (Weintraub et al., 2010a), the 
study population was composed mostly of males with early onset PD. The 
disease duration, slightly more than 20 years, was higher than that described in 
a general population of PD patients (Fahn et al., 2011b), corroborating previous 
findings that younger patients have slower disease progression (Wickremaratchi 
et al., 2009). 
 
The first formal description of DDS was published by our centre in the year 
2000 (Giovannoni et al., 2000), and the increased research interest in this ICB 
dating back many years allowed the inclusion of a significant number of patients 
with DDS. Multiple ICBs were seen in approximately 40% of patients, similar to 
a previous finding from a longitudinal study (Antonini et al., 2017). 
 
A similar proportion of patients were exposed to DA in both groups. There was 
a trend for higher peak DA dose and higher DA dose at death in the PD+DDS 
group that did not reach significance. Previous research has identified DA as 
the strongest risk factor for ICBs in general (Averbeck et al., 2014), but the main 
risk factor for DDS is the use of levodopa (O'Sullivan et al., 2009). Therefore, 
the lack of differences in DA is likely a consequence of the inclusion of patients 
with DDS. This could also explain the higher total dopaminergic treatment dose 
seen in PD+ICB, as patients with DDS tend to use dopaminergic medication in 
excess of what is needed to control motor symptoms (O'Sullivan et al., 2009). 
 
There is an asymmetry of striatum involvement in PD, with the dorsal parts 
being more severely affected compared to the ventral (Kish et al., 1988). As a 
consequence of the nigral degeneration associated with PD, there is reduction 
of TH in the striatum which correlates with disease duration, initially in the 
putamen, followed by the caudate and eventually the NAc (Jellinger, 2011). 
This pattern of progression was reproduced in the present study, where TH 
levels were highest in the NAc, followed by the caudate and the putamen. The 
fact that the ventral striatum tends to be affected later in the disease course led 
researchers to postulate that ICBs are a consequence of overstimulation of a 
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relatively preserved reward pathway by dopaminergic medication. This 
observation is supported by the dopamine overdose hypothesis, whereby the 
doses of levodopa needed to treat PD motor symptoms could overdose 
relatively intact dopaminergic structures and lead to functional disruption 
(Gotham et al., 1988). 
 
Alpha-synuclein pathology reaches the neostriatum at Braak stage III and 
increases with PD progression (Mori et al., 2008). Contrary to the TH analysis, 
there was no gradient of alpha-synuclein staining between the NAc, dorsal 
putamen and caudate when both groups were analysed together. Comparison 
between groups, however, showed that PD+DDS had lower alpha-synuclein 
load in the NAc compared to PD-ICB. It is still under debate whether Lewy 
pathology is a direct consequence of the pathological process or an 
epiphenomenon (Jellinger, 2011) but the fact that the NAc was the only region 
with different levels of alpha-synuclein points to an important role of this 
structure and of alpha-synuclein pathology in the genesis of DDS. It is unlikely 
that differences in disease progression were behind the lower alpha-synuclein 
levels as both groups had similar disease duration and Lewy pathology staging, 
and TH levels in the NAc did not differ. It is possible that individual susceptibility 
is behind the lower levels of aggregated alpha synuclein found in patients with 
DDS, however, further studies are needed to answer this question. 
 
Alpha-synuclein is a negative regulator of dopamine release as suggested by 
studies with cultured neurons and animal modes reporting inhibition of vesicle 
exocytosis by overexpression of this molecule (Abeliovich et al., 2000, Nemani 
et al., 2010). Although these studies did not consider the abnormally 
aggregated form of alpha-synuclein seen in PD, they may offer an explanation 
for how lower levels of alpha-synuclein could lead to excessive dopaminergic 
stimulation. Conversely, higher alpha-synuclein levels in PD-ICB would result in 
less dopaminergic stimulation that would be protective against DDS. 
Additionally, lower alpha-synuclein pathology levels in the NAc suggests a 
better-preserved ventral striatum, providing further evidence to support the 
dopamine overdose hypothesis as an explanation for ICBs. 
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D2R are widely expressed throughout the striatum (Hurd et al., 2001) and have 
been shown to be downregulated in the initial stages of PD (Antonini et al., 
1997) and to normalise following chronic exposure to levodopa (Luquin-Piudo 
and Sanz, 2011). No significant differences in D2R levels were seen between 
groups, in line with a previous PET study involving PD patients with impulse 
control disorders (Payer et al., 2015). The fact that PD+DDS had non-
significantly lower levels of D2R in the NAc coupled with the trend for higher 
peak and end DA doses could suggest that the lack of differences in D2R levels 
is an artefact of the small sample size, as downregulation of D2R has been 
shown to occur with DA use (Antonini et al., 1994, Payer et al., 2014). However, 
since the trend for lower D2R levels was only seen in the NAc this should be 
interpreted with caution. 
 
Upregulation of D3R has been described in animal models after exposure to 
drugs of abuse and levodopa (Payer et al., 2014) and in the NAc of individuals 
following death from cocaine overdose (Mash and Staley, 1999). However, 
functional neuroimaging studies in humans with behavioural and drug addiction 
have consistently shown reduced D2R/D3R availability, which has been 
attributed to excessive synaptic dopamine (Payer et al., 2014). The expression 
of D3R in the NAc is regulated by the release of brain-derived neurotrophic 
factor from dopaminergic fibres, a possible explanation for how PD related 
degeneration could influence D3R levels (Guillin et al., 2001). Although D3R 
density does not appear to be altered by disease progression in animal models 
of PD (Luquin-Piudo and Sanz, 2011), a contradictory finding from a post 
mortem study has been published. The authors reported reduction of D3R in 
the striatum of PD patients compared to healthy controls, but reduction in the 
NAc was only seen after 10 years of disease progression (Ryoo et al., 1998).  
 
In PD, D3R levels have been assessed in PET studies involving PD+ICB and 
post mortem studies of PD-ICB. PET studies reported reduced uptake of the 
tracer in the ventral striatum of patients with different types of ICBs. The 
interpretation of these findings differs according to the study methodology. Two 
studies have assessed patients after stimuli presentation, one examined 
patients with DDS after levodopa intake (Evans et al., 2006), and the other 
patients with diverse ICBs after presentation of visual cues (O'Sullivan et al., 
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2011). The reduction in tracer binding seen in both studies is most likely a 
consequence of excessive dopamine release to stimuli, which would fit with the 
dopamine overdose hypothesis. Other PET studies, however, assessed 
patients with pathological gambling (Steeves et al., 2009) and PD with impulse 
control disorders (Payer et al., 2015) at baseline, without stimulus presentation. 
In this case, reduced tracer binding does not necessarily mean increased 
dopaminergic tone, it could be a consequence of reduced expression of 
dopamine receptors (Stark and Claassen, 2017). Only one of these studies 
used a highly selective D3R tracer, whereby the authors reported lower binding 
of the tracer in the limbic striatum, attributed to excessive synaptic dopamine 
(Payer et al., 2015). Since patients were assessed without levodopa, an 
alternative explanation is that the reduced tracer uptake is a consequence of 
lower D3R availability in the limbic striatum. Although no patients with DDS 
were included in that study, there appears to be a common hedonic 
representation of ICBs in the brain as different behavioural addictions are 
associated with similar pathophysiological findings (O'Sullivan et al., 2011), 
allowing extrapolation of these results to our study population. The results of the 
present study suggest that DDS is not associated with changes in NAc D3R 
levels, corroborating excessive dopamine release as an explanation for lower 
ventral striatum tracer binding reported in PET studies. However, it is possible 
that the sample size was not large enough to detect subtle differences.  
 
Midbrain D2/D3 auto-receptors are able to modulate striatal dopamine levels 
after reward and the binding potential of these receptors has been negatively 
correlated with impulsivity (Buckholtz et al., 2010). Reduced D2/3 receptors in 
the midbrain caused by PD degeneration could, therefore, contribute to 
excessive ventral striatal dopamine and DDS. Future studies assessing 
midbrain auto-receptors are needed to answer this question.  
 
Braak and McKeith staging showed that both groups were at similar stages of 
PD progression and cortical Lewy pathology. Alzheimer’s disease pathology 
also did not differ and was generally low in both groups. It has been shown that 
individuals with early onset PD have lower density of cortical Lewy pathology 
and less Alzheimer’s disease pathological changes (Halliday and McCann, 
2010), which is in line with our results. The similar degrees of Lewy and 
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Alzheimer’s pathology offer additional support for the hypothesis that our 
findings were not a consequence of different levels of neurodegeneration. 
 
There are limitations to this study. Clinical data was analysed retrospectively, 
which is a problem inherent in brain bank studies. All patients were seen by 
specialists throughout disease progression and clinical data was thorough, 
minimising this issue. Furthermore, ICBs are usually under-reported (Perez-
Lloret et al., 2012b) and this increases the risk of false negatives in the control 
group. To minimise this problem our controls were selected consecutively 
starting with more recent donations, when clinicians were more aware of ICBs. 
Lastly, the lack of a control group without neurodegenerative disease limits the 




This is the first post mortem study to assess alpha-synuclein pathology, TH 
reactivity, D2R and D3R levels in PD+DDS. Patients with DDS showed reduced 
alpha-synuclein load in the NAc compared to controls pointing to an important 
role for this structure in the genesis of behavioural addictions. Dopamine 
overdose could be motivated by lower Lewy pathology levels and PD treatment, 
resulting in an increased dopaminergic tone in a relatively preserved ventral 
striatum, ultimately leading to the development of DDS. This novel finding 
needs to be replicated by future studies. 
 
Future research should assess PD patients in different stages of disease 
progression, include patients with other types of ICBs, analyse the influence of 
genetic polymorphisms in the expression of D2R and D3R and study additional 
brain areas of the dopaminergic reward pathway, such as the ventral tegmental 








Summary of findings 
 
In the longest follow up study of PD+ICB to date, 46 patients were examined 
eight years after initial assessment. All but one participant experienced partial or 
complete improvement of the abnormal behaviour. However, 58% of them still 
had ICBs at the end of the follow up period, a lower remission rate than 
previously reported. Despite the most common therapeutic measure being 
cessation of DA, 40% of patients were still using oral/transcutaneous DA at the 
end of the follow up period, which could be explained in part by the 
development of DAWS in some subjects. Dopaminergic treatment dose was 
higher in the last visit, probably as a consequence of disease progression and 
increased medication requirements by patients. Corroborating previous findings, 
ICBs were associated with depression and worse quality of life but were not 
associated with increased risk of cognitive impairment. Although reduction of 
dopaminergic medication is considered the gold standard treatment of ICBs, for 
a significant proportion of patients it did not guarantee long term remission. 
Considering the possibility of long-term sensitisation, patients with remitted 
ICBs are at risk of recurrence during future treatment adjustments required for 
disease progression. Therefore, once a PD patient develops ICBs, close 
vigilance is required throughout the whole disease course, after remission and, 
particularly, after increases in dopaminergic treatment.  
 
Another study looked into the clinical features of CSB in PD. CSB is an ICB that 
is particularly difficult to diagnose because of the sensitive nature of sexual 
behaviour. PD+ICB who participated in 3 previous research projects at the 
National Hospital for Neurology and Neurosurgery underwent a thorough 
clinical assessment followed by review of hospital notes. CSB was more 
frequently seen in males and appeared earlier than other ICBs. Individuals with 
CSB were more likely to develop multiple ICBs with negative impact on mental 
well-being and quality of life. For the first time, higher doses of levodopa were 
associated with CSB. The main clinical implication arising from this finding is 




A retrospective analysis of PD patients with DDS who donated their brains to 
the QSBB was the first study to investigate the outcome of DDS until death. A 
search on the QSBB archives revealed that 193 donations with pathologically 
confirmed PD were received between 2005 and 2016. A higher prevalence of 
DDS (8.8%) than previously reported was found. Furthermore, DDS was 
associated with male sex, younger age at PD onset, longer disease duration 
and levodopa-induced dyskinesias, corroborating previous research. Treatment 
strategies included reduction of levodopa, reduction/cessation of DA and 
initiation of infusion therapies. Remission rate was approximately 50%. Patients 
who failed to achieve remission were exposed to higher peak DA dose, a novel 
finding that needs to be replicated by future studies. 
 
Despite punding being initially described in a PD patient in 1994, little is known 
about the cognitive and neuropsychiatric profile of patients who develop this 
behavioural abnormality. Forty-seven individuals with PD and punding were 
compared to 25 PD patients without punding or other ICBs. Patients with 
punding showed increased self-rated impulsivity and anxiety levels, higher 
prevalence of PD-related motor fluctuations and worse frontal lobe function in 
comparison to PD-ICB. Reduction in DA dose occurred in both groups, but 
patients with punding were submitted to a significantly larger reduction. These 
results offer an interesting insight into the mechanisms associated with punding. 
Higher dopaminergic stimulation in individuals with reduced inhibitory control 
could be the mechanism driving this behavioural abnormality.  
 
Preliminary data suggests that apomorphine infusion carries less risk of 
triggering ICBs in PD compared to other DA. This could be a consequence of its 
pharmacological profile as it binds mainly to D1R and D2R, akin to levodopa 
and opposed to oral/transcutaneous DA, which have stronger affinity for D3R. 
In an attempt to assess apomorphine’s proclivity to trigger ICBs, a retrospective 
analysis of all patients with PD actively using apomorphine via continuous 
infusion in the years of 2013 and 2014 at the National Hospital for Neurology 
and Neurosurgery, London, UK, was conducted. Twenty-eight patients were 
included with mean age at PD onset of 51 years and approximately 18 years of 
disease duration. Five patients discontinued the treatment and nearly 90% had 
at least one side effect. Twelve patients had ICBs before being prescribed 
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apomorphine, among these, six had complete remission and no recurrence 
after starting apomorphine, and six were still symptomatic when apomorphine 
infusion started (4 improved and 2 did not experience worsening). Only one 
patient among the 16 with no previous history of ICBs developed a behavioural 
addiction: mild compulsive eating during concomitant use of levodopa. The data 
from this analysis suggests that apomorphine has indeed lower risk of triggering 
ICBs, indicating that it is a viable treatment option for patients with ICBs who 
failed to achieve good symptomatic control after cessation of 
oral/transcutaneous DA. 
 
Saccadic abnormalities have been previously reported in PD patients and 
healthy individuals with high impulsivity levels. To the present date, no studies 
have assessed eye movements of PD+ICB. Fifteen PD+ICB were assessed 
using a pro-saccades and an anti-saccades task and compared to 15 PD-ICB 
matched by age at PD onset and PD duration and 15 HC matched by age. No 
differences were found in the pro-saccades task confirming previous findings 
that automatic saccades are preserved in PD. In the anti-saccades task 
PD+ICB made hypometric voluntary saccades compared to healthy participants 
and a significantly higher number of direction errors compared to both PD-ICB 
and healthy individuals, showing an inability to suppress automatic saccades. 
One important conclusion from this work is that saccadic assessment has the 
potential to evolve into a marker of ICBs to guide therapeutic decision in 
patients at risk, provided this finding is confirmed by future studies. This would 
have a significant impact in clinical care as ICBs are commonly under-reported.  
 
Two main theories have been postulated to explain ICBs in PD: excessive 
dopaminergic release leading to overstimulation of a relatively preserved ventral 
striatum; and excessive stimulation of D3R, abundant in the limbic striatum. The 
former is supported by observations from PET studies and the latter by clinical 
research showing a strong association between ICBs and DA. Only one PET 
study has used tracer that binds specifically to D3R in PD+ICB and found no 
upregulation of this receptor. To date, no post mortem studies with individuals 
who were diagnosed with PD and ICBs in life have been conducted. Brain 
samples from 24 individuals with PD+DDS from the QSBB were compared to 
29 PD-ICB, matched by sex, age at PD onset, PD duration and age at death. 
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Immunohistochemistry techniques were used to assess alpha-synuclein and 
tyrosine hydroxylase levels in the NAc, dorsal putamen and dorsal caudate. 
Western immunoblotting was used to compare levels of alpha-synuclein, D2R 
and D3R in the NAc, dorsal putamen and inferior frontal cortex. Patients with 
DDS had significantly lower levels of alpha-synuclein in the NAc compared to 
controls. D2R and D3R levels did not differ. These findings suggest an 
important role for the NAc in the expression of ICBs. Individual susceptibility to 
Lewy pathology could result in lower levels of aggregated alpha-synuclein 
ultimately leading to excessive dopaminergic stimulation of dopamine receptors 
in the ventral striatum, supporting the dopamine overdose hypothesis as an 


























Directions for future research 
 
Further studies are needed to confirm the novel findings reported in this thesis: 
the association between CSB and higher doses of levodopa; higher peak DA 
dose and lower remission rate of DDS; frontal dysfunction and punding 
behaviour; increased anti-saccadic direction error rate in PD+ICB; and lower 
levels of alpha-synuclein in the NAc of PD+DDS. 
 
Future prospective clinical studies are needed to compare the efficacy of 
different treatment strategies and the outcomes of specific types of ICBs in PD 
patients. Furthermore, apomorphine safety needs to be validated by 
randomised clinical trials and/or prospective clinical studies. 
 
One promising methods of identifying PD+ICB were explored in this thesis: anti-
saccadic direction error rate. If this finding is confirmed by other authors, the 
feasibility of creating a bedside version of the anti-saccades test in order to 
identify individuals at risk or who have already developed ICBs should be 
tested. 
 
D3R should also be investigated in patients at different stages of disease 
progression to assess how protein levels of this receptor in the NAc are affected 
by disease progression, and whether pre-morbid differences are associated 
with ICBs. Another important question that could be answered by genome wide 
association studies is whether genetic polymorphisms of D3R influence the risk 
of ICBs in PD. Study of additional brain areas of the dopaminergic reward 
pathway, such as the ventral tegmental area and the subiculum of the 
hipoccampus, are also required to understand their roles in behavioural 
addiction. Other neurotransmitters could be implicated in ICBs and the study of 
opioid and serotoninergic receptors could provide important insights into the 
pathophysiology of ICBs. Finally, separate analysis of the shell and core of the 
NAc could contribute to our understanding of the different types of ICBs as 
research with animal models have associated different regions of the NAc with 
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